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ABSTRACT
Adrenal corticosteroid hormones play diverse and important roles
in development and homeostasis. Their complex effects are predominantly
mediated by intracellular receptors, which are of two types;
mineralocorticoid (MR, type I) and glucocorticoid (GR, type II). MR bind
aldosterone and physiological glucocorticoids (Cortisol, corticosterone)
with equivalent high affinity in vitro, whereas GR show a low affinity for
aldosterone but bind physiological glucocorticoids and the synthetic
glucocorticoid dexamethasone with high affinity. In vivo, kidney MR
selectively bind aldosterone despite a hundred-fold molar excess of
circulating glucocorticoids. This selectivity is due to the high activity of
the enzyme 1 ip-hydroxysteroid dehydrogenase (lip-OHSD) which catalyses
the reversible conversion of physiological glucocorticoids to inactive
products, but does not metabolise aldosterone, thus preventing
glucocorticoid access to renal MR. This thesis describes firstly the
presence and subregional distribution of lip-OHSD in rat brain using
Northern analysis, in situ hybridisation, and an lip-OHSD activity assay.
The enzyme was not only found in aldosterone selective regions, such as
periventricular areas of the hypothalamus, but also in hippocampus
where corticosterone is the physiological ligand for MR, and, more
surprisingly, in cerebellum which contains very low levels of MR.
Therefore it was postulated that lip-OHSD might modulate glucocorticoid
access to both types of corticosteroid receptor in brain. Furthermore,
brain but not renal, lip-OHSD was up-regulated by chronic glucocorticoid
but not aldosterone administration, suggesting a role for the enzyme in
controlling long-term neuronal glucocorticoid exposure. The importance
of lip-OHSD in brain was further substantiated by the finding of high 1 ip-
OHSD mRNA levels and activity in rat brain subregions in the early
postnatal period, with regionally specific developmental patterns of
activity. The enzyme may play an important role in the developing brain
by protecting tissues from (or exposing them to) elevated corticosterone
levels. To understand the molecular mechanisms underlying tissue-
specific and ontogenic regulation of lip-OHSD a rat genomic clone was
isolated and partially sequenced. Differential promoter usage of the gene
was demonstrated in kidney; three transcription start sites were detected
within one kilobase of 5' flanking region of the gene, using primer
extension and ribonuclease protection analyses. Corresponding
transcripts were detected on Northern blots of kidney, but not liver RNA,
using specific oligonucleotide probes. Sequence analysis revealed a
number of putative transcription factor binding sites. These findings
might explain, at least in part, tissue-specific differences in the regulation
of llp-OHSD mRNA and activity.
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1.1 Adrenocortical steroids
1.1.1 Discovery of the corticosteroids
In the 1930's, various groups of workers began the isolation of pure
crystalline compounds from adrenal extracts (Mason et al, 1936;
Wintersteiner & Pfiffner, 1936). Advances in steroid chemistry led to the
separation of numerous compounds and some were found to possess
significant biological activity: corticosterone (compound B of Kendall),
cortisone (compound E of Kendall), Cortisol (compound F of Kendall), 11-
dehydrocorticosterone (compound A of Wintersteiner & Pfiffner), 11-
deoxycortisol (compound S of Reichstein), oestrone, and progesterone. In
1940, Hartman and Spoor prepared a concentrate producing high sodium
retaining activity and the active principle was named the sodium factor.
Further purification was achieved and its physico-chemical properties
together with its hydrophylic nature led Simpson and Tait (1953) to call
this compound "electrocortin". The definitive name of aldosterone was
given after elucidation of the structure which showed that electrocortin
was the 18-aldehyde of corticosterone (Simpson et al, 1954).
1.1.2. Biosynthesis of the adrenal cortical hormones
The adrenal cortex comprises three morphologically distinct
regions. The outermost region, the zona glomerulosa, is composed of small
clusters of compact cells and secretes aldosterone, the major
mineralocorticoid. The cells in the middle layer, the zona fasciculata, are
larger and are arranged in radiating cords. The innermost layer, the zona
reticularis, is composed of smaller cells arranged in a loosely reticular
pattern. Zona fasciculata and reticularis are functionally
indistinguishable. They produce the glucocorticoids, Cortisol and/or
corticosterone and synthesise relatively large amounts of adrenal
androgens.
All the adrenal cortical hormones are steroids derived initially from
cholesterol, the basic ring stucture of which is preserved throughout the








Figure 1.1. Cholesterol. The numbers refer to the conventional designation
of carbon atoms.
Some of the steps involved in the steroidogenesis are shown in Fig.
1.2. The end products fall into two main categories, the C21 steroids, which
have a two-carbon side-chain attached at C17, and the C19 steroids, which
have either a =0 or -OH group at C17. The C19 steroids possess androgenic
activity but removal of a further carbon atom (C19) results in CI8
compounds with oestrogenic properties. The C21 steroids possess both
mineralocorticoid and glucocorticoid activities and the further small
differences in structure between them determine which of these
predominates. Aldosterone structure is represented as a 1 ip-hydroxy, 18-
aldehyde but in solution the molecule harbours an 11,18-hemiacetal
bridge (Edwards and Hayman, 1991). Cortisol is the major glucocorticoid in
many species including man, but corticosterone is the predominant
glucocorticoid in rat and mouse. Recent studies have shown that two
distinct ll(3-hydroxylase proteins are expressed in the adrenal cortex of
rat (Lauber & Muller, 1989; Matsukawa et al, 1990), mouse (Domalik et al,
1991) and human (Curnow et al, 1991). One of these proteins, found only in
the zona glomerulosa, perform s all steps necessary for the synthesis of
aldosterone. The second protein found in all cortical zones, perform s 11-J3
and 18-hydroxylations but lacks the 18-oxidase activity needed for
aldosterone biosynthesis. Thus, distinct forms of 1 ip-hydroxylase catalyse
the formation of mineralocorticoids and glucocorticoids.
Adrenal steroid hormones are liberated as soon as they are




F>gyrg—L2j. Synthesis of (a) glucocorticoid hormones, (b) mineralocorticoid
hormones, and (c) androgens.
(adapted from R.N. Hardy, 1981)
circulation, both glucocorticoids and mineralocorticoids tend to bind to
plasma proteins; Cortisol and corticosterone combine mainly (89.5%) with
an a-globulin, which is called corticosteroid-binding globulin (CBG) or
transcortin. A further 6.6% is bound to albumin and the remaining 4% is
free. Only 62.6% of aldosterone is bound (41.6 % to albumin, and 21% to
CBG) but the total amounts of aldosterone in the plasma (< 400 pmol/1) are
minute by comparison with total plasma glucocorticoid concentration
(~ 140-700 nmol/1) (Dunn et al, 1981). The half-life of Cortisol is 50-90 min
as opposed to 15-25 min for aldosterone.
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1.1.3. Actions on target tissues
1.1.3.1 Glucocorticoids
The glucocorticoids exert a multiplicity of actions on a wide range
of tissues. They have an important role in the control of carbohydrate, fat,
protein and purine metabolism and influence the function of the
cardiovascular system, skeletal muscle, the central nervous system,
lymphoid, connective and other tissues. They exert an important
"permissive" action and thereby influence the responses of many tissues
to other hormones e.g. catecholamines. They have a powerful anti¬
inflammatory effect and also increase the capacity to withstand almost
any stress, whether it derives from the internal or external environment.
In some species, e.g. sheep but not man, glucocorticoids play a crucial role
in the initiation of parturition. The actions of glucocorticoids briefly
reviewed thereafter are detailed in (Orth et al, 1991).
Effects on metabolism;
Glucocorticoids maintain the reserves of glycogen in the liver by
multiple merchanisms. They activate glycogen synthase by
dephosphorylation and inactivate the glycogen-mobilising enzyme
glycogen phosphorylase. They stimulate breakdown of protein and release
of amino acids from skeletal muscle. They also directly activate key
hepatic gluconeogenic enzymes, such as glucose-6-phosphate and
phosphoenol pyruvate carboxykinase (PEPCK). The PEPCK gene contains
two glucocorticoid responsive elements (GRE) located in its 5'-flanking
region that mediate activation of the transcription of the PEPCK gene by
interaction with the glucocorticoid-receptor (Type II) complex.
Glucocorticoids also exert an anti-insulin effect, inhibiting glucose uptake
and utilisation in peripheral tissues, in part by direct inhibition of
glucose transport into the cells. Other gluconeogenic hormones such as
glucagon and epinephrine, are ineffective without the permissive effect
of glucocorticoids. Glucocorticoids enhance the sensitivity of lipolysis to
catecholamines in target tissues and the glycerol released during lipolysis
provides a substrate for glucose.
Effects on immunological function and inflammatory processes:
Various effects of the glucocorticoids on components of the
immunological and inflammatory responses have been described. One of
the principal glucocorticoid effects on immune cells is on their traffic to
and from the peripheral circulation. The decrease in peripheral
lymphocytes number is due to redistribution of lymphocytes from the
intravascular compartment to the spleen, lymph nodes, thoracic duct, and
bone marrow. Glucocorticoids exert immunosuppressive effects on T cells
in vitro, such as inhibition of proliferation and inhibition of
transcription of the gene for interleukin 2, a potent T cell growth factor.
Glucocorticoids also inhibit the proliferation of B cells and monocytes and
inhibit the phagocytic and cytotoxic function of macrophages.
Glucocorticoids inhibit the mediators of inflammation such as histamine, a
potent vasoactive agent, prostaglandins, and plasminogen activators
which produce active kinins that cause the vasodilatation and increased
capillary permeability characteristic of inflammation.
Effects on musculoskeletal and connective tissues :
Glucocorticoids exert direct effects on bone by inhibiting osteoblast
function, thus decreasing new bone formation, and indirectly by
decreasing intestinal calcium absorption.
Their catabolic effect on muscle protein (mentioned earlier) is the
basis for profound myopathy that sometimes results from glucocorticoids
excess.
Glucocorticoids modulate fibroblasts proliferation and a number of
differentiated functions of fibroblasts. They also suppress synthesis of the
extracellular matrix components, collagen and hyaluronidate. Therefore
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excess glucocorticoids results in impaired wound healing and friable
connective tissues.
Effects on fluid and electrolyte homeostasis :
Evidence of glucocorticoids modulation of blood pressure comes
from patients with glucocorticoid excess, but the basis for the
hypertension in such patients is not clearly understood.
A defect in free water clearance in patients with glucocorticoids
deficiency is associated with increased plasma arginine vasopressin (AVP)
concentrations. Administration of Cortisol, but not aldosterone, restores
water diuresis. Glucocorticoid receptors are present in AVP producing
cells of the parvicellular division of the paraventricular nucleus and
glucocorticoid deficiency increases the AVP mRNA levels in the
paraventricular nucleus but not in the supraoptic or suprachiasmatic
nucleus of the rat.
Glucocorticoids induce increased plasma atrial natriuretic factor
(ANF) levels in intact and adrenalectomised animals. They stimulate
increased ANF mRNA content and increase processing of the ANF(1-126)
precursor into mature ANF(99-126). These effects explain suppression of
natriuresis after adrenal enucleation (=removal of the adrenals, with the
capsule and adherent zona glomerulosa cells left in situ)
Gastrointestinal effects:
Glucocorticoids have direct effect on sodium transport in the colon.
The use of steroids analogues specific for glucocorticoid receptors and of
of mineralocorticoid receptors blockers demonstrated that this is a true
glucocorticoid receptor-mediated effect. Moreover, it has been shown that
in the rat descending colon Na.K-ATPase ai and (3-subunit gene expression
is acutely regulated by dexamethasone but not aldosterone (Fuller &
Verity, 1990).
Developmental effects:
Excess glucocorticoid inhibit linear skeletal growth in children,
presumably due to, at least in part, direct inhibitory effects on bone and
connective tissues as reported earlier.
Pulmonary differentiation is dependent on and is accelerated by
glucocorticoids. Glucocorticoids induce synthesis and release of surfactant
by type II pneumocytes. The effect on surfactant gene transcription
depend on glucocorticoids levels : lower concentrations are stimulatory
but higher levels are inhibitory.
Neural crest cells are precursors of a variety of more differentiated
cell types, including autonomic ganglion cells and adrenomedullary cells.
Under the influence of glucocorticoids, neural crest precursor cells that
invade the embryonic adrenal gland cease to express neuron-specific
gene products, such as neurofilaments, and acquire the characteristic
morphology of adrenomedullary chromaffin cells.
ACTH secretion:
The glucocorticoids strongly inhibit the release of
adrenocorticotrophin hormone (ACTH) from the anterior pituitary. This is
discussed under "control of secretion", section 1.1.4.
1.1.3.2 Mineralocorticoids
Aldosterone is the most potent endogenous mineralocorticoid. It
promotes reabsorption of Na+ and excretion of K+ from urine, sweat, saliva
and gastrointestinal contents. Its most important physiological action is
that which it exerts on the renal tubules, since electrolyte excretion is
normally controlled by this means. Aldosterone acts on the distal
convoluted tubules to promote reabsorption of Na+ in exchange for K+ or
H + , and thereby increases extracellular volume and blood pressure.
Aldosterone acts on the brain in some species to promote salt appetite and
increase blood pressure (McEwen et al, 1986a, De Kloet, 1991).
Specific actions of glucocorticoids and mineralocorticoids in the
central nervous system will be further detailed in Chapter 3 and 4.
1.1.4. Control of secretion
Glucocorticoids
The structure of the adrenal cortex is maintained by ACTH which
also stimulates the synthesis and release of glucocorticoids and androgens.
ACTH interacts with membrane-bound receptors on the adrenocortical
cells that activate adenylate cyclase and increase intracellular cyclic AMP
(cAMP). This, in turn, activates a cAMP-dependent protein kinase (protein
kinase A) that ultimately leads to activation of the first step in adrenal
steroidogenesis: the conversion of cholesterol to pregnenolone. ACTH also
enhances the later steps in steroidogenesis via cAMP and stimulates the
synthesis of i) low-density lipoprotein (LDL) receptor which increases the
uptake of cholesterol, ii) adrenodoxin which is needed for transfer of
reducing equivalents, and iii) sterol carrier protein 2 which is required
for transport of cholesterol from intracellular lipid stores to mitochondria
ACTH secretion is regulated by multiple hormones. Corticotropin-
releasing hormone (CRH-41) and arginine vasopressin (AVP) are
physiologically the most important, but catecholamines, angiotensin II,
serotonin, oxytocin, ANF, cholecystokinin, vasoactive intestinal peptide,
PHI-27 (a gastrointestinal and hypothalamic peptide) and gastrin-
releasing peptide have been implicated (reviewed by Jones & Gillham,
1988). CRH-41 is synthesised by neurons of the parvicellular division of
the hypothalamic paraventricular nucleus (Swanson et al, 1983). Their
axons project to the median eminence, where CRH is secreted in the
hypophyseal portal blood and carried to the pituitary. CRH acts on the
anterior pituitary corticotrope cells by binding to cell surface receptors
and activating adenylate cyclase, thereby increasing intracellular cAMP
levels and activating cAMP-dependent protein kinase A. This results
within a few seconds in secretion of ACTH and subsequently in increased
pro-opiomelanocortin (POMC) gene transcription (Giguere et al, 1982;
Lundblad & Roberts, 1988).
In addition, there are three control and response systems which
may operate simultaneously (Fig.1.3.): 1) an intrinsic circadian rhythm
mediated by the hypothalamus and CRH-41, modified by light and sleep,
and resulting in a fluctuating level of plasma Cortisol (or corticosterone)
with a maximum at about 06.00 h and with a minimum level at 22.00 h in
man; 2) a response to mental and physical stress such as hypoglycaemia,
hypoxia, asphyxia, hypotension, haemorrage, anaesthesia and surgery,
probably also via CRH-41 and ACTH; 3) a feed back loop with modulation of
ACTH secretion by Cortisol or corticosterone (and synthetic
glucocorticoids) at the level of the pituitary, hypothalamus . (PVN) and
higher brain areas (hippocampus). It has been proposed /that negative
- ty'KtCW tjfs V r, o> U.V
feedback of corticosteroids on stress-induced HPA activity is mediated
primarily by GR in the PVN and the anterior pituitary but MR and GR
mediate coordinately the corticosteroid control of the hippocampal
influence on the HPA axis, which is state-dependent, conditional, and
modulatory. In addition, MR may mediate the control of basal activity of
the HPA axis, particularly when glucocorticoids levels are low and occupy
few GR (morning in rat, evening in man)(reviewed by De Kloet, 1991).
STRESS
ORCADIAN FACTORS
Figure 1.3.: Control of glucocorticoid secretion: the hypothalamo-
pituitary-adrenocortical axis. —> : stimulation; —x : inhibition
Mineralocorticoids
The secretion of aldosterone is controlled largely by the renin-
angiotensin system and by potassium. ACTH and other POMC-derived
peptides, sodium ions, and other agents such as AVP, beta-adrenergic
1 0
agents, serotonin, dopamine, ANF and somatostatin are minor modulators
(Quinn & Williams, 1988).
Renin is an enzyme released from the juxtaglomerular cells in the
kidney and cleaves the a 2 globulin angiotensinogen, leaving the
decapeptide angiotensin I. This in turn loses two further amino acids due
to the action of angiotensin converting enzyme (ACE), which occurs
mainly in the lungs. The resulting octapeptide, angiotensin II, is
responsible for stimulating the synthesis and release of aldosterone. The
release of renin is stimulated by many situations but particularly under
circumstances such as a decrease in the filtered load of sodium in the
renal glomerulus and a reduction in pressure in the afferent glomerular
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Figure 1.4. : The renin-angiotensin-aldosterone regulatory system. ACE=
angiotensin converting enzyme. A I, A II & A III: angiotensin I, II & III.
The intracellular mechanism of aldosterone secretion has been
extensively studied. There is a general agreement on the main role of
calcium as mediator of aldosterone secretion. In glomerulosa cells,
characterised by a sustained response to angiotensin II, a general two-
branch model has been proposed: calmodulin and C-kinase. The
calmodulin branch is involved in the initial response and is triggered
through the increase of inositol 1,4,5-triphosphate and endoplasmic
reticulum Ca++ mobilisation which leads to activation of various kinases,
followed by increased aldosterone secretion. The delayed response is
mediated by the C-kinase system: the increase of Ca++ and diacylglycerol
convert the C-kinase into its Ca+ + -sensitive forms with the production of
phosphoproteins leading to increased aldosterone secretion. Other
mechanisms have been proposed for potassium and ACTH: they increase
Ca + + influx or activate the cAMP system without affecting diacylglycerol
or inositol 1,4,5 triphosphate (Rasmussen, 1986).
1.2. Steroid receptors
1.2.1. Introduction
In the classic model, steroid hormones elicit their effects on target
cells after traversing the cell membrane and activating endogenous
intracellular steroid hormones receptors.
These steroid hormone receptors function as hormone-dependent
nuclear transcription factors that modulate cell function by altering the
expression of specific genes or gene networks (Reviewed by Yamamoto,
1985).
In addition to the well-known nuclear actions of intracellular
steroid receptors, direct steroid action on membranes may occur via
membrane receptors. Rapid behavorial responses to short-term exposure
to steroids have been reported, for example short-term exposure of rats to
progesterone is associated with rapid changes in behavior (Schumacher et
al, 1990).
Recently, Orchinik et al (1991) have identified a corticosterone-
specific, high affinity receptor in synaptic membranes from an
amphibian brain. Aldosterone and dexamethasone (a synthetic
glucocorticoid) are poor ligands for this membrane-bound receptor which
appeared to mediate male reproductive behavior.
Wehling et al (1992) described an aldosterone-specific membrane
receptor in human mononuclear leukocytes. In contrast to the cytosolic
mineralocorticoid receptor which does not distinguish between
aldosterone and Cortisol or corticosterone in vitro (see section 1.2.3.),
aldosterone was found to bind to this aldosterone-membrane receptor with
a Kd of 0.15 nM and was not displaced by Cortisol or canrenone (a
mineralocorticoid antagonist) at concentrations of up to 0.1 pM. This
receptor appeared to mediate aldosterone stimulation of the sodium-
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proton-exchanger in human mononuclear leukocytes in vitro, an effect
detected 1 or 2 minutes after the addition of aldosterone.
In this chapter I shall only refer to the intracellular steroid
receptors as they have been extensively studied and they are more likely
to be directly affected by intracellular enzymes which metabolise steroids.
1.2.2. Steroid receptor superfamily
Within the past seven years, the human and rat cDNAs of the major
nuclear steroid receptors have been cloned (reviewed by Green &
Chambon, 1988; Evans, 1988; Berg, 1989; Beato, 1989; O'Malley, 1990; King,
199i.). Comparative analysis of steroid receptor sequences with each other
and with other nuclear receptors led to the identification of a steroid
hormone receptor superfamily which includes the receptors for
glucocorticoid hormone (GR), mineralocorticoid (MR), thyroid (TRa, TRp
and TRy), oestrogens (ER), androgens (AR), progestagens (PR), retinoic
acid (RARa,RARp & RARy), vitamin D3 (VDR). Other superfamily members
have been identified, although their activating ligand is unknown. For
this reason, these superfamily members are referred to as "orphans"
(reviewed by O'Malley, 1990; King, 1991). Orphans includes two ER-related
proteins called ERR1 and ERR2, COUP transcription factor, the nerve
growth factor-induced NGFI-B protein, dioxin receptor, the hepatic
nuclear factor HNF4, the drosophila gene encoded by E75 locus, and the
drosophila gene tailess and certain oncogene products (v-erb A) and c-erb
A identified subsequently as a thyroid hormone receptor (Weinberger et
al, 1986; Sap et al, 1986).
Steroid hormone mediated transcriptional regulation involves five
main reactions requiring different functional domains of the steroid
receptor:
1) steroid hormone binding to its receptor and transforming it from
an inactive to an active state. This involves dissociation of the receptor
from the inhibitory protein Hsp90. 2) dimerisation of the receptor which
is essential for efficient DNA-binding activity 3) transfer of the hormone-
receptor complex from the cytoplasm to the nucleus (at least for the
glucocorticoid receptor) 4) specific binding of the hormone-receptor
complex to short DNA sequences called steroid response elements (SRE),
found usually in the 5'-regulatory region of target genes 5) interaction
with the transcription machinery which activates or represses basal
transcription of genes containing SREs.
1.2.2.1. Functional domains of steroid receptors
Proteolytic digestion, mutational analysis and construction of
chimaeric receptors have revealed a clear-cut domain structure shared by
every member of the steroid receptor superfamily (reviewed by Green &
Chambon, 1988; Evans, 1988; Berg, 1989; Beato, 1989; O'Malley, 1990; King,
199<t). Sequence comparison has revealed a N-terminal region which is
highly variable among species with respect to both sequence and length,
a highly conserved DNA-binding domain and a C-terminal ligand-binding
domain. The non-conserved N-terminal region corresponds to the major
immunoreactive epitope of the glucocorticoid receptor (Carlstedt-Duke et
al, 1982). The DNA-binding and ligand-binding domains appear to form
independent structural and functional entities. Throughout all the steroid
receptors these two domains, in particular the DNA-binding domain, share
maximal sequence homology (Fig. 1.5).
In response to hormone binding, the ligand-binding domain (or
region E) affect all aspects of receptor activity. This includes receptor
dimerisation, nuclear localisation, DNA-binding and transcriptional
activation.
Overlapping hydrophobic segments within region E promote
dimerisation and steroid binding activity by forming a hydrophobic
pocket within which one molecule of steroid hormone is proposed to bind.
Two nuclear localisation signals have been defined for the GR (Picard and
Yamamoto, 1987) one of them is encoded in the ligand binding domain and
the other in the hinge region, and both signals would direct the hormone-
receptor complex to the nucleus.
Transcriptional activation domains of the steroid receptors are
located both in the ligand binding domain and in the N-terminal region of
the molecule. Activation of transcription may involve interaction of the
DNA-bound hormone-receptor complex with a component of the
transcriptional machinery and initiation or stabilisation of the formation
of a transcription initiation complex (Hollenberg & Evans, 1988).
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Figure 1.5. Schematic amino acid comparison of members of the steroid
hormone receptor superfamily. Primary amino acid sequences have been
aligned on the basis of the regions of maximum amino acid similarity, with
the percentage amino acid identity indicated for each region in relation to
the GR. The amino acid position for each domain boundary is shown. Amino
acid numbers for all receptors represent the human forms with the
exception of v-erb-A and E75.
(adapted from Evans, 1988)
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Another possibility is that steroid receptors displace nucleosomes
thus allowing transcription factor recognition of previously inaccessible
DNA sites (Richard-Foy & Hager, 1987; Cordingley et al, 1987)
The DNA-binding domain (also called region C) is sufficient for
specific DNA binding in vitro and in vivo, although high affinity DNA
binding requires additional information encoded within N- and C-terminal
sequences (Danielsen et al, 1987). Region C is highly basic and contains a
number of conserved cysteine residues, eight of which are involved in
forming two zinc fingers (Evans & Hollenberg, 1988; Frankel & Pabo,
1988). Zinc fingers were first described in Xenopus laevis transcription
factor TFIIIA in which a pattern of two conserved cysteines and two
histidines residues are coordinated to a zinc atom (Miller et al, 1985; Lee et
al, 1989). In the case of the glucocorticoid receptor each zinc finger
consists of two pairs of cysteines co-ordinated to a zinc atom (Hard et al,
1990). Two copies of the zinc finger motif are present in the DNA-binding
domain and the zinc ion present in each finger is essential for DNA-
binding activity (Fig. 1.6). The N-terminal zinc finger is involved in
sequence-specific contacts; two amino acids, located at the beginning of
the a helix which directly interacts with DNA, have been shown to be
critical in determining specificity of GR versus ER (Mader et al, 1989;
Danielsen et al, 1989). Mutational analysis in the second finger indicates
that this region is also required for efficient DNA-binding (Danielsen et
al, 1987; Hollenberg et al, 1987). In addition, there are evidence that for TR,
which can bind both an ERE and a TRE, the second zinc finger is involved
in discriminating between half site spacing of the SRE (Umesono & Evans,
1989).
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Figure 1.6. : Model of the dimeric complex between the GR DNA-binding
domain and the GRE. The residues essential for discrimination between
GRE and ERE as well as two AT base pairs in the center of each of the GRE-
half site, indicating the differences between this GRE and the consensus
ERE sequences, are coloured in red. Residues important for protein-
protein interactions are coloured in green, (from Hard et al, 1990)
1.2.2.2. Steroid response elements
Many steroid hormone responsive genes have been cloned. Gene-
transfer experiment and comparative analysis of hormone responsive
genes has allowed identification of consensus sequences for steroid
response elements (Martinez & Wahli, 1991). They can be divided into two
groups: a) responses to glucocorticoids, progesterone, androgens and
mineralocorticoids are mediated by a single element (AGAACANNNTGTTCT)
and, GR, PR, AR, and MR all encode the "Gly-Ser" pair of specificity amino
acids; b) responses to oestrogens, thyroid hormones, retinoic acid and
vitamin D3
are mediated by ERE-like sequences that have in common the "Glu-Gly"
pair of specificity amino acid.
This promiscuous DNA-binding behaviour observed amongst
members of the steroid hormone receptor superfamily contrasts with the
hormone-specific activation of genes in specialised cell types. This could
be explained, in part, by the differential ability of steroid receptors to
recognise distinct features of a common response element. For example,
PR and GR binding to a GRE is very similar but mutations in the MMTV GRE
differentially affect induction by progesterone or glucocorticoid (von der
Ahe et al, 1986; Chalepakis et al, 1988). Also, it is becoming clear that
steroid receptors contain promoter-specific and cell-type specific
transcriptional activation domains that restrict the transcriptional
activity of certain steroid receptors to particular promoters and cell types
(Tora et al, 1989).
In addition, there is increasing evidence which suggests that the
affinity of a particular steroid receptor for its response element can be
modulated by accessory proteins (reviewed by Hager & Archer, 1991).
1.2.3. Corticosteroid receptors: how many types?
A second order of promiscuous behaviour has been observed
between MR and GR. MR have been shown to bind and be transformed by
both aldosterone and glucocorticoids in vitro (Krozowski and Funder,
1983). In vivo, MR bind to aldosterone in tissues such as kidney, parotid
and colon, but Cortisol (or corticosterone) is the physiological ligand to
MR in hippocampus and heart. Cloning of human GR (Hollenberg et al,
1985) and MR (Arriza et al, 1987) cDNAs has demostrated that the two
receptors are highly homologous; human MR and GR have 57% identity in
the steroid-binding domain and 94% sequence identity in the DNA-binding
domain (respectively, 59% and 76% for rat MR and GR). Furthermore,
isolation of a rat MR cDNA from a brain cDNA library offered the
possibility of demonstrating that the renal MR which bind aldosterone in
vivo are identical at least at the level of the mRNA, to the brain MR which
bind corticosterone in vivo (Arriza et al, 1988; Patel et al, 1989).
The hormone binding specificity of human MR has been
investigated by Arriza et al (1988) in CV1 cells which lack endogenous
steroid receptors. In these experiments an expression vector encoding the
human MR (trans-vector) is co-transfected into cells with a reporter
vector (cis-vector) as shown in figure 1.7.
Figure 1.7. The co-transfection assay
T rans-vector
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The reporter gene is a chimaera of two components: a regulatory
region from a gene known to be sensitive to glucocorticoids (GRE from
Mouse mammary tumour virus = MMTV) linked to the coding region of a
gene whose expression can be easily measured (CAT=bacterial
chloramphenicol acetyl transferase). MMTV promoter was chosen because
a) the DNA-binding domain of the MR and the GR were found to be nearly
identical (94% homology) and were therefore likely to have identical DNA
binding specificity; and b) to date no mineralocorticoid sensitive gene has
clearly been demonstrated. Glucocorticoids (Cortisol and corticosterone)
were found to be effective in activating both MR and GR, and,
surprisingly, activated MR at a ten-fold lower concentration than GR (Kj :
5 nM versus 0.5 nM). The MR was thus found to have little intrinsic ability
to discriminate between mineralocorticoids and glucocorticoids.
Therefore, the questions posed were: what is the physiological role of MR
as a high affinity glucocorticoid receptor in vivo; and what is the nature
of the factor(s) conferring aldosterone selectivity upon MR in kidney and
other epithelial tissues, despite the 100-fold higher concentrations of
competitive circulating glucocorticoids?
In an attempt to answer the first question, Arriza et al (1988),
prompted by the finding that GR and MR act through common responsive
elements, speculated that MR could provide a high-sensitivity, low
response function to glucocorticoids, while the GR would act with low
sensitivity but high response. This is particularly relevant to cells in
which the MR and the GR are coexpressed such as hippocampal neurons
(Evans & Arriza, 1989).
The factor which confers in vivo aldosterone selectivity on renal
MR was originally thought to be CBG. CBG sequesters glucocorticoids and,
because of its differential tissue distribution, could influence local
glucocorticoid concentration. High levels of CBG in kidney would reduce
available glucocorticoids from plasma, conferring aldosterone selectivity,
whereas levels of CBG in the hippocampus would suggest that
glucocorticoids may be the predominant ligand for MR (Funder and
Sheppard, 1987). This model was abandoned when it was discovered that
10-day-old rats lack CBG but still show aldosterone selectivity in kidney MR
(Sheppard & Funder, 1987).
Relatively recent studies from two groups, our group in Edinburgh
and John Funder's team in Melbourne, demonstrated that
mineralocorticoid-specific actions of MR are determined, at least in part,
by a steroid modifying enzyme 1 ip-hydroxysteroid dehydrogenase (llp-
OHSD) (Edwards et al, 1988; Funder et al, 1988). ll(3-OHSD metabolises
glucocorticoids to forms which do not bind to the MR, thus allowing
aldosterone, which is not a substrate for the enzyme by virtue of its 11-18




1.3.1. Background and historical aspects
After secretion, glucocorticoids are actively metabolised in the liver
and a variety of other tissues. Figure 1.8 depicts the principal pathways of
Cortisol metabolism in man. One of the transformations Cortisol undergoes
is its conversion to cortisone (corticosterone to 11-dehydrocorticosterone
in rat), by oxidation of the hydroxyl group in position 11, to a keto group.
This step is important in that glucocorticoids possessing a hydroxyl group
at Ci i are active whilst those with a keto group are inactive. The first
studies on cortisol-cortisone conversion were done in the 1950s, where
labelled Cortisol (Hellman et al, 1954; Migeon et al, 1956; Peterson et al,
1955) or cortisone (Burnstein et al, 1953; Burton et al, 1953) was
administrated to volunteers and the various metabolites produced were
identified. It was found that conversion of Cortisol to cortisone was
reversible and mediated by the enzyme 1 ip-hydroxysteroid dehydrogenase
(ll(3-OHSD). In 1960, Osinsky described ll(3-OHSD activity in homogenates of
human placenta and showed that the enzyme required NADP+ or NADPH,
depending upon the direction of the reaction.
Between 1960 and 1985, other in vitro studies demonstrated the
presence of 11J3-OHSD activity in homogenates and subcellular fraction of
%
lung (Koerner, 1966; Murphy ., 1981; Nicholas , 1982; Abramovitz et
al, 1982 & 1984), kidney (Ganis et al, 1956; Murphy, 1981), liver (Amelung
et al, 1953; Bush et al, 1968; Hurlock & Talalay, 1959, Koerner & Hellman,
1964), intestine (Burton et al, 1953), gonads (Koerner, 1966; Murphy, 1981),
uterus (Murphy , 1977, 1981), skeletal muscle (Murphy, 1981), and
brain (Peterson et al, 1965, Grosser, 1966).
However it was only in the late 1980s that the crucial role of the
enzyme was discovered after observations of congenital and acquired llfi-
deficiency in man.
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1.3.2. 11 (3-dehydrogenase deficiency : syndrome of apparent
mineralocorticoid excess and liquorice-induced hypertension
The syndrome of apparent mineralocorticoid excess is a rare but
often fatal cause of mineralocorticoid hypertension. Worldwide only 21
children and one adult have been reported (Sdiackleton & Stewart, 1990).
The clinical picture is of severe hypertension with suppression of the
renin-angiotensin-aldosterone axis and hypokalemia. It was in the late
tt '
1970s that Ulick (1979) first documented a defect in the peripheral
metabolism of Cortisol to cortisone, as evidenced by marked elevation of
the ratio of the urinary steroid metabolites tetrahydrocortisol (5(3-THF) +
allo-tetrahydrocortisol (5a-THF) to tetrahydrocortisone (THE) (see Fig.
1.8.). This impaired conversion was confirmed by giving lla-^H-cortisol.
When one mole of this steroid is converted to cortisone, one mole of ^H-
H2O is produced. Patients with this syndrome produce virtually no ^H-H20.
For several years the mineralocorticoid responsible for this
condition was unknown. Numerous bioassays on plasma and urine from
such patients failed to detect increased mineralocorticoid activity and
hence the term syndrome of "apparent mineralocorticoid excess" (AME)
was coined. In 1983, Oberfield et al documented sodium retention,
potassium loss and hypertension, all suggesting marked mineralocorticoid
excess, following ACTH and Cortisol infusion in their AME patient. This
effect of Cortisol appeared to be mediated by mineralocorticoid receptors
since administration of spironolactone, an aldosterone antagonist, resulted
in reduction of blood pressure, natriuresis and antikaliuresis, and
replacement of Cortisol by the pure glucocorticoid dexamethasone, which
bind to GR rather than MR, produced a marked natriuresis, potassium
retention and recovery of the renin-angiotensin-aldosterone system.
Oberfield et al (1983) postulated an abnormality in the MR, recognising
Cortisol as a mineralocorticoid. Stewart et al (1988) in Edinburgh suggested
that renal 11)3-dehydrogenase was an important physiological mechanism,
protecting exposure of the kidney MR to Cortisol by shuttling it to the
inactive steroid cortisone. Failure of this mechanism in AME results in the
kidney seeing Cortisol as a potent mineralocorticoid. This mechanism is
illustrated in Figure 1.9.
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Figure 1.8. Major pathways of Cortisol metabolism. The broad arrow indicates
a shift of metabolism towards Cortisol in the syndrome of apparent
mineralocorticoid excess. DH= Dihydro; TH=tetrahydro.















Figure 1.9. Enzyme mediated receptor protection
(illustration by Brian Walker)
This mechanism was demonstrated by observing the effects of
inhibiting the conversion of Cortisol to cortisone in vivo.
It had been recognised for many years that ingestion of liquorice can
produce a mineralocorticoid excess syndrome. This was thought to be due
to the binding of the active component of liquorice (glycyrrhizic acid = GI
or its hydrolytic product glycyrrhetinic acid = GE) to the mineralocorticoid
receptor. The affinity however is very low, (10~4 that of aldosterone) and
the circulating levels in patients on liquorice are much lower than would
be required to activate the receptor. In addition, liquorice does not
produce sodium retention in the absence of functioning adrenal tissue
(see Stewart & Edwards, 1991 for review). This led Stewart et al to examine
the possibility that liquorice acts by inhibiting ll(3-OHSD. Their studies in
normal volunteers confirmed that the sodium retention produced by
liquorice is indeed associated with a significant change in Cortisol
metabolism indicating inhibition of ll(3-OHSD (Stewart et al, 1987). Animal
experiments performed in parallel with these studies in man have
confirmed that GI and GE inhibit renal 118-OHSD both in vivo and in vitro
b o
(Monder et al, 1989). In vitro a Kj of 10"y M for GE was observed, indicating
potent inhibition. Furthermore, animal studies also show that
carbenoxolone (the hemisuccinate derivative of GE) potentiates the
mineralocorticoid effect of corticosterone, for example sodium transport
in toad bladder (Gaeggeler et al, 1989; Brem et al, 1989) and in rat (Sou.ness
& Morris, 1989). However, carbenoxolone may also inhibit 5p-reductase as
well as lip-OHSD (Latif et al, 1990), placing limitations on interpreting the
effects of carbenoxolone as being solely related to altered glucocorticoid
metabolism (Monder, 1991a).
1.3.3. Purification, production of antibodies and cloning of lip-OHSD
1.3.3.1. Purification of rat liver 11 ^-dehydrogenase
A long-running debate about lip-OHSD enzyme is whether the 11 p-
dehydrogenase and the 11 p-reductase are two separate enzymes,
components of an 1 lp-hydroxysteroid dehydrogenase complex, or a single
multifunctional enzyme that contains both dehydrogenase and reductase
activities. To determine which, if any, of these hypotheses is correct,
tmo
La.kshmi and Monder, in New York, undertook the purification of lip-
OHSD. They were successful in purifying the lip-dehydrogenase
component of the complex but the purified enzyme was devoid of 11 p -
reductase activity (Lakshmi & Monder, 1988). They therefore proposed that
the lip-dehydrogenase and the 1 ip-reductase were structurally two
independent units. This was supported by the finding that AME patients
are deficient in 1 ip-dehydrogenase activity but they convert cortisone to
Cortisol normally.
Purification of the rat liver lip-dehydrogenase was achieved in a
single step from detergent solubilised extracts of rat liver microsomes,
after absorbing the enzyme on a NADP-sepharose affinity column. The
molecular weight of monomers of the enzyme is 34 kD and the enzyme is a
glycoprotein.
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1.3.3.2. Production of antisera
Polyclonal antibodies were generated against the purified enzyme
in rabbits. The antibodies were immunoprecipitins but 1 ^-dehydrogenase
activity was not completely suppressed in the antigen-antibody complex,
suggesting that the epitopic regions did not include the active site. Two
antibody preparations, 56-125 and 56-126, used to detect 11 p -
dehydrogenase antigen in Western blots, generated different staining
patterns for kidney, liver, brain, testis and heart. Using the two antibodies
together, the total number of antibody-reacting components in kidney
was three, and that in liver was two. In brain a shorter species of 26 kD
was detected and in testis a 47 kD was found in addition of the 34 kD species
present in every tissues and corresponding to the purified enzyme. These
were the first data indicating that the enzyme may occur in several forms,
and that the distribution of these forms is to some extent tissue-specific
(Monder & Lakshmi, 1990).
Castello et al, (1989), in an independent study, generated a mouse
anti-lip-OHSD monoclonal antibody from rat microsomal proteins. They
detected a single 35 kD species on immunoblots of kidney. Interestingly,
this antibody bound both oxidative and reductive llJi-OHSD enzymatic
activities, as detected by capture of the antigen (solubilised renal
microsomal proteins) by the anti-1 lp-OHSD antibody followed by
incubation of this complex with 3 H-corticosterone or 3H-11-
dehydrocorticosterone and measurement by HPLC of the 3H-metabolites
formed.
1.3.3.3. Cloning of cDNAs
Agarwal and coworkers (1989), in New York, isolated a rat liver
cDNA clone encoding lip-OHSD by screening a lambda expression library
with the antibodies raised against 1 lp-dehydrogenase. Sequencing of a
1265 bp insert revealed an 861 bp open reading frame predicting a
polypeptide of 287 amino acids with a molecular weight of 31.8 kD. The
difference between this value and the previously reported 34 kD
molecular weight of the enzyme was attributed to oligosaccharide residues,
as the enzyme is a glycoprotein, which was confirmed by the finding that
two potential "Asn-X-Ser" N-glycosylation sites were located at residues
158-160 and 203-205. The cDNA was expressed in Chinese hamster ovary
cells by transfection of a recombinant plasmid containing the ll|3-OHSD
cDNA driven by the SV40 promoter. It was found that both 11(3-
dehydrogenase and 11 (3-reductase activities were encoded by this cDNA.
Nevertheless, these activities were expressed at levels that were too low to
perform kinetics or physico-chemical studies, so that it was not clear if
the reductase activity of this enzyme was physiologically significant. To
address this problem the cDNA was then expressed in osteosarcoma cells
infected with recombinant vaccinia virus which permit expression of
relatively high levels of the enzyme (Agarwal et al, 1990). This study
confirmed that the recombinant enzyme contained both oxidising and
reducing capabilities. Its enzymatic properties were similar to those found
in rat liver homogenates: molecular weight, sugar content, optimum pH
and kinetics constants were comparable; 1 l|5-reductase is quite labile but
can be stabilised if accumulation of NADP+ is prevented; GE is a potent
inhibitor of 11|5-dehydrogenase but inhibits 1 1(3-reductase poorly.
Interestingly, 11(5-dehydrogenase activity of cells treated with 50 ng/ml of
Al-tunicamycin was decreased by 50% compared with that of untreated
cells but 11(3-reductase was not affected by the treatment. These data
suggest that glycosylation is important for 11 (3-dehydrogenase activity.
This rat liver cDNA was also used as a probe to investigate the
distribution of ll|3-(j)HSD mRNA in various tissues (Agarwal et al, 1989;
Moisan et al, 1990a; Krozowski et al, 1990; Whorwood et al, 1991). A single
species of approximately 1700 nucleotides was found in most tissues but
kidney contains at least 3 other species (1900 nt, 1600 nt, 1500 nt) and
colon contains a large species of 3.4 kb. These data provided another piece
of evidence for the existence of multiple ll(3-OHSD isoforms. This will be
reviewed in detail in Chapter 5.
Tannin et al (1991) isolated a human ll(3-OHSD cDNA clone from a
testis library by hybridisation with the rat liver cDNA. The open reading
frame of this cDNA is of 876 bp, which predicts a protein of 292 amino
acids. The sequence is 77% identical at the amino acid level to the rat cDNA.
Surprisingly, only a single mRNA species was detected in human kidney
using this cDNA as a probe.
The availibility of human cDNA allowed localisation of the ll(3-OHSD
gene to chromosome 1. This ll|3-OHSD gene was then isolated from a
chromosome 1-specific human genomic library using the human cDNA as
a probe (Tannin et al, 1991). Human lip-OHSD gene consists of 6 exons and
is at least 9 kb long. Cloning of the rat homologue of this gene is presented
in Chapter 5.
Very recently variant cDNA clones were isolated from a rat kidney
library. In particular, a 5' truncated cDNA clone present only in kidney
was identified. The missing fragment (26 amino acids) encodes for a
hydrophobic peptide which could be a signal sequence for membrane
insertion (Krozowski et al, 1992). Thus the deletion of the leader sequence
from the microsomal lip-OHSD protein may result in a nuclear localisation
of the kidney-specific lip-OHSD form. Our study on the rat gene shows that
these two mRNAs are generated from a single gene by differential
promoter usage (Chapter 5). In addition they showed the presence of three
alternate sites of polyadenylation which contributes to the differences in
mRNA sizes detected on Northern blot of kidney.
Finally, an lip-OHSD cDNA was cloned from a sheep liver cDNA
library using the rat liver cDNA as a probe. 72% sequence identity was
found between this cDNA and the rat liver cDNA (Yang et al, 1991).
1.3.4. lip-hydroxysteroid dehydrogenase : tissue-specific protector of the
mineralocorticoid receptor
1.3.4.1. Original studies
The role of lip-OHSD as a factor conferring aldosterone specificity
was demonstrated experimentally by studies carried on in our laboratory
(Edwards et al, 1988) and in Melbourne (Funder et al, 1988). The two studies
led to the same conclusions and they will be presented in parallel.
The first step was to show that lip-OHSD is selectively expressed in
aldosterone target tissues but not in other organs containing MR. For this,
conversion of 3H-cortisol to 3H-cortisone by rat tissues minces (Funder et
al, 1988) or conversion of 3 H-corticosterone to 3 H - 1 1 -
dehydrocorticosterone (Edwards et al, 1988) in rat tissue homogenates was
analysed. lip-OHSD activity, estimated as the percentage conversion of 3H-
cortisol to 3H-cortisone (or 3H-corticosterone), was highest in kidney,
next highest in parotid, and lowest but still significant in colon: all three
tissues being classical mineralocorticoid target tissues. Under the
conditions of the study, no discernible activity was found in hippocampus
and heart, which both contains high levels of MR but are not selective for
aldosterone (Fig. 1.10. A). Enzyme activity was higher in the distal than in
the proximal tubules of the kidney. However, localisation of the enzyme by
immunohistochemistry, using an antibody raised against a purified
hepatic lip-OHSD (see section 1.3.3.), showed that the enzyme was
principally in the proximal tubules. Edwards et al then suggested that the
enzyme was acting as a paracrine protector of the MR which are mainly
present in distal convoluted tubules and cortical collecting ducts. This is
no longer the prevailing model as will be discussed later.
Funder et al looked at the effect of in vivo carbenoxolone treatment
on in vitro conversion of 3H-cortisol to 3H-cortisone and found that
treatment with carbenoxolone (an 11J3-OHSD blocker, similar in structure
to GE) was followed by a substantial reduction in enzyme activity in
aldosterone target tissues (Fig. 1.10.B).
Finally, both teams compared the binding of aldosterone and
corticosterone in the absence or presence of an lip-OHSD inhibitor
(carbenoxolone or GI). Funder et al did receptor binding analysis on
cytosolic preparations of kidney, parotid, colon, hippocampus and heart.
They found that in the presence of carbenoxolone the level of
corticosterone binding markedly increased and approaches if not equals
that of aldosterone whereas no differences were observed in hippocampus
or heart after treatment (Fig. 1.11). Edwards' et al approach was to compare
the uptake of 3 H-corticosterone in kidney, with and without GI
pretreatment of the animals. The binding of the labelled steroid was
detected by autoradiography and is presented in Fig. 1.12. The uptake of
3H-corticosterone in untreated animals is very low and not really
different from the non-specific binding control; in contrast, after
inhibition of 11J3-OHSD by GI, the pattern of 3H-corticosterone binding was
greatly changed and was now similar to that of aldosterone.
These latter experiments clearly demonstrated that glucocorticoids
gain access to renal MR when the enzyme is inhibited in vivo, strongly
supporting that the role of the enzyme in a normal situation is to prevent
glucocorticoid occupancy of MR and thereby to confer aldosterone
specificity in the tissue where it is expressed. This model fits with the
tissue-specific and non-intrinsic specificity of the MR for aldosterone.
The enzyme is present and active in 10-day-old rats (Funder et al, 1988)
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Analysis of in vitro conversion of [3H] Cortisol (F) to [-^H]
cortisone (E) by 9-day-old rat tissue minces by H.P.L.C.
(B) Analysis of the effect of in vivo carbonexolonc treatment
on in vitro conversion of [3H] Cortisol (F) to [3H] cortisone (E)
by 9-day-old rat tissue minces by H.P.L.C.
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Figure 1.11. . .
MR (type I sites) binding of adrenal steroids in vivo in 9-
day-old adrenalectomised rats; uptake and retention of [3H]
aldosterone ([3H] Aldo) and [3H] corticosterone ([3H] B), and
effect of treatment with carbonexolone (CBX).
(adapted from Funder et al, 1988)
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Figure 1.12. : Autoradiographs of rat kidney sections showing binding of 3H-
corticosterone. In (a) the label alone was given in vivo. In (b) the
rat was given glycyrrhizic acid followed by the labelled steroid c)
the same protocol was followed as in (b) with the addition of a large
dose of unlabelled aldosterone.
(adapted from Edwards & Hayman, 1991)
Another important result provided by Funder et al, in this study,
was to show that 11-dehydrocorticosterone, the product of the reaction
catalysed by lip-OHSD, has very low affinity for MR and therefore does not
compete with aldosterone.
1.3.4.2. Further studies of llf-OHSD in kidney
Kidney has been and is still, by far, the most investigated tissue to
define lip-OHSD function as a factor conferring mineralocorticoid
specificity. Localisation of lip-OHSD activity, immunoreactivity and mRNA
have been examined in order to connect the functional relationships with
the anatomical locations of lip-OHSD and MR.
The first approach used to localise the enzyme was by
immunohistochemistry. As reported in section 1.3.3.1, Lakshmi and
Monder had purified the hepatic 1 ip-dehydrogenase and raised antibodies
against this enzyme. These antisera were used first by Edwards and
coworkers (1988) who detected the enzyme mainly in the proximal tubules
and not in the distal nephron. Immunostaining was also present either in
or immediately adjacent to the vasa recta alongside the papillary
collecting tubules. In a separate study, Castello et al (1989) raised a
monoclonal antibody against rat renal lip-OHSD from solubilised
microsomal proteins. Immunohistochemistry using this monoclonal
antibody showed intense staining in proximal tubule cells and peritubular
interstitial cells, confirming Edwards' et al data. Rundle et al (1989) also
used the antisera raised by Lakshmi and Monder to explore the anatomical
relationship of lip-OHSD and the MR. Again they found lip-OHSD in the
proximal tubules whereas MR were located in distal convoluted tubules,
connected pieces and initial cortical collecting tubules.
All these studies showed that lip-OHSD and MR are not colocalised
and led the authors to the conclusion that the action of lip-OHSD in the
kidney was paracrine rather than autocrine. However, there are problems
with this idea since the physical distance between the proximal lip-OHSD
and the distal MR is great, and since lip-OHSD activity was found both in
proximal and distal tubules of the kidney (Edwards et al, 1988).
In 1990, Bonvalet and coworkers, in Paris, reported that the
distribution of lip-OHSD activity along the rabbit nephron corresponds to
the renal mineralocorticoid target sites. They examined the conversion of
3H-corticosterone to 3 H-11-dehydrocorticosterone in microdissected
tubular segments. They found a very high activity of the enzyme in
cortical collecting tubules, the cortical part of the thick ascending limb
and in the medullary collecting tubules from the outer medulla. Low levels
of activity were detected in proximal tubules. In a later study from the
same group, this distribution was confirmed in the mouse nephron
(Kenouch et al, 1991). These important findings were further
substantiated by the study of Naray-Fejes-T6th and coworkers (1991), who
used freshly isolated rabbit cortical collecting duct cells or primary
culture of cortical collecting duct cells grown as monolayers on permeable
supports, to examine the metabolism of corticosterone. They found that
both cell preparations rapidly converted 3H-corticosterone to 3H-11-
dehydrocorticosterone, which was the only metabolite detected. However
the apparent Km value of lip-OHSD for corticosterone was ~ 60 nM, 100-fold
lower than the Km of lip-OHSD for corticosterone in the rat liver. Neither
freshly isolated nor cultured collecting duct cells converted 3H-11-
dehydrocorticosterone back to 3H-corticosterone. Taken together these
data provide functional evidence for lip-OHSD activity in renal
aldosterone target cells and suggest an autocrine mechanism for enzyme-
mediated receptor protection. These findings also indicate that this
enzyme might be a collecting duct-specific isoform of lip-OHSD given the
different Km value; this could also explain the discrepancy between these
data and the immunohistochemical studies.
Another method to localise the enzyme in the kidney was the
utilisation of the cDNA in in situ hybridisation studies. 32P or 35S labelled
antisense cRNA probes were synthesised from lip-OHSD cDNA (see section
2.2.3.) and hybridised to rat renal section under stringent conditions.
Macroscopically, as shown on the in situ hybridisation performed by
myself (Fig. 1.13), lip-OHSD mRNA expression was highest in the juxta
medullary cortex-outer medulla with lower expression in the outer cortex
and inner medulla, closely resembling the pattern of aldosterone binding
in vivo. Microscopic analysis demonstrated lip-OHSD mRNA expression in
all tubular regions, with high expression in proximal and distal tubular
epithelia, including the connecting tubule and cortical collecting duct
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(Yau et al, 1991). In a separate study, Stewart et al (1991) reported similar
results. These findings reconciled all the previous studies showing the
presence of lip-OHSD in both proximal and distal tubules of the kidney.
Clearly several isoforms of the enzyme are present in this organ: they
should be closely related since the cDNA hybridises to every form, but
sufficiently different for the antibodies to recognise only the isoform
Figure 1.13. : Autoradiogram of a rat kidney section hybridised with
a 35S-labelled cRNA antisense probe.
A
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restricted to the proximal tubules. In parallel with these in situ
hybridisation studies, Krozowski et al (1990) have shown that
hybridisation of the llp-OHSD cDNA to Northern blots of kidney total RNA
revealed at least four lip-OHSD mRNA species that are not explained by
differences in polyadenylation signal. Recently, the same group reported
the isolation of variant llp-OHSD cDNA clones from a rat kidney library,
which will probably provide more information about the lip-OHSD kidney
isoforms (Krozowski et al, 1992). This group also reported that the distal
tubular lip-OHSD isoform is NAD+-dependent, whereas the previously
reported hepatic and proximal tubule-specific species is NADP+-dependent
(Mercer & Krozowski, 1992). For this, they used a histochemical technique
which links steroid metabolism with the production of a colour reaction.
11-hydroxyandrostenedione was used as a substrate and its
dehydrogenation is followed in kidney sections by the production of a
diformazan derivative of nitroblue tetrazolium following reduction of
NAD + to NADH. Under these conditions activity was seen only in distal
tubules and only when NAD+ was the cofactor. However, no activity was
detected by this method when physiological glucocorticoids
(corticosterone or Cortisol) were used as substrates, in either proximal or
distal tubules even when cofactor was appropriate. The authors
interpretation of this is that the 20 reductase enzyme uses the reduced
cofactor at the expense of the color reaction, but no evidence for this was
provided.
In conclusion, it is clear that several lip-OHSD species are present
in different part of the kidney. There is undoubtly a high 11 p -
dehydrogenase activity in the renal aldosterone target cells, which
strongly supports the hypothesis that lip-OHSD plays a crucial role in
aldosterone specificity of renal MR in a autocrine fashion. What remains
to be clarified is the structural (and maybe functional) differences
between proximal and distal lip-OHSD. A lot of information on this subject
will hopefully be deduced from the cloning of a new renal cDNA
(Krozowski et al, 1992) and from our cloning of the rat gene (Chapter 5).
1.3.5. 1 lp-hydroxysteroid dehydrogenase : modulator of glucocorticoid -
glucocorticoid receptor interaction.
Initially it was thought that llp-OHSD was present only in
aldosterone target tissues and that the non-selectivity of the MR in heart
and hippocampus could be explained by a lack of this enzyme in these
tissues. Indeed lip-OHSD bioactivity was detected only in aldosterone target
tissues in earliest studies (Edwards et al, 1988; Funder et al, 1988). However
the enzyme has long been known to be present in tissues which are not
thought to be aldosterone targets or to contain MR, many of which have a
high concentration of GR. Such tissues include liver, lung, skin, testis,
mammary gland, ovary, proximal and distal tubules, pituitary and
placenta.
Skin
The association of lip-OHSD with the GR raises the possibility that
lip-OHSD modulates access of Cortisol to this receptor. Teelucksingh and
co-workers (1990) from our laboratory, examined this possibility in the
skin. Cutaneous vasoconstriction has been shown to be a GR-mediated
response (Marks et al, 1982). When hydrocortisone was applied to the
forearm of volunteers overnight under an occlusive dressing, there was
minimal vasoconstriction. However, when GE (an lip-OHSD blocker),
which alone has no effect, was added to the preparation there was a
marked potentiation of the response. Furthermore, these authors showed
by immunohistochemistry and by in vitro enzymology that llp-OHSD is
present in the skin. These data have offered an explanation for the anti¬
inflammatory properties of topical GE (Adamson & Tillman, 1955) and
carbenoxolone (Csonka & Murray, 1971).
Vascular smooth muscle and heart
Corticosteroid hormones play an important role in the control of
blood pressure but the mechanisms involved are unknown. The presence
of MR and GR in vascular smooth muscle (Meyer & Nicholls, 1981; Kornel3
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et al, 1982) and in heart (Arriza et al, 1987; Barnett . :... 1988; Funder et al,
1973) provides evidence of direct action of corticosteroids on the arterial
wall. lip-OHSD activity has been reported in these tissues (Kornel et al,
1982; Kolanowski et al, 1981; Funder et al, 1989) and lip-OHSD mRNA has
been localised in the cytoplasm of vascular and cardiac smooth muscle but
not in endothelium (Walker et al, 1991). Thus lip-OHSD is appropriately
sited to modulate access of glucocorticoids to vascular receptors and could
influence vascular resistance (as they do in the skin), cardiac output and
thereby blood pressure.
Testis
High levels of lip-OHSD were also found in testis. It is known that
Cortisol inhibits testosterone production, testicular metabolism and sperm
formation through GR-mediated processes (Bambino & Hseuh, 1981, Welsh
et al, 1982). The inhibitory effects of Cortisol on the synthesis of
testosterone is determined by the availability of active steroids derived
from the circulation. In the rat testis, lip-OHSD is found only in Leydig
cells and increases with the postnatal increases in Leydig cell number and
the developmental rise in serum testosterone (Phillips et al, 1990). The
concomitant appearance of lip-OHSD and testosterone at puberty led the
authors to postulate that the enzyme mediates corticosteroid-dependent
androgen production. Absence of lip-OHSD prior to 20 days of age permits
Cortisol (or corticosterone) to bind and activate GR, interfering with
testosterone synthesis. Beyond 25 days, lip-OHSD converts the
glucocorticoid to its inactive 11-oxo-form and releases the inhibition,
permitting testosterone production to proceed. This was further supported
by in vivo data showing that carbenoxolone potentiates corticosterone
inhibition of LH-induced testosterone release (Monder et al, 1991b)
Ovary
GR are present in the ovary (Schreiber et al, 1982) and may affect
ovarian physiology (Inazu et al, 1990; Baldwin & Sawyer, 1974). lip-OHSD
activity and mRNA has been found in human ovaries (Murphy, 1981;
Tannin et al, 1991) and in rat where it has been localised by in situ
hybridisation and immunohistochemistry in oocytes and luteal bodies
(Benediflcsson et al, 1992). Thus, lip-OHSD may modulate glucocorticoid
effects on ovarian function.
mammary gland
Glucocorticoids induce milk production in mammary gland via the
GR (Jahn et al, 1987; Quirk et al, 1988). High levels of lip-OHSD activity are
present in the adipose cells of the mammary gland but this activity
decreases just after parturition (Quirk et al, 1990a). Activity of lip-OHSD in
adipose cells from pregnant rats is 3-fold higher than in lactating rats
(Quirk et al, 1990b). Thus lip-OHSD in mammary gland may constitute one
of the physiological mechanisms preventing premature milk production
in response to glucocorticoids.
Colon
Fuller & Verity (1990), from Melbourne, demonstrated that in the
rat descending colon Na.K-ATPase al, and P- subunit gene expression is
acutely regulated by dexamethasone but not aldosterone which suggest
again a GR-mediated effect. Treatment with carbenoxolone sodium also
induced subunit gene expression in intact but not adrenalectomised rats,
suggesting that inhibition of lip-OHSD by carbenoxolone increases
endogenous glucocorticoid occupancy of GR. This effect of glucocorticoid
was confirmed when adrenalectomised animals were pre-treated with
carbenoxolone prior to corticosterone (Fuller & Verity, 1991).
In summary, lip-OHSD clearly plays a role in regulating the access
of high levels of glucocorticoids not only to the MR but also to the GR in
target cells.
1.3.6. 1 ip-hydroxysteroid dehydrogenase in fetal tissues and accessory
organs
1.3.6.1. Placenta
The level of active corticosteroid to which the fetus is exposed at
any given point of the gestation is crucial to its development and
maturation. Excess glucocorticoids has deleterious effects ranging from
growth retardation (MacHover Reinisch & Simon, 1978) to major
teratogenesis. High activity of 1 ip-dehyrogenase in the human placenta
provides a barrier to the transfer of active glucocorticoids to the fetus
( J. Ldpez Beraal & Craft, 1981; Giannopoulos et al, 1982;
Beitins et al, 1973; Waddell et al, 1988). In keeping with this role of barrier,
activity of the 1 lp-reductase component of lip-OHSD is relatively low in
placenta (Ldpez Bernal et al, 1980; Ldpez-Bernal et al, 1982;). lip-OHSD in
placenta resembles lip-OHSD in distal tubules in that its activity is
essentially 1 ip-dehydrogenase and its role is to inactivate circulating
glucocorticoids. In baboons, placental lip-OHSD activity is apparently
regulated by estrogens in vivo (Baggia et al, 1990).
1.3.6.2. Fetal lung
As reviewed earlier (section 1.1.3.1.), glucocorticoids are essential
for normal pulmonary differentiation. Although 11-oxidation of
glucocorticoids is predominant in the fetus (Murphy, 1981), the fetal lung
possesses the ability to reduce ("activate") the abundant fetal supplies of
cortisone (or 11-dehydrocorticosterone) and this activity increases with
gestational age (Smith et al, 1973; Torday^ 1980). Abramovitz et al, 1982
explain these variations by changes in proportions of epithelial and
fibroblast-like cells, with 1 ip-reduction restricted to fibroblasts and 11 p-
dehydrogenation located in epithelial cells, i.e. alveolar type II cells.
The ratio of reduced to oxidised steroid in tissues at critical stages of
development may provide important clues to determining key molecular
events necessary to complete development. lip-OHSD may play a dominant
role in ensuring adequate exposure to glucocorticoids at critical stages of
development of each maturing organ.
1.4. Aims of the thesis
The aim of this thesis was first to investigate the role of lip-OHSD in
the central nervous system. Adrenal steroids have been reported to have a
wide range of actions in the central nervous system, from regulation of
cell growth and differentiation, through effects on neuronal and glial
metabolism, to changes in appetite and behavioral patterns. Both MR and
GR are present in the brain. Glucocorticoids are in vivo ligands of both
receptors and aldosterone binds specifically to MR in some neurons
despite competitive concentrations of circulating glucocorticoids. The
studies described in Chapter 3 show that ll(3-OHSD is present in brain in
aldosterone-selective tissues but also in areas where MR are not selective
or in cells that contain only GR. Therefore lip-OHSD appears to have
various roles in the brain from conferring aldosterone selectivity to
modulating access of glucocorticoids to MR and / or GR. ll(3-OHSD activity
is regulated in the brain by glucocorticoids and during development in a
cell-specific manner (Chapter 4), which led us to the cloning of llfl-OHSD
gene (Chapter 5) to determine the molecular basis of this tissue-specific
and ontogenic regulation.
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In general, basic protocols outlined below are detailed in Sambrook
et al (1989).
2.1 DNA analysis techniques
2.1.1. Restriction endonuclease digestion and electrophoresis of DNA
DNA was digested using 1-3 unit of restriction enzyme per 1 pg of
DNA, lx restriction buffer (supplied with the enzyme) and dH2 0 to the
required volume. Digestion reactions were incubated at 37°C (except BssH
II, 50°C) for 1-2 h for plasmid or phage DNA and a minimum of 4 h for
mammalian genomic DNA. Enzyme activity was terminated by heating
digests to 60°C for 10 min or by addition of stop mix/loading buffer (30%
Ficoll, 0.25% bromophenol blue, 0.25% xylene cyanol, 0.5M EDTA).
For investigatory purposes, 0.2-0.4 pg of DNA was routinely digested
in a final volume of 10 pi. For cloning purposes or Southern blot analysis
of mammalian DNA, 10-15 pg of DNA were digested in a final volume of 50-
200 pi.
Digested DNA was visualised after electrophoresis through an
agarose gel containing 0.5 pg/ml of the fluorescent dye ethidium bromide.
The concentration of agarose was varied depending on the size of DNA
fragments to be resolved; for example, 1% gels were routinely used to
separate fragments below 2 kb and above 200 bp, whereas gels as low as
0.5% were used to separate very large fragments. Gels were generally
electrophoresed at 60-80 mA in TBE buffer (10 x TBE = 1M Tris-HCl, 0.8M
Boric acid, 20 mM EDTA, pH 8.3). The size marker routinely used was "1
kilobase DNA ladder" (Gibco BRL ) which gives a range of mol. wt. sizes
between 75 bp and 12 kb.
2.1.2. Subcloning of DNA fragments
Subcloning DNA fragments into plasmid was routinely performed as
needed for synthesising specific single stranded RNA transcripts or for
DNA sequencing. The subclone could then be selected by analysis of
minipreparation of plasmid DNA (see section 2.1.3.1.).
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2.1.2.1. Plasmid vector
pBIuescript II (stratagene): A 3 kb plasmid vector derived from
pUC 19 (Messing, 1983), retaining both the capacity for a high copy
number and the ampicillin resistance gene (P -lactamase) (Vieira &
Messing, 1982). It contains an artificial polylinker inserted into the |3-
galactosidase gene (lac-Z) providing a convenient test for recombinant
plasmid known as the blue/white test : non-recombinant plasmids are able
to synthesise the enzyme which breaks down the chromogenic substrate
X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside) to release a blue
product, however in recombinant plasmid the lac-Z gene is interrupted by
foreign DNA and the colonies remain white. This vector also contains the
phage T3 and T7 promoter sequences flanking the polylinker thus
enabling in vitro synthesis of specific single stranded RNA transcripts,
both sense and antisense.
2.1.2.2. Bacterial strains
All strains were E. coli K12
JM83: A ara, (lac-pro AB), rsp L, F80, lac Z M15, (rk+, mk+) (Vieira &
Messing, 1982). This was the host for pBIuescript based plasmids. The lac Z
M15 gene is integrated into the host chromosome.
PLK17:hsd (rk-, mk+) supE44, lac Z, gal K2, gal T22, met Bl, trp R55,
hsd R2. This was the host strain for screening the X DASH II genomic
library (section 2.1.4.).
LE392: hsd R514 (rk-, mk+) supE44, sup F58, lac Y1 or A (lac 1ZY), gal
K2, gal T22, met Bl, trp R55. This was the host for X DASH phage based
vectors. It was used for large scale X DNA preparation (section 2.1.3.3.).
2.1.2.3. Bacterial media
LB (Luria-Bertoni) broth and agar; Per litre: 10 g bacto-
tryptone (Difco), 5g bacto-yeast extract (Difco), 10 g NaCl. pH 7.5. LB agar
contained 15 g agar (Difco) per litre.
NZY broth, NZY agar and Top-agar; Per litre: 5g NaCL, 2g
MgSO4.H20, 5g yeast extract, 10 g NZ amine (casein hydrolysate). In
addition, NZY agar contained 15 g agar per litre and Top agar contained 7g
agarose (Sigma) per litre.
Terrific broth (Tartof and Hobbs, 1987): per litre; 15 g bacto-
tryptone (Difco), 30g bacto-yeast extract (Difco), 5 ml glycerol, 1/10
volumes of 1M K2HPO4 added before inoculation. A richer medium than LB
broth, it was used for large scale cultures for plasmid preparation since it
gave a higher density culture and a better yield of DNA.
Media additives: The antibiotic ampicillin (Sigma) was used to
select for plasmid maintenance at a concentration of 100 pg/ml. Stocks
were prepared at lOOOx concentration and stored at -20°C.
The chromogenic substrate X-gal (5-bromo-4-chloro-3-indolyl-b-
D-galactoside) of the blue/white test was added to the LB agar medium at a
concentration of 0.02%. Stocks were prepared at lOOOx concentration in
dimethylformamide and stored at -20°C.
All media were sterilised by autoclaving. Additives were filter sterilised.
Bacteria were grown at 37°C with good aeration for liquid cultures.
Bacterial stocks were routinely made in 20% glycerol and frozen at -70°C.
2.1.2.4. Constructing subclones
DNA fragments of interest were purified following fractionation on
a low melting point (LMP) agarose gel. The appropriate band was cut out of
the gel and DNA was purified from agarose by spinning the gel slice for 30
min in a microcentrifuge filter (Sigma). The latter consist of a 2.5 ml
microcentrifuge tube containing a removable filter insert. The filter is a
sterile cellulose acetate membrane of 0.22pm pores. The DNA solution was
then cleaned by phenol/chloroform extraction (l:lvolume) and
concentrated by ethanol precipitation (1/10 volumes of 3M NaOAC and 2.5
volumes of cold (-20°C) ethanol added, left at -70°C for at least 15 min or at
-20°C for a minimum of 30 min). The DNA was then pelleted by
centrifugation for at least 10 min and the pellet rinsed in 70% ethanol,
dried under vacuum and resuspended in an appropriate volume of TE
(lOmM Tris-HCl, 1 mM EDTA, pH 7.5). The purified DNA fragment was then
inserted into the plasmid vector using the enzyme DNA ligase prepared
from phage T4. Ratios of vector to insert DNA were varied around a
standard of 1:3 on a molar basis. Ligations were carried out with 25 ng of
linear vector in a 10 pi reaction volume (lOx ligation buffer: 0.5 M Tris-HCl
pH7.4, 0.1 M MgCl2, 10 mM Spermidine, lmg/ml BSA, 10 mM ATP, 0.1 M DTT)
with 1 pi (10 units) of T4 DNA ligase at 16°C overnight.
2.1.2.5. Bacterial transformation
E. coli JM83 cells were made competent for DNA uptake by the CaCl2
method (Sambrook et al, 1989). Cells were grown in 100 ml of LB medium to
mid log phase (A550=0.4-0.5). After harvesting, the cells were resuspended
in 10 ml of ice-cold 0.1 M CaCl2. The cells were then repelleted and
resuspended in 2 ml of ice-cold 0.1 M CaCl2 and stored at 4°C for up to 4
days. For transformation, the ligated plasmid DNA (< 10 pi) was added to 200
pi of cell suspension and left to adsorb for 30 min at 0°C. After a 90 second
heatshock at 42°C, the cells were chilled on ice for 1 min, 0.8 ml of LB
added and the cells allowed to develop antibiotic resistance at 37°C for 1
hour. Suitable aliquots of the transformation were then plated on selective
media and grown overnight at 37°C.
2.1.3. DNA preparation
2.1.3.1. Plasmid DNA minipreparation
This method is a shortened protocol of the alkaline-lysis mini-
preparation method, in which the volumes and incubation times have
been altered (Stephen et al, 1990). 10 ml of LB broth with appropriate
antibiotic added, was inoculated with a selected single colony. This was
grown overnight at 37°C in a sterile tube. 1.5 ml of the culture was pelleted
by centrifugation at 13 krpm for 1 min in a microcentrifuge tube and
resuspended in 150 p.1 of GTE solution (50 mM glucose, 25 mM Tris-HCl
pH8.0, lOmM EDTA). Cells were lysed by adding 300 p.1 of a freshly prepared
solution of 0.2 M NaOH/ 1% SDS and placing the tube on ice for 5 min. Cell
debris and chromosomal DNA was precipitated by addition of 225 pi of ice-
cold 3M potassium acetate (pH 4.8) and incubation on ice for 5 min. After
centrifugation, supernatant was removed, and the plasmid DNA
precipitated with one volume of absolute ethanol. After spinning for 5
min, the plasmid pellet was rinsed with 70% ethanol, dried and
resuspended in 40 pi of TE. The resulting DNA was sufficiently pure for
restriction enzyme digestion or DNA sequencing.
2.1.3.2. Large scale plasmid preparation
This protocol is very similar to the minipreparation method and
same solutions are used. 500 ml of LB broth or terrific broth plus
appropriate antibiotic, was inoculated with a selected bacterial colony and
shaken at 37°C overnight. The culture was decanted into two 250 ml
centrifuge bottles and spun at 6 krpm for 5 min. The pellets were
resuspended in 18 ml of cold GTE solution plus 10 mg/ml lysozyme. Then 40
ml 0.2 M NaOH/ 1%SDS was stirred in and incubated for 10 min at room
temperature. 20 ml of 3M potassium acetate (pH 4.8) was added and the
bottle stored on ice until a white precipitate formed. This was spun out at 5
krpm for 15 min at 4°C. The supernatant was filtered through ga'ze to
remove corse precipitate, and 0.6 volumes of isopropanol added to
precipitate plasmid DNA. Samples were left for 10 min at room temperature
and centrifuged at 10 krpm for 20 min to pellet the plasmid DNA. Pellets
were washed with 70% ethanol, lyophilised until almost dried and
redissolved in 2.7 ml of TE. The plasmid DNA was then purified by CsCl
gradient centrifugation. 2.7 g CsCl and 240 p.1 ethidium bromide were added
and the resulting solution was decanted in Beckman 3.5 ml
ultracentrifugation tubes. Samples were spun for at least 4 h, routinely
overnight, at 100 krpm in a Beckman Ti 100.3 rotor at 20°C. Plasmid bands
were removed with a 18 gauge needle mounted on a 2 ml s^nnge. The
ethidium bromide was removed by serial extractions with butanol until the
samples were clear. CsCl was removed by precipitating the DNA with 3
volumes of 70% ethanol for 30 min at -20°C. CsCl was redissolved by
warming the tube at 37 °C before centrifugation at 10 krpm, for 15 min, to
pellet the DNA. The plasmid DNA pellet was then rinsed with 70% ethanol,
dried and resuspended in 1ml of TE.
2.1.3.3. Large scale bacteriophage DNA preparation
First, a stock of high titer phage was prepared. Appropriate host
cells (LE392) were grown overnight in LB broth containing lOmM MgCl2
and 0.4% maltose as the sugar induces the maltose operon, which contains
the gene (lamb) coding for the X bacteriophage receptor. These cells were
spun down at 3 krpm and resuspended in 0.5 x culture volume of 10 mM
MgS04,105 phages in 100 pi of SM buffer (SM= per litre: 5.8 g NaCl, 2.0 g
MgS04, 50 ml 1M Tris-HCl pH7.5, 5 ml 2% gelatine) were inoculated to 100 pi
of the cell culture and the mixture was incubated 20 min at 37°C to allow
the bacteriophage particles to adsorb. Then 3 ml of top-agar at 46°C were
added, swirled to mix, and immediately plated onto pre-poured NZY-agar 85
mm diameter petri dishes. When the top-agar had hardened, plates were
inverted and incubated overnight at 37°C. The plate was inspected for
complete lysis of bacteria and confluent plaques. 5 ml of SM was added onto
the plate, which was then agitated at room temperature for at least 4
hours. This SM solution containing a high titer of phage was then pipetted
in a sterile tube and kept at 4°C.
For large scale preparation of phage DNA, 50 pi of high titer phage
stock (corresponding to approximately 5x10^ pfu) was inoculated to 10* 0
LE392 cells harvested as above and diluted in SM buffer. This was
incubated 20 min at 37°C and then added to 500 ml of NZY broth,
prewarmed at 37°C, in a 2 litre conical flask. Lysis of bacteria started after
12 h incubation after which 10 ml of chloroform was added. Lysed cultures
were then treated with DNase I and RNAase, each to a final concentration
of 1 pg/ml for 30 min at room temperature. An equal volume of 20% PEG
6000 (Polyethylene glycol, MW 6000, Sigma), 2M NaCl was added to
precipitate phage particles and incubated on ice for 1-2 h. Loose
precipitates were decanted into 250 ml bottles and spun at 10 krpm for 20
min to pellet the phages. The pellet was resuspend in 3 ml of SM and
extracted three times with chloroform to remove all traces of PEG. 0.75
g/ml CsCl was added to the aqueous phase and this was spun in Beckmann
3.5 ml tubes (Ti 100.3 rotor) at lOOkrpm for 3 h at 20°C. Phages formed an
opaque band in the CsCl gradient, which was extracted and dialysed against
lOOxTE at room temperature for 1 h to remove the CsCl. Phage particles
were then disrupted by the addition of SDS to 0.1% and EDTA to 10 mM and
incubated at 68°C for 15 min. 100pg/ml proteinase K was added and
incubated at 50°C for 30 min, followed by phenol/chloroform extraction.
Phage DNA was then precipitated by addition of NaCl to 0.2 M and two
volumes of ethanol. The DNA pellet was resuspended in TE. This
bacteriophage DNA was sufficiently pure for enzymatic manipulations.
2.1.4. Phage library screening
The library used was a Sprague Dawley rat genomic library in the
lambda DASH II vector (Stratagene, cat n° 945501) and was obtained from
Dr John Mullins, Centre for Genome Research, Edinburgh. DNA was
prepared from testis and partial digests performed with Sau3A I. Inserts
(9-22 kb) were cloned into the BamHI site of X DASH II.
The library was plated on NZY medium in 20 x 20 cm plates at a
maximum density of 2 x 10^ plaques per plate to obtain almost confluent
lysis. 5 of these plates were prepared so that 10^ plaques were screened. To
achieve this, PLK17 cells, previously grown to stationary phase in LB
broth plus lOmM MgCl2 and 0.4% maltose, were spun down and
resuspended in 0.5 x volumes of 10 mM MgSOq.. 1 ml of this bacterial
suspension was inoculated with an appropriate volume of phage stock
(previously titrated) in a 50 ml sterile tube and incubated 20 min at 37°C.
The cells were then diluted with 40 ml of molten top-agar (46°C), swirled to
mix, and immediately plated onto pre-poured dry NZY agar plate and
incubated at 37°C overnight. The phages plaques on the resulting plates
were overlaid with dry Nitrocellulose (Schleicher & Schuell) filters which
were keyed in place with a needle containing waterproof ink. Transfers
were performed in duplicate to cut down false positives. The first filter was
left for 2 min and the second 7min. After lifting, filters were submerged,
plaques facing up, in dishes containing the following solutions:
(1) 1.5 M NaCl, 0.5 M NaOH. 2 min to denature DNA
(2) 1.5 M NaCl, 0.5 M Tris-HCl pH8.0. 5 min to neutralise the pH
(3) 0.2 M Tris-HCl ph 7.5, 2 x SSC. 30 sec. to rinse filters
The phage DNA was fixed to the dry filters by baking 2 h at 80°C. The
filters were hybridised and washed as described for Southern blots
(section 2.1.5.) and were exposed to autoradiographic film for 1-3 days at -
70°C. Duplicate filters were screened with the same probe, and plaques on
the original agar plate which corresponded to duplicate spots on the film
were selected as potentially positive clones. This was done by cutting out
the relevant area of top agar and placing it in 1 ml of SM buffer in a
microcentrifuge tube. This stock, which contained a mixture of positive
and negative clones, could be stored at 4°C indefinitely while secondary
and tertiary screens were carried out. This was done by repeating the
procedure above, plating from the selected stock on 85 mm petri dishes at a
lower density until a pure stock of the positive phage clones was selected.
DNA was then prepared from the clone as described in section 2.1.3.3.
2.1.5 Southern blot analysis
2.1.5.1. Capillary transfer
This method of transferring DNA from an agarose gel to a
nitrocellulose or a nylon membrane broadly follows the method of
Southern (1975). Following photography of the gel stained with ethidium
bromide, the DNA was denatured by immersion in 3 volumes of denaturing
solution (1.5 M NaCl, 0.5 M NaOH) for 40 min. This was followed by 30 min
in neutralising solution (0.5 M Tris-HCl, 1.5 M NaCl pH5.5). The gel was then
laid on a transfer apparatus; a wick of Whatman 3MM filter paper with a
reservoir of 20 x SSC (20 x SSC= 3M NaCl, 0.3 M Na Citrate, pH 7.4). A
nitrocellulose (Schleicher & Schuell) or a nylon (Hybond-N, Amersham)
membrane was carefully placed in direct contact with the entire gel. Two
sheets of Whatman 3MM filter paper were placed over the membrane
followed by paper towels to a depth of 5 cm. An even weight (1 kg) was
placed on the assembly and transfer carried out overnight. The membrane




Pre-hybridisation and hybridisation were carried out in 50%
formamide, 5x SSPE, 5x Denhardt's solution (0.1 % BSA, 0.1 % Ficoll, 0.1 %
polyvinylpyrolidone), 200pg/ml denatured herring testis DNA, 0.1% SDS
and ImM EDTA for cDNA hybridisation and in 6x SSC, 4x Denhardt's
solution, 0.5% SDS for oligonucleotide hybridisation. These solutions were
stable for several months at room temperature. Filters were sealed in
plastic bags with about 10 ml of hybridisation mix per 20 cm^ of filter.
After prehybridisation (42°C for cDNA, 50 °C for oligonucleotide) for at
least 20 min, the radioactive probe was carefully added to the bag and
hybridised overnight. The bag was then carefully open, the probe
disposed of , and the filters were washed in solution of the appropriate
stringency (standard wash was 2xSSC, 0.1% SDS for 15-30 min ) until the
signal reached an acceptable level. Filters were then wrapped in clingfilm
and autoradiographed at -70°C with Kodak XAR-5 film. Films were
developed in Kodak D19 developer solution (Ilford) for 2 min and fixed in
1/5 Amfix fixer (Champion).
2.1.6. DNA sequencing
DNA sequences of supercoiled plasmid templates were determined by the
dideoxy nucleotide chain termination method using a Sequenase (version
1) kit (United States Biochemical) according to the manufacturer's
protocol.
2.1.6.1 Preparation of double stranded DNA templates for sequencing
Prior to sequencing reaction, the DNA template must be denatured
to allow access of the sequencing primer. This was achieived by alkaline
denaturation which also hydrolyses contaminating RNA. 2 to 5 pg of CsCl
purified (section 2.1.3.2.) or minipreparation purifed (section 2.1.3.1)
supercoiled plasmid DNA were added to 25 pi of denaturation solution (0.2 M
NaOH, 2mM EDTA) and incubated at 37°C for 15 min. 2.5 pi of neutralising
solution (0.4 M NaOAc pH4.5) was then added, followed by 80 pi of ethanol to
precipitate the DNA. After 15 min at -70°C and centrifugation for 5 min at
13 krpm, the pellet was rinsed with 70% ethanol and resuspended in sterile
dH20.
2.1.6.2 Sequencing protocol
The first step of the sequencing reaction involved annealing the
primer (either the universal or reverse M13 primers, or oligonucleotides
specific to internal regions of the insert) to the template, followed by
elongation from this primer by the enzyme T7 DNA polymerase. The
second step involved chain termination. For each template four separate
sequencing reactions were performed. All contained primer, template and
all four dNTPs (dATP was radiolabeled) but each contained a different
dideoxynucleotide (ddNTP). Incorporation of a ddNTP into the newly
synthesised DNA strand resulted in chain termination, as no 3'-OH group
was available to form the next phosphodiester bond. A series of DNA
fragments was therefore generated, all originating at the primer, and
terminating at the sites of incorporation of the appropriate ddNTP.
The annealing reaction contained 2-5 pg of denatured template and
1 pmole of primer in annealing buffer (40 mM Tris-HCl pH7.5, 20 mM
MgCl2, 50 mM NaCl) in a volume of 10 pi. This was mixed and centrifuged
briefly before incubation for 15-30 min at 37°C. Elongation was achieved
by addition of 1 pi DTT 0.1 M, 2 pi nucleotide mix (dGTP, dCTP, and dTTP 7.5
pM each in solution), 5 pCi [a -35S] dATP (Amersham) and 3 units of T7 DNA
polymerase for 5 min at room temperature. Four tubes labelled G, A, T, and
C containing 2.5 pi of the corresponding termination mix (80 pM of each
dNTP and 8 pM of one ddNTP) were pre-incubated for 1 min before addition
of 4.5 pi of the elongation reaction to each tube and incubation for a
further 5 min at 37°C. Reactions were then stopped by the addition of 5 pi
of stop solution (95% formamide, 20 mM EDTA 0.05% bromophenol blue,
0.05 % xylene cyanol FF). The sequencing reactions could be analysed
immediately or stored at -20°C. The radiolabeled fragments produced by
the sequencing reaction can be resolved on polyacrylamide gels (Sanger
& Coulson, 1975) and detected by autoradiography.
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2.1.6.3. Polyacrylamide urea gel electrophoresis of sequencing reactions.
Sequencing gels were run between a 37.5 x 45 cm and a 32 x 42.5 cm
glass plates in 1 x TBE buffer (section 2.1.1.). The smaller glass plate was
siliconised by applying dimethyldichlorosilane in trichloroethane (BDH)
to ensure that the gel would not adhere to it at the dismanteling step. The 2
plates were separated by wedge spacer (IBI) creating a gradient gel effect,
and held together with bulldog clips. The gel mix contained per 100ml; 42 g
urea, 15 ml 40% acrylamide stock (19 % acrylamide, 2% bisacrylamide), 10
ml 10 x TBE, 600 pi of 10% ammonium persulfate (crosslinking agent),
brought to 100 ml with dH2 0 and filtered through Whatman #1 filter
paper. 40 pi of polymerisation catalyst TEMED (N'-
tetramethylethylenediamine) was added immediately before pouring to
catalyse the polymerisation.
The gel was allowed to set for at least two hours and was then
attached to a perspex vertical gel apparatus (IBI, Model STS-45). The wells
were flushed out with electrophoresis buffer before loading the samples to
remove unpolymerised acrylamide/ urea solution, and the gel was pre-
electrophoresed at 70 watts for at least an hour. The samples were heated at
80°C for 5 mins and 2.5 pi of each sequencing reaction loaded per well.
Samples were electrophoresed at 70 watts for 2 h for a standard run. The
glass plates were then separated from each other and the outer plate
carrying the gel was immersed in 10% methanol, 10% acetic acid for 10
min in order to fix the gel. Finally, the gel was peeled away from the plate
onto a Whatman 3MM filter paper, covered with clingfilm and dried under
vacuum at 80°C on a slab dryer (Bio-Rad, Model 583). Overnight exposure to
Kodak XAR-5 film was usually sufficient to clearly read 200-300 nucleotides
of sequence.
2.2 Preparation of radiolabeled nucleic acid probe
2.2.1. Random priming of DNA
The technique is based on the method of Feinberg & Vogelstein
(1983) where random hexanucleotides act as primers for polymerase chain
extension in the presence of radiolabeled nucleotides. A BCL random
primed labelling kit was used. This was a convenient technique since the
reaction could be carried out in the presence of minimal amounts of DNA
(10 ng), and did not require purification of DNA restriction fragment from
agarose, which was only melted and diluted (3 ml dH2 0/ g of gel).
Routinely, 25 ng of DNA was denaturated for 10 min by heating to 100°C.
The sample was cooled to room temperature and 5 pi of 4 x random prime
buffer/dNTPs was added, followed by 5 pi [3 2p] dCTP (3000 Ci/ mmol,
Amersham) and 1 pi of Klenow fragment of DNA polymerase I. Random
prime buffer consists of a mixture of all possible hexanucleotides in 4 x
Klenow buffer and 25 pM dATP, dGTP, dTTP. The reaction was incubated at
37°C for 1-2 hours and terminated by adding 2 pi of 0.25M EDTA. In order to
reduce the amount of non-incorporated [3 2 pj dCTP, the probe was
precipitated by addition of 5 pg of yeast tRNA (acting as a DNA carrier),
NaCl to 0.2 M, and 2.5 volumes of ethanol. After 10 min centrifugation, the
pellet was rinsed in 70% ethanol, dried under vacuum and resuspended in
100 pi ofTE.The probe was denaturated by boiling 5 min immediately
before addition to the hybridisation bag.
2.2.2 Oligonucleotide labelling
2.2.2.1. 5' end labelling
Oligonucleotides were radiolabeled by T4 polynucleotide kinase.
This enzyme transfers the y-phosphate from [3 2pj y-ATP to the 5' OH group
of a dephosphorylated oligonucleotide. 30 ng of single stranded
oligonucleotide was mixed with 30 pCi [32p] y-ATP (3000 Ci/ mmol,
Amersham) and 10 units T4 polynucleotide kinase (BCL) in a total volume
of 20 pi kinase buffer (100 mM Tris-HCl pH 8.0, 0.01 mM MgCl2, 0.005 mM
DTT) and incubated for 45 min at 37°C. The reaction mixture was
terminated by heating 10 min at 68°C. The labelled oligonucleotide was
either directly used (for Southern blot hybridisation) or precipitated in
presence of 50 pg yeast tRNA, 2M ammonium acetate and 3 volumes of
ethanol at -70°C and resuspended in TE (for primer extension analysis).
Specific activity of the labelled oligonucleotide was usually of 0.5- 1 xlO^
cpm/pg of oligonucleotide, as estimated by counting the radioactivity of an
aliquot of the probe purified from free nucleotides and checked on a small
polyacrylamide gel.
2.2.2.2. 3' end "tailing" labelling
This method was used when very high specific activity was
required as for hybridisation of oligonucleotide onto Northern blot of total
RNA.
Oligonucleotides were radiolabeled by the addition of a
homopolymeric tail of [32p] a-CTP to the 3' end using the enzyme terminal
deoxynucleotidyl transferase. 20 ng of single stranded oligonucleotide was
mixed with 100 pCi [32p] a-CTP (3000 Ci/ mmol, Amersham) and 30 units
terminal deoxynucleotidyl transferase (BCL) in a total volume of 20 pi
reaction buffer (50 mM Tris-HCl, 200 mM potassium cacodylate, 2.5 mM
C0CI2, 0.5 mg/ml BSA pH 6.6) and incubated for 1-2 h at 37°C. The reaction
mixture was terminated by heating 10 min at 68°C and the labelled
oligonucleotide was purified by ethanol precipitation as described for 5'
end labelling. Specific activity of the labelled oligonucleotide was of 2- 5
xlO^ cpm/pg of oligonucleotide, as estimated by counting the radioactivity
of an aliquot of the probe purified from free nucleotides.
2.2.3. Synthesis of radioactive RNA probe
RNA probes were produced in vitro using T3 or T7 phage
polymerase systems and were used for in situ hybridisation or RNase
protection assays.
A plasmid containing the insert of interest and a flanking T3 or T7
promoter sequence (eg in pBluescript vector) was linearised with a
restriction enzyme distal to the insert. After phenol/chloroform
extraction and ethanol precipitation, 0.5-1 pg linear DNA template was
incubated with a ribonucleotide mix (ATP,CTP,GTP,UTP), 32p or 35s UTP, 10
mM DTT, RNase inhibitor (Promega) and the appropriate polymerase in a
total volume of 10 pi in transcription buffer (5x transcription buffer =
200mM Tris-HCl, pH 7.5; 30 mM MgCl2; 10 mM spermidine; 50 mM NaCl) for 1
h at 37°C. The proportions of labeled and cold UTP were adjusted to yield
probes of the specific activity required. DNA templates were then degraded
using RQ1 DNase (Promega). The probe was purified by
phenol/chloroform extraction and ethanol precipitation in presence of
carrier. The pellet was resuspended in 100 pi DEP-treated dH20 (0.1%
diethylpyrocarbonate in double distilled water, autoclaved) and 1 pi was
run on a 20 x 20 cm 4% polyacrylamide urea gel to check the integrity of
the probe. The probe was diluted at the concentration required in the
appropriate hybridisation mix (see section 2.3.) and kept at -20°C. RNA
probes were usually kept no more than 3-4 days since degradation occur
rapidly.
2.3 RNA analysis techniques
2.3.1. Tissue dissection
Male rats were killed and the organs of interest rapidly removed and
dissected on ice. Tissues were immediately frozen in liquid nitrogen. The
rat brain was dissected as follow: The brain was taken out of the skull and
turned upside down; the cerebellum was separated from the underlying
brainstem by severing the cerebellar peduncles; the hypothalamus was
removed as a block lying between the optic chiasm and the mammilary
body and extending 1 mm from each side of the midline and 2mm deep. The
remainder of the brain was split into halves along the midsaggital plane,
then, on each side, the fornix was severed and the hippocampus removed
by peeling it away from the wall of the lateral ventricle; a sample of
parietal cortex was also dissected.
2.3.2. RNA isolation from rat tissues
Total RNA was extracted following the method of (Chomczynski _
1987). Tissues were homogenised in a denaturing solution (4M
guanidinium thiocyanate, 0.025M sodium citrate, 0.5% sarcosyl and 0.1 M p-
mercaptoethanol) at a concentration of 5 to 10 ml per g of tissue, using a
Dounce tissue grinder. DNA was precipitated by addition of sodium acetate
to 0.2M, pH4, and proteins were removed by phenol/chloroform
extraction. The aqueous phase containing RNA was precipitated twice with
isopropanol and finally resuspended in DEP-treated dH2 0. RNA
concentration and purity was assayed spectrophotometrically and aliquots
stored at -70°C prior to use.
2.3.3. RNA electrophoresis and Northern blot analysis
RNA was fractionated on 1% or 1.2% agarose gels under denaturing
conditions to minimise secondary structure which alters mobility. For 100
ml gel mix, the agarose was melt into 88 ml of DEP-treated dH20 and after
cooling to 55°C, 10 ml of 10 x MOPS buffer (0.4 M
Morpholinopropanesulphuric acid pH7, 100 mM NaOAc, 10 mM EDTA pH8)
and 2 ml of formaldehyde solution was added and the gel poured quickly.
RNA samples (up to 25 pg) in 5 pi were mixed with 2.25 pi of 10 x MOPS
buffer, 4 pi formaldehyde and 11.25 pi formamide, before denaturation for
10 min at 65°C. Then, 1 pi of lmg/ml ethidium bromide and 2.5 x loading
buffer (section 2.1.1) was added and samples were loaded and
electrophoresed at 80 mA for 4-5 hours. Then gels were soaked in 20 x SSC
to remove formaldehyde and blotted onto nitrocellulose (Hybond C extra)
or nylon (Hybond N) (Amersham International, UK) by capillary transfer
overnight as for Southern blot (section 2.1.5.) in 20 x SSC. Filters were
processed as for Southern blots.
Hybridisation to cDNA probe was as for Southern blot, however a
different protocol had to be used for hybridisation of oligonucleotides on
Northern blot. This protocol followed the method of Henderson et al (1991).
Hybridisation buffer contained lx SSC, 2x Denhardt's solution, 1% nonfat
dry milk, 10% dextran sulfate, 2% SDS, 200pg/ml herring testis DNA, and
200pg/ml polyadenylic acid. Hybridisation temperature were 5°-10°C
below the Tm5 0> the temperature at which 50% of the DNA probe/mRNA
hybrids melt. The Tm50 was calculated using the following equation:
Tm 50= 16.6 (log[Na+]) + 81.5 + 0.41 (% G+C) - 675/ (number of bases in the
probe) where [Na+] is the molar concentration of Na+ in the hybridisation
mix, and % G+C is the percentage of guanidine plus cytosine residues in
the probe. The length of the labelled nucleotide tail (section 2.2.2.2.) was
not considered in the total probe length. Post-hybridisation washes and
autoradiography were as for Southern blot analysis although less
stringent.
2.3.4. In situ hybridisation on rat tissue sections
Adult or juvenile male Wistar rats (180-220g) were decapitated and the
organs of interest rapidly removed on ice. Tissues were dissected and
immediately frozen on dry ice. Tissue was stored at -85°C prior to section¬
ing in a cryostat at -20°C. 10 pm sections were mounted onto gelatin and
poly-L-lysine-coated slides, and stored at -85°C until hybridisation was
performed.
Before hybridisation, tissue sections were fixed in 4%
paraformaldehyde/0.1M phosphate buffer and washed in 2xSSC made up in
DEP-treated water. Filter sterilised prehybridization buffer containing
50% formamide, 0.6M NaCl, lOmM Tris-HCl pH7.5, 0.02 % ficoll, 0.02%
polyvinylpyrrolidone, 0.1% BSA, 1 mM EDTA, 0.5 mg/ml denatured salmon
sperm DNA, 0.5 mg/ml total yeast RNA and 0.05 mg/ml yeast tRNA was
pipetted onto the sections (200 pi/ slide) and the slides were incubated at
37-42°C for 2 h in sealed boxes.
The RNA probe was denatured and added to hybridisation buffer
(50% formamide, 0.6M NaCl, lOmM Tris-HCl pH7.5, 0.02 % ficoll, 0.02%
polyvinylpyrrolidone, 0.1% BSA, 1 mM EDTA, 0.1 mg/ml denatured salmon
sperm DNA, 0.05 mg/ml total yeast RNA, 0.05 mg/ml yeast tRNA, O.lg/ml
Dextran sulphate, and 10 mM DTT) to a final concentration of 10 x 10^
cpm/ml and applied to the slides (200 pi) after the prehybridisation buffer
had been drain off. The slides were incubated overnight at 37-42°C in
sealed boxes. Following hybridisation the slides were rinsed twice in 2x SSC
for 30 min at room temperature prior to RNase A digestion (30pg/ml for 30
min at 37° C). The slides were washed in reducing salt concentrations to a
maximum stringency of O.lxSSC at 60°C for 60 min. After dehydration in
increasing concentrations of ethanol (50%,70% & 90%) containing 0.3M
sodium acetate, sections were air dried and exposed to autoradiographic
film (Hyperfilm p-max, Amersham International, UK). Similar sections
were dipped in photographic emulsion (Ilford, UK) and stored at 4°C for
20-30 days before being developed and counterstained with haematoxylin
and eosin.
Controls, carried out to test both the specificity of the hybridisation
method and the probe included pretreatment of sections with RNase A (100
pg/ml for 1 h at 37°C) prior to hybridisation with an antisense probe and
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hybridisation using labelled-RNA "sense" probe (not complementary to
mRNA under test, and applied at lOxlO^cpm/ml).
2.3.5. Primer extension analysis
This method was used to map 5' termini of llfi-OHSD mRNA.(Moisan et al,
The test RNA is hybridised with an excess of a single stranded DNA
primer (a synthetic oligonucleotide), complementary to the mRNA and
radiolabeled at its 5' terminus. Reverse transcriptase is then used to
extend this primer to produce cDNA complementary to the RNA template.
The length of the resulting end-labelled cDNA, as measured by
electrophoresis through a polyacrylamide gel under denaturing
conditions, followed by autoradiography, reflects the distance between the
end-labelled nucleotide of the primer and the 5' terminus of the RNA. Best
results were obtained when the primer was a 30-40 mer and when it was
located 100-200 bp from the 5' terminus.
Oligonucleotides were labelled with 32p_y_[A.TP] and T4 polynucleotide
kinase (section 2.2.2.1.). 10^ cpm were hybridised in solution to total RNA
samples (50 pg) at 60°C for 1 hour in annealing buffer (100 mM KC1, 10 mM
MgCl2> 25 mM Tris-HCl pH 8.5) in a total volume of 12 pi. Primer extension
reactions were carried out in 40 pi of 30 mM KC1, 8 mM MgCl2, 50 mM Tris-
HCl, 500 pM each dNTP, 50 pg/ml actinomycin D, 20 units of RNasin
(Promega, UK) and 50 units of AMV reverse transcriptase (Life Science) at
42°C for 30 min. After phenol-chloroform extraction and ethanol
precipitation, the size of the reaction product was analysed on a 6%
polyacrylamide gel by comparison with a sequencing reaction used as a
size ladder (section 2.1.6.3.).
2.3.6. RNase protection assay
This method was also used to map 5' termini of ll(3-OHSD mRNA and to
locate the 5' and 3' splice junctions in relation to sites of cleavage with
restriction enzymes in the cloned rat lip-OHSD gene (Moisan et al, 1992b).
For this an excess of radiolabeled single stranded RNA, complementary
to appropriate segments of the template DNA, is hybridised in solution
1992b)
with the RNA being tested so that all complementary sequences are driven
into radiolabeled RNA:RNA hybrids. The unhybridised material (non-
complementary RNA and tails of the RNA probe that do not hybridise) is
then removed by digestion with RNase, which specifically degrades single
stranded RNA. The size of the protected radiolabeled RNA:RNA hybrid
fragment is then detected by electrophoresis through a polyacrylamide
gel under denaturing conditions, followed by autoradiography.
5x10^ cpm of 32p[UTP]-labeled antisense RNA probes was hybridised to
RNA samples (25-50 pg) overnight at 46°C in 80% formamide, 0.4 M NaCl, 40
mM Pipes pH 6.7 and 1 mM EDTA. Non-hybridised RNA was degraded by the
additon of RNAses A (40 pg/ml) and T1 (2 pg/ml) (Boehringer Mannheim)
for 1 hour at 30°C. Following proteinase K treatment and
phenol/chloroform extraction, the samples were ethanol precipitated and
analysed on a 6% polyacrylamide gel in parallel with a sequencing
reaction (section 2.1.6.3.).
2.4 lip-OHSD enzyme assay
Adult male Wistar rats (180-220 g) were decapitated and the organs
of interest rapidly removed and dissected on ice as described for RNA
isolation (section 2.3.1.). Tissues were homogenised in 5 ml of Krebs-
Ringer bicarbonate buffer (118 mM NaCl, 3.8 mM KC1, 1.19 mM KH2PO4, 2.54
mM CaCl2-2H20, 1.19 mM MgS04.7H20, 25 mM NaHCC>3 and 0.2% glucose,
gassed with 95% 02/5% CO2 to pH7.4 ) using a dounce tissue grinder. The
total protein content of the homogenate was estimated colorimetrically
(Bio-Rad protein assay kit).
0.5 mg/ml of total protein was then incubated with a final concentration
of 12nM 1,2,6,7,^ H-corticosterone (specific activity :84Ci/mmol, Amersham)
in Krebs-Ringer buffer (+0.2% BSA) in a total volume of 250 to 1 ml,
depending on the amount of tissue available, for 60 min at 37° C. In some
experiments, the enzyme co-substrate NADP+ was added before incubation,
at a final concentration of 200 pM. After incubation, steroids were
extracted with 1 volume of ethyl acetate, dried, and resuspended in ethanol
containing 5 mg/ml of unlabelled corticosterone and 11-
dehydrocorticosterone. Steroids were separated by thin-layer
chromatography on silica gel plates using as solvent a mixture of 95%
chloroform / 5% ethanol (92:8). Areas corresponding to steroids were
identified under UV light and scraped into vials before elution with liquid
scintillant (Cocktail T, BDH). Radioactivity was quantitated with a p
counter. lip-OHSD activity was determined as the percentage conversion
of ^ H-corticosterone to 11-dehydrocorticosterone, calculated from the
radioactivity of each fraction.
For inhibition studies, the llp-OHSD inhibitor p-glycyrrhetinic acid
(GE) was diluted in ethanol at a concentration of 10"2 M and subsequently
diluted in water. GE was added to tissue homogenates at 10~4 M, 10"^ M, 10" ^
M final concentration and lip-OHSD activity assayed as above.
2.5. In vivo studies
Male rats (Wistar, 200g) were maintained under conditions of controlled
lighting (lights-on from 0.500 to 19.00 h) and temperature (22°C) and
water and food ad libitum. Groups of animals (n=3-6 per group) were
anesthetised with intraperitoneal fentanyl citrate (0.3 mg/kg, Janssen),
fluanisone (10 mg/kg, Janssen) and midazolam (5 mg/kg, Roche) and
adrenalectomised or sham-operated (surgery was done by June Noble,
Centre for Biomedical Research, W.G.H.). Adrenalectomised animals were
injected with dexamethasone at a dose of 0.2 mg/kg body weight/day, sub-
cutaneously, or aldosterone (20pg/kg body weight/day, sub-cutaneously),
the remainder received vehicle (5% ethanol-saline). A further group of
adrenally-intact rats was injected with the antiglucocorticoid RU38486
(Roussel-UCLAF) (10 mg/kg body weight/day, sub-cutaneously). Rats were
sacrificed one or ten days after surgery.
Statistics
Data were assessed by ANOVA followed by Scheffe's test or Student's t-test..
Significance was set at p<0.05. Values are expressed as means±SEM.
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3.1 Introduction
Brain contains two distinct types of intracellular corticosteroid
receptors, mineralocorticoid (or type I) and glucocorticoid (or type II)
(Reul & De Kloet, 1985; Evans & Arriza, 1989). Glucocorticoid receptors (GR)
are widely distributed in neurons and glial cells throughout the brain, as
judged by immunocytochemical (Fuxe et al, 1985; van Eekelen et al, 1987)
and cRNA/mRNA hybridisation procedures (Aronsson et al, 1988; van
Eekelen et al, 1988; Chao et al, 1989; Herman et al, 1989; Sousa et al, 1989)
which confirmed previous autoradiography using [3H] RU 28362 (a pure
glucocorticoid) (Reul & De Kloet, 1986). High levels of GR are found in
hippocampus and septum, parvocellular neurons of the paraventricular
nucleus where glucocorticoids control the synthesis and release of CRH
and vasopressin (Swanson & Simmonds, 1989), ascending monoaminergic
neurons of the brain stem, where glucocorticoids control the synthesis of
neuropeptide Y, POMC, enkephalin and dynorphin (Fuxe et al, 1985),
supraoptic nucleus and cerebellum. Moderate GR concentrations are also
found throughout the cortical hemispheres and in many thalamic nuclei,
in a patch-like distribution in the striatal areas and in the central
amygdaloid nucleus.
MR and their mRNAs show a more selective distribution (Krozowski
& Funder, 1983; Arriza et al, 1987 & 1988, van Eekelen et al, 1988; Herman et
al, 1989), with high levels in the limbic system (hippocampus, lateral
septum and medial and central amygdala), olfactory nucleus, layer II of
the cortex and brain stem sensory and motor neurons. Labelled ligand
binding studies revealed that most limbic regions retain [3H]aldosterone
and [3H]corticosterone equally well, whereas preferential labelling by
[3H]aldosterone was observed in the induseum griseum, the anterior
hypothalamus, circumventricular areas, such as choroid plexus, and brain
stem regions (Birmingham et al, 1984; McEwen et al, 1986b). MR mRNAs
have been reported in anterior hypothalamus, subfornical organs, and
choroid plexus (van Eekelen, 1989) and in hypothalamic regions after
glucocorticoid treatment (Swanson & Simmonds, 1989).
Brain MR and GR were first characterised by their different


























Table 3.1 : Binding affinities of rat hippocampal corticosteroid receptors
(from De Kloet, 1991).
GR show the highest affinity for potent synthetic glucocorticoids
such as dexamethasone and RU 28362 and the antiglucocorticoid RU38486, a
lesser affinity for corticosterone (B) and Cortisol (F), and a much lower
affintiy for aldosterone and the antimineralocorticoid spironolactone. In
contrast, MR show negligible affinity for the above RU compounds,
moderate affinity for dexamethasone, and equival high affinity for
aldosterone and corticosterone, which, moreover, is about ten times
higher than that shown by GR for corticosterone. In species where
Cortisol is the major circulating glucocorticoid, both MR and GR show a
higher affinity for Cortisol. Because corticosterone circulates in distingly
higher amount than aldosterone hippocampal MR are occupied by
corticosterone and hippocampal MR could be considered as glucocorticoid
receptors. Accordingly, the nomemclature type 1/ type II was adopted by
some authors. Binding kinetics studies, in the light of the observed higher
affinity of MR compared to GR for corticosterone, showed that
corticosterone at low dose (down to 2.5 nM) extensively occupies MR in the
hippocampus, whereas at the circadian peak and after stress,
corticosterone progressively occupies GR. This observation led to the
concept of a binary glucorticoid response in which MR could provide a
high-sensitivity, low response function to glucocorticoids, while the GR
would act with low sensitivity but high response (reviewed in Evans &
Arriza, 1989; De Kloet, 1991).
MR are apparently structurally identical in all tissues investigated
including kidney and brain, and are translated from a single mRNA
species (Arriza et al, 1987 & 1988, Patel, 1989). As discussed in the general
introduction (section 1.2.3.), the recombinant human MR expressed in CV1
cells show the same binding affinities that those found by radioligand
binding studies in vitro described above. The concept of a MR as a receptor
with no inherent specificity for mineralocorticoids over glucocorticoids
remains controversial since MR in kidney and in certain areas of the
brain listed above, are, in vivo, relatively insensitive to glucocorticoids.
Thus, MR in circumventricular organs, medial amygdala and anterior
hypothalamus, selectively bind aldosterone whereas corticosterone and
dexamethasone are ineffective (McEwen et al, 1986b). Aldosterone at these
sites affects salt appetite and blood pressure regulation. Salt hunger
developing in adrenalectomised animals can be reduced by low dose of
aldosterone (O.lpg/h) whereas corticosterone infused at a dose
corresponding to stress levels (50 pg/h), neither mimics nor blocks the
effect of aldosterone. However this effect is blocked by the
antimineralocorticoid RU 28318 which also almost totally inhibits [^H ]
aldosterone uptake in rat forebrain (McEwen et al, 1986a). Furthermore,
lesions of the anteroventral third ventricle, AV3V (which includes the
medial preoptic area and OVLT) attenuate salt appetite and affect blood
pressure (Berecek et al, 1982), but in contrast hippocampectomy (which
removes limbic system MR) does not alter the actions of adrenal steroids
on salt appetite (Magarinos et al, 1986). Aldosterone may act
synergistically with the central renin-angiotensin-system (Fluharty &
Epstein, 1983, Sakai et al, 1986), atrial natriuretic peptide and ACTH to
satisfy salt appetite.
Chronic adrenal insufficiency or adrenalectomy result in reduced
blood pressure that can be restored by corticosterone replacement or
aldosterone during salt loading. Aldosterone replacement requires
increased participation of the renin-angiotensin system, vasopressin, and
norepinephrine to maintain blood pressure (Yagil et al, 1986, 1988).
Furthermore, intracerebroventricular (icv) infusion of aldosterone (10
ng/h) in rats or dogs produces significant increases in resting blood
pressure. In rats this effect is blocked by the concomitant icv infusion of
prorenone, an aldosterone antagonist, and enhanced by salt intake. RU
28318, a selective mineralocorticoid antagonist, infused icv, inhibits the
development of aldosterone-induced hypertension. Corticosterone, at a
dose of 10 ng/h icv for up to 4 weeks is ineffective. In addition,
concomitant infusion of corticosterone antagonises the effect of icv
infused aldosterone, suggesting competitive inhibition at the MR site
involved in central cardiovascular control (reviewed by G6mez-Sdnchez,
1991; De Kloet, 1991).
In contrast, in the hippocampus and septum MR preferentially
bind corticosterone in vivo, and their function may even be antagonised
by aldosterone. For example, aldosterone blocks the serotonin response to
corticosterone in the hippocampus. Bilateral adrenalectomy in rats leads
to a reduction in serotonin turnover in dorsal hippocampus. A low dose of
corticosterone given subcutaneously immediately after adrenalectomy
restores the serotonin turnover to normal values but pretreatment of
adrenalectomised rats with aldosterone prevents the uptake of
corticosterone to these receptors and thus blocks the response (De Kloet et
al, 1983)
GR may also show regional differences in sensitivity to
corticosteroids, despite a structural homogeneity. Thus, low doses of
corticosterone can prevent the post-adrenalectomy rise of GR levels in
hypothalamus and hippocampus, but not in cortex and cerebellum
(Brinton & McEwen, 1987; Luttge et al, 1989), whereas low-dose
dexamethasone prevents the rise in all brain regions. The mechanism(s)
responsible for these site-specific differences in corticosterone
sensitivity of cerebral MR and GR in vivo are unknown, although a
possible explanation, at least in cerebral cortex where MR and GR are
colocalised, is that regulation of both MR and GR levels is mediated by
corticosterone binding to MR (Luttge et al, 1989).
The role of lip-OHSD described in kidney provided a convenient
starting point for studies on brain, as lip-OHSD became the obvious
candidate for mediating corticosteroid specificity within the central
nervous system, particularly since CBG has been shown to be not
expressed in the brain (Hammond, 1990) and its transport from the blood is
prevented by the blood brain barrier. Previous recent studies had found
ll(3-OHSD activity absent in hippocampal extracts in vitro (Edwards et al,
1988; Funder et al, 1988). However, llp-OHSD activity in brain had been
reported in earlier studies in rat (Mahesh & Ulrich, 1960; Grosser & Bliss,
1963; Peterson et al, 1965), in mouse ( Grosser, 1966), in dog ( Eik-Nes &
, 1965) and in baboons (£rroSSer , 1968). In addition, it was found that
dehydrogenase activity was enhanced by adding NADP+ in the incubation
buffer (Peterson et al, 1965; Grosser & Bliss, 1963).
The aim of this study was thus to investigate lip-OHSD distribution
in the brain as a first step to the study of its possible role in the localised
differences in corticosterone binding to MR and/or GR in the brain.
3.2 Results
3.2.1. NADP+-dependent lip-OHSD in vitro activity in brain
In tissue homogenates, lip-OHSD activity expressed as the
percentage conversion of 3 H-corticosterone to ^H-11 -dehy drocorti-
costerone in 60 min (see section 2.4), showed very low levels of activity in
the absence of NADP+ in every brain region tested (under 10%
conversion), except in cerebellum where 18 % conversion was found. This
was significantly more than heart which showed 0.8% conversion
(indistinguishable from the assay blank values) but modest level
compared to kidney in which 63.4% conversion was found under these
conditions. As NADP+ is a co-substrate for lip-OHSD, we looked at the
effects of various concentrations of NADP+ on 1 ip-OHSD activity by adding
it to the incubation buffer (Fig. 3.1.). Addition of 200 pM NADP+ led to a
modest increase in activity in kidney (by 15.6%) and heart (by 14.2%) but
a marked increase in lip-OHSD activity in cerebellum (by 46%) (all
p<0.001; ANOVA followed by unpaired students t test). Because the brain
does not store high levels of NADP+ (Glock & McLean, 1955), we, thereafter,
systematically added it to the incubation buffer at a final concentration of
200 pM.
In these conditions we found lip-OHSD activity in every brain
subregion (Fig. 3.2). Highest levels of activity, similar to those found in
kidney under the same experimental conditions, were found in
cerebellum, hippocampus, cortex and pituitary.
NADP concentration (pM)
Figure 3.1. : Effect of NADP+ on 11(3-OHSD activity in homogenates of
cerebellum compared to kidney and heart. n=5 for 0 and 200 pM NADP+,
otherwise n=2.
cerebellum cotex hippoc. hypoth. brain si spiral cord pL kidney heart
Figure 3.2, : ilp-OHSu activity in homogenates of rat brain subregion. n=5
The co-substrate NADP+ was added at a Final concentration of
200 pM
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3.2.2.11(3-0HSD mRNA expression: subregional distribution and cellular
localisation
Northern blots (20pg total RNA) (see section 2.3.2.) hybridised with
32p-iabelled lip-OHSD cDNA probe under stringent conditions (last post-
hybridisation wash was in 0.2 xSSC, 0.1 % SDS at 60°C and for 30 min.)
showed lip-OHSD mRNA expression in every region of the brain, although
at levels lower than in liver and kidney (Fig 3.3). No expression was
detected in heart under this condition. Within the brain, cerebellum,
cortex and hippocampus showed high ll(3-OHSD mRNA expression with
lower expression in brain stem, spinal cord, hypothalamus and pituitary.
The signals detected in testis, pituitary and hypothalamus were weaker
than expected since a high llfJ-OHSD activity was found in these tissues.
Loading of RNA on the gel was judged only by O.D. and by visualisation of
the RNA under UV after staining the gel with ethidium bromide. Testis
RNA was obviously underloaded but not pituitary or hypothalamus. Thus,
discrepancy between mRNA and in vitro activity in these two tissues
might be due to dissection artefacts or to the presence of a different 11(5-
OHSD species not recognised by the cDNA employed.
Li K He T Lu Ce Hi Co Hy St P Sc
Figure 3.3. : Northern blot (20 pg total RNA per lane), hybridised with
32P-labelled 11J3-OHSD cDNA probe. Li= liver, K=kidney, He=
Heart, T=Testis, Lu= lung, Ce= Cerebellum, Hi= Hippocampus, Co=
parietal cortex, Hy= Hypothalamus, St=brain stem, P= pituitary,
Sc= Spinal cord.
In situ hybridisation using 3 5 s abeled cRNA antisense probes
confirmed localised cerebral lip-OHSD mRNA expression. Data from
microscopy of emulsion-coated sections, counterstained with haema-
toxylin and eosin, are summarised in Table 3.2. Highest levels of lip-OHSD
mRNA were found in parietal cortex neurons (layer IV), modest expression
was found in the caudal part of the frontal cortex (layer IV only) and
piriform cortex. Other cortical neurons did not express lip-OHSD mRNA.
Most, if not all, hippocampal neurons showed high expression of lip-OHSD
mRNA (Fig. 3.4a & b), with the highest levels in CA3 pyramidal cells.
Hypothalamus generally showed low lip-OHSD mRNA expression but
localised expression was found in the anterior part of the medial preoptic
area (including the organ vasculosum of the lamina terminalis; OVLT) and
the posterior part of the arcuate nucleus around the posterior margin of
v\o c sko^-v
the third ventricle ( •) In a later in situ hybridisation study in the
hypothalamus (Yau et al, 1991b) high levels of lip-OHSD mRNA were found
in paraventricular nucleus. There was also high mRNA expression in
anterior lobe of pituitary, vasculature in the meninges and choroid
plexus. lip-OHSD mRNA is very abundantly expressed in the cerebellar
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frontal (layer IV) +(+)
frontal (other layers) ±
piriform +++
parietal (layers II and III) -h-
parietal (layer IV) +++(+)





pituitary (neurointermediate lobe) ±
Table 3.2. : Distribution of llp-OHSD mRNA expression by in situ
hybridisation histochemistry in selected forebrain regions and pituitary.
Key; - absent, ± very weak (just above background), + weak, ++ moderate, +++
strong. (+) denotes higher expression in some areas of the structure
indicated
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Figure 3.4. : In situ hybridisation of rat brain sections hybridised with
35S-labelled llfi-OHSD cRNA antisense probe.
(a) autoradiograph of a coronal section of forebrain.
(b) high power view of CA3 hippocampus
(c) No hybridisation was detected when the sense probe was used
in the same conditions.
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Figure 3.6. : (n)Autoradiograph of a coronal section of rat cerebellum and
brain stem hybridised with a 35s-iabelled lip-OHSD cRNA
antisense probe. No hybridisation was detected when the
sense probe was used in the same conditions, (b)
3.3 Discussion
We found lip-OHSD bioactivity and mRNA expression in rat brain.
In NADP+ unsupplemented brain subregions homogenates, enzyme
activity is low but is markedly increased, to levels similar to those found in
kidney, when the co-substrate NADP+ is added to the incubation medium.
Although brain levels of NADP+ and other adenine dinucleotides are very
low compared to liver, kidney and other tissues (Glock & McLean, 1955), it
is likely that brain, a tissue that is largely metabolically-dependent on the
circulation, will resynthesise rather than store energy-pathway related
molecules such as NADP+. Thus the large discrepancy between basal and
NADP + -supplemented lip-OHSD activity in brain in vitro may reflect rapid
depletion of endogenous dinucleotide in the reaction mixture and this
might be responsible for previous negative findings (Edwards et al, 1988;
Funder et al, 1988). Whether limitation of NADP+ concentrations plays any
role in vivo in the regulation of llp-OHSD activity remains to be deter¬
mined.
Lakshmi et al (1991), also found highest NADP+-dependent activity
in cerebellum, hippocampus, cortex and pituitary. They showed that these
tissues contain 1 ip-reductase as well as 1 ip-dehydrogenase activity,
although in every brain subregion the ratio is in favour of
dehydrogenation. They also show that Cortisol is a poor substrate for rat
hippocampal lip-OHSD, providing another explanation for Funder et al
(1988) negative results, and suggesting species and tissue differences in
11P-OHSD specificity.
lip-OHSD in all brain areas investigated showed expression of an
apparently single mRNA species of identical size to that found in liver. In
addition, Western blot analysis revealed a 34 kD immunoreactive species as
found in liver but an additional 26 kD species was also detected using one
of the antibody (56-125). However, this 26 kD species seems to have no lip-
OHSD activity (Lakshmi et al, 1991).
In situ hybridization localised 11B-OHSD mRNA expression to
pyramidal and granule cell neuronal layers of the hippocampus with
highest expression in the CA3 field. Whether lip-OHSD functions to
regulate access of corticosterone to hippocampal glucocorticoid and/or
MRs, and thereby affects the functions of either or both receptors,
remains to be determined. However, as ll(3-OHSD, MR and GR mRNAs are
expressed in the majority of hippocampal neurons co-localisation is very
probable. Furthermore, utilisation of the quantitative autoradiographic
[ 14C]2-deoxyglucose uptake technique in conscious rats, provided evidence
for lip-OHSD in vivo relevance. Indeed, it has been shown that inhibition
of lip-OHSDby glycyrrhetinic acid in vivo, increases glucose utilisation in
hippocampus, particularly in CA3 field, and also in several regions of the
hypothalamus including the pre-optic area, the arcuate nucleus and
paraventricular nucleus (Seckl et al, 1991). Glucocorticoids affect
behaviour and memory via the hippocampal corticosteroid receptors.
Impairment of these functions in rat emerge with age or after exposure to
chronic stress, due to a decrease in GR concentrations in the hippocampus,
which leads to dysfunction of the HPA axis and hypersecretion of
glucocorticoids. Sustained exposure to glucocorticoids, in turn, produces a
cascade of metabolic effects that can result in neural degeneration and a
loss of cognitive function (Sapolsky et al, 1986). A possible role for 1 ip-
OHSD could be to protect hippocampal pyramidal and granules cells from
glucocorticoid neurotoxic effects. Also, not all aldosterone binding to
hippocampal MR is readily displaced by excess corticosterone and
aldosterone may antagonise the MR-mediated actions of corticosterone on
hippocampal serotonin turnover (De Kloet et al, 1983, McEwen et al, 1986a).
Thus, there may be a subpopulation of hippocampal MR aldosterone-
selective that are protected, at least in part, from corticosterone by 11P -
OHSD.
In cerebellum and neocortex there were also high levels of 11P -
OHSD bioactivity and mRNA expression. These regions have much GR
immunoreactivity and mRNA expression (Sousa et al, 1989), but little MR
expression (Arriza et al, 1988). In addition, the post-adrenalectomy rise in
GR levels in these tissues is down-regulated by very low-dose
dexamethasone but not corticosterone (Brinton & McEwen, 1987). An
alternative explanation to that evoked by Luttge et al, (1989), is the
presence of active llp-OHSD which metabolises corticosterone but not
dexamethasone.
Much pharmacological and ligand-binding data suggest that
periventricular areas of the hypothalamus are the location of the cent'
aldosterone-mediated effects on salt and water homeostasis • e
introduction). We have found only very modest lip-OHSD mRNA expression
and bioactivity in whole hypothalamic extracts, in vitro, but in situ
hybridisation demonstrated localised higher llp-OHSD mRNA expression in
the most anterior region of the medial preoptic area/OVLT and the
periventricular posterior part of the arcuate nucleus. Thus, lip-OHSD
predominates in those hypothalamic areas where MRs are thought to be
aldosterone-selective and where central action of aldosterone on salt
appetite and blood pressure regulation are thought to take place. At this
sites lip-OHSD could play the same role that it does in kidney, i.e.
conferring aldosterone specificity to the MR. Therefore, abnormalities of
lip-OHSD activity might allow excessive binding of corticosterone to
normally "aldosterone-selective" hypothalamic MRs leading to neurogenic
hypertension. However, Gdmez-Sanchez (1991), found that icv infusion of
carbonexolone (an lip-OHSD inhibitor) produces hypertension in rat,
which can be blocked by administration of the antimineralocorticoid
RU28318. This effect is surprising since chronic icv infusion of
corticosterone has no effect and icv infusion of a glucocorticoid agonist
(RU 28362) decreases blood pressure. Furthermore, concomitant icv
infusion of corticosterone and aldosterone result in corticosterone
counteracting the pressor response to aldosterone. Enhanced binding of
corticosterone to the MR at this site, due to llp-OHSD inhibition, would thus
be expected to decrease blood pressure. Since it is impossible to know
which sites are affected by icv infusion of a particular compound, further
study is necessary to interprete this effect of carbenoxolone. In
particular, carbenoxolone is not very lipid-soluble and might not access
equally all areas of the brain. It would be of interest to see if GE, which is
much more lipid-soluble would produce the same effects as carbenoxolone.
Finally, carbonexolone is not a specific inhibitor of lip-OHSD, and for
example it may inhibit 5P-reductase (Latif et al, 1990), which would
prolonged the half-life of aldosterone and tetrahydroaldosterone, thus
increasing mineralocorticoid activity.
Moderately high lip-OHSD mRNA expression (and bioactivity) was
also found in anterior pituitary, suggesting that lip-OHSD might influence
the access of corticosterone to receptors at this site, and providing a
possible explanation for observed preferential binding of dexamethasone,
compared with corticosterone, to pituitary (De Kloet et al, 1975). Lakshmi
et al (1991) found very high lip-OHSD activity in the pituitary and they
postulated that presence of lip-OHSD might provide a short term
mechanism for preventing prolonged retention of active glucocorticoids
in the gland and thus sensitivity to short term fluctuations of circulating
steroid may be enhanced. Any role for lip-OHSD in the regulation of the
hypothalamic-pituitary adrenal axis by physiological corticosteroids
remains to be determined.
Very recently, Sakai et al, (1992), reported the distribution and
localisation of 11 (3-OHSD-like labelling in rat forebrain by
immunocytochemistry. They used two antisera (56-125 & 56-126) directed
against different epitopes on lip-OHSD. Both antisera gave virtually
identical staining patterns, although on Western blot 56-125 recognises an
additional species of 26 Kd in the brain. Their study largely confirmed our
in situ hybridisation data, showing higher labelling in neurons of the
hippocampus and cerebral cortex. lip-OHSD immunoreactivity was also
detected in the preoptic area, central nucleus of the amygdala and bed
nucleus of the stria terminalis, but there, preferentially in the glial cells.
In summary, high lip-OHSD bioactivity, mRNA expression and
immunoreactivity is found in rat brain. In brain subregions where MR
retain aldosterone specifically in vivo, lip-OHSD role may be similar to
that described in kidney. However, presence of lip-OHSD in tissues that do
not contain MR but where GR is very abundant, or in tissues where MR
does not display specificity for aldosterone, suggests that lip-OHSD
regulates the access of glucocorticoids to GR at these sites as it does in the
skin (Teelucksingh et al, 1990) or in testis (Phillips et al, 1989).
It remains to be seen if lip-OHSD and MR (and GR) co-localise to the same
cells in the brain areas, whether this co-presence confers specificity to
aldosterone on these cells and whether the more prevalent glial cell
localisation has any significance.
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4.1 After corticosteroid manipulation
4.1.1. Introduction
The brain is extremely sensitive to glucocorticoids and variations
within the normal physiological range produce detectable changes in the
threshold to certains sensations as well as higher functions, such as
concentration, memory and intellectual performance. In general,
deficiency depresses cerebral activity, causing apathy and lassitude, loss
of weight and appetite. Glucocorticoid excess, however, leads to mental
overstimulation, resulting in a marked feeling of well-being,
hyperactivity, increased appetite, reduced sleep and sometimes tension
and irritability. It is therefore unsurprising to find a high incidence of
neuropsychiatric disorders both in patients with Cushing's syndrome and
Addison's disease (von Zerssen, 1976). Glucocorticoid hypersecretion
emerges with age or as a result of chronic stress, and alters the sensitivity
of the system of feedback regulation. This negative feedback is mediated
by the pituitary, hypothalamus, and a number of suprahypothalamic sites,
including the hippocampus. Involvement of the hippocampus is supported
by studies showing that lesions in the hippocampus produce
glucocorticoid hypersecretion and negative feedback insensitivity
(Sapolsky et al, 1986). The inhibitory effects of glucocorticoids at the
hippocampus appear to be mediated by the GR. Changes in GR
concentrations in hippocampus but not in hypothalamus or pituitary are
found as an effect of age (decrease of GR) or after neonatal handling
(increase of GR) (Meaney et al, 1988).
In Chapter 3 we reported 110-OHSD mRNA expression,
immunoreactivity and bioactivity in rat brain, with particularly high
expression in cerebellum, hippocampus and neocortex, and hypothesised
that 110-OHSD might control the access of corticosterone or Cortisol to
brain receptors and thereby modulate the effects of glucocorticoids on
cerebral function. It is particularly interesting that 110-OHSD is present in
hippocampus where it could perhaps protects sensitive neurons from the
deleterious effects of glucocorticoid hypersecretion. To investigate this
further, we have examined the effects of acute and chronic corticosteroid
manipulation on lip-OHSD in brain and kidney.
4.1.2. Results : lip-OHSD is up-regulated by glucocorticoids in brain
Five groups of rats were used for this study (n=3-6 per group). One
group was adrenalectomised in order to clear endogenous corticosteroids, a
second group was adrenalectomised and replaced with dexamethasone (0.2
mg/ kg), by sub-cutaneous injection every day to study the effect of
glucocorticoids, a third group was adrenalectomised and replaced with
aldosterone (20 pg/kg), by sub-cutaneous injection every day, to study the
effect of mineralocorticoids, a fourth group of intact animals was treated
with the antiglucocorticoid RU38486 (10 mg/kg) and the control group was
sham-operated and received vehicle. Rats were sacrificed 1 or 10 days
after treatment (see section 2.5. for more details on the methods).
Twenty-four hours after adrenalectomy there were no significant
changes in lip-OHSD activity in brain subregions (Fig. 4.1.). By contrast,
10 days after adrenalectomy lip-OHSD activity had fallen in hippocampus
(by 14.4% ), parietal cortex (by 12.3%) and cerebellum (by 7.2%),
compared to sham-operated rats (Fig. 4.2). Dexamethasone replacement led
to a reversal of the adrenalectomy-mediated changes in lip-OHSD
bioactivity in all brain regions examined, with rises in hippocampus (by
37.2%), parietal cortex (33.1%) and cerebellum (12.7%), when compared to
adrenalectomy alone. In both hippocampus and parietal cortex, but not
cerebellum, dexamethasone treatment significantly elevated lip-OHSD
activity above sham-operated control values. Treatment of intact rats with
the antiglucocorticoid RU38486 for 10 days led to a marked significant
decrease of llp-OHSD activity in hippocampus (28.2% fall). Aldosterone
replacement had no effect on hippocampal enzyme activity in
adrenalectomised rats. None of the treatments altered renal lip-OHSD
activity (Fig 4.1 and 4.2).
To test whether the changes in hippocampal lip-OHSD activity occurred
at the level of transcription, we analysed the effects of 10 day-
adrenalectomy and dexamethasone replacement by Northern blots (this
experiment was done by Susan Low). RNA was extracted from a set of tissue
of the 10-day experiment animals (n=5 per group) and hybridised with a





















Figure 4.1. : Effect of acute (24 h) corticosteroid manipulations on 11|3-
OHSD bioactivity in rat brain subregions and kidney.
Adx=adrenalectomy, sham=sham-operated controls, adx+dex=
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Figure 4. 2, : Effect of chronic (10 days) corticosteroid manipulations on
113-OHSD bioactivity in rat brain subregions and kidney.
Adx=adrenalectomy, sham=sham-operated controls, adx+dex=
adrenalectomy and dexamethasone replacement, RU38486 was
given to intact rats, adx+aldo=adrenalectomy and
aldosterone replacement.
*p<0.05 compared with sham-operated control.
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dexamethasone replacement (Dex) for 10 days on lip-OHSD
mRNA expression in rat hippocampus. Autoradiograph of a
Northern blot hybridised with 32p_ja^)ejecj np-OHSD cDNA
probe (solid arrow), then rehybridised with a similarly
labelled probe to 7S RNA (open arrow) to control for RNA






Figure 4.4. : Effects of sham-operation (SHAM) or adrenalectomy (ADX) ±
dexamethasone replacement (DEX) for 10 days on ilji-OHSD
mRNA expression in rat hippocampus. lip-OHSD mRNA levels
are shown as percentage expression in sham-operated
controls (control mean normalised to 100%).
hybridisation wash in 0.2 x SSC, 60°C for 30 min.). The same Northern blot
was reprobed with a cDNA encoding for 7S (Balmain et al, 1982) using the
same conditions of hybridisation, to control for RNA loading. lip-OHSD
mRNA expression fell by 23% after adrenalectomy (compared to sham-
operated animals) and rose by 70% (compared to adrenalectomised rats)
after replacement with dexamethasone (Figs. 4.3 and 4.4), thus paralleling
the changes in bioactivity.
4.1.3. Discussion
Previous studies have suggested that lip-OHSD activity is under
complex hormonal control, with tissue-specific regulation by thyroid
hormones, sex steroids and insulin. L-thyroxine injected intraperitoneally
in rat in vivo inhibits lip-OHSD activity in liver but not in kiney; it
requires several days before the effect on hepatic lip-OHSD could be
detected (40% decrease after 7 days, 80% decrease after 17 days), and the
thyroid hormone is ineffective in vitro (Koerner & Hellman, 1964; Zumoff
et al, 1983). In addition, lip-OHSD activity was found higher in male than
in female rat liver and kidney homogenates (Koerner & Hellman, 1964).
Gonadectomy operated on rat male decrease lip-OHSD in liver to female
levels and replacement with testosterone in male restore the activity to
normal control values and increase lip-OHSD activity in female to male
values. Hypophysectomy has no effect on lip-OHSD activity in male rat but
increase the activity in female to male values, suggesting that the
pituitary exert a repressive action on lip-OHSD activity in female (Lax et
al, 1978). Induction of lip-OHSD activity by estrogen has been shown in
baboon placenta; lip-OHSD activity in baboon placenta at midgestation was
increased 3-fold by androstenedione treatment (an estrogen precursor),
and fetectomy markedly reduced placental lip-OHSD activity compared to
intact untreated baboons near term. In addition cortisone and especially
progesterone showed a dose dependent competitive inhibitory effect on
placental lip-OHSD (Baggia et al, 1990). Induction of lip-OHSD activity by
glucocorticoids has been reported in cultured human skin fibroblasts. In
human fibroblasts 11P -reductase activity is higher than 11 p -
dehydrogenase activity but both activities were induced by treatment of
the cells by dexamethasone, an effect blocked by glucocorticoids
antagonists. In contrast 8-bromo-cAMP, phorbol esters, or insulin
decrease both lip-OHSD activities in these cells (Hammami & Siiteri, 1991).
Levels of lip-OHSD activity in rat kiney were found unaltered by
dexamethasone treatment or thyroxine administration in vivo or by
castration in either sex; in contrast, estrogen administration increases
enzyme activity in male rats (Smith & Funder, 1991).
Here we confirm the absence of corticosteroid regulation of renal 11 p-
OHSD activity but, by contrast, show regulation of 11(3-OHSD activity in
subregions of the rat brain in vivo by chronic, but not acute
manipulations of glucocorticoid levels.
Adrenalectomy significantly attenuated enzyme activity in each brain
region studied, an effect presumably due to depletion of glucocorticoids
since (i) it was mimicked by treatment of adrenally-intact rats with
RU38486 and (ii) it was reversed by dexamethasone, but not by
replacement with aldosterone. Indeed, supraphysiological replacement
with dexamethasone, a synthetic (non-metabolised) glucocorticoid,
potentiated lip-OHSD activity (compared with control) in hippocampus and
parietal cortex, but not cerebellum. These subregional differences in the
effects of dexamethasone might be due to tissue-specific regulatory
factors. Since acute (24h) adrenal steroid alterations had no effect on 1 ip-
OHSD activity, the chronic effects of glucocorticoids on cerebral lip-OHSD
may be indirectly mediated, i.e. via a second messenger, or perhaps
turnover of the protein is slow. Nevertheless, the Northern analysis
demonstrates that glucocorticoid effects on hippocampal enzyme activity
occur, at least in part, at the level of lip-OHSD gene transcription. Similar
glucocorticoid-mediated up-regulation of lip-OHSD in cell culture also
suggests a direct effect (Hammami & Siiteri, 1991). Furthermore, both
human and rat lip-OHSD gene promoter regions contain sequences
resembling glucocorticoid response elements (Tannin et al, 1991; Moisan
et al, 1992b, Chapter 5). Interestingly, 4 days of treatment with thyroxine
produces no effect on rat liver lip-OHSD, but decrease in lip-OHSD activity
is detected after 7 days of thyroxine administration.
Since either chronic excess and deficiency of circulating
glucocorticoids exert deleterious effects on the brain, including neuronal
loss particularly in the hippocampus (Sapolsky et al, 1986; Sloviter et al,
1989), glucocorticoid-mediated regulation of lip-OHSD activity may
function to protect sensitive neurons from long-term elevation or fall of
glucocorticoid levels, i.e. glucocorticoid regulation of brain lip-OHSD may
maintain optimal exposure of neurons to glucocorticoids and preserve
essential "tonic" neurochemical functions, whilst not attenuating the
effects of the diurnal variation or acute stress.
The absence of glucocorticoid regulation of kidney lip-OHSD provides
further support to the growing body of data suggesting there is a distinct
high activity renal lip-OHSD isoform showing little or no regulation by
hormones (Krozowski et al, 1990) or during ontogenesis (Moisan et al,
1992a, section 4.2). Teleologically this would accord with the need for renal
lip-OHSD to protect MR in the distal convoluted tubule and cortical
collecting duct from any prevailing level of circulating glucocorticoid,
thus ensuring selective aldosterone access even during chronic stress or
in states of excess endogenous or exogenous Cortisol.
MR in the hippocampus are apparently non-selective and
bind corticosterone in vivo. However, these data have been derived from
in vivo administration of radio-labelled ligands to animals which have
undergone prior adrenalectomy to clear endogenous corticosteroids. Often,
but not always, adrenalectomy has been performed several days before
administration of steroid and any activity of cerebral lip-OHSD may have
been attenuated. Thus there may be a subpopulation of hippocampal MR




Glucocorticoids play an important role during development, affecting
the growth and differentiation of a number of tissues and organs,
including the central nervous system (for review see De Kloet et al, 1988).
High dose glucocorticoid administration during the early postnatal period
in rodents leads to permanent inhibition of brain growth, with reduced
neurogenesis and glial proliferation, attenuated dendrite formation and
behavioural and neuroendocrine impairments (Meyer, 1985). Conversely,
adrenalectomy of 11-day-old rats is followed by neuronal and glial
proliferation (Yehuda et al, 1989) which is reversed by corticosterone
replacement. Hence corticosterone is thought to exert an antiproliferative
effect on postnatal neurogenesis and glial mitosis in the normal intact
animal. These effects are most marked during the first two weeks of life
and thus close control of circulating glucocorticoid levels during this time
appears critical for normal brain development.
Low and constant levels of circulating glucocorticoids were thought to be
ensured by the hyporesponsiveness of the hypothalamic-pituitary-
adrenal (HPA) axis to stressful stimuli during the first two weeks of life in
the rat, and the absence of circadian fluctuations in plasma glucocorticoid
concentrations in neonates (Schapiro, 1962). However it has been
recently found that various stressors trigger an adult-like pituitary ACTH
response in 10-day-old rats, the magnitude of which is affected by
corticosterone (Walker et al, 1991). Although the corticosterone response
is smaller than that seen in the adult, CBG levels are very low in the
neonate and free glucocorticoid levels may be similar. Brain MR which, at
least in part, mediate corticosterone feedback on the HPA axis (Levin et al,
1988), are at near adult levels within 3 days of birth, and show the same
topography than in the adult, i.e. hippocampus, septum, amygdala and
cortical layer II (Rosenfeld et al, 1990; Sarrieau et al, 1988). In contrast, GR
levels are low after birth and reach adult levels after 4 weeks of age.
Immunocytochemistry of GR protein showed that the staining intensity
was high at birth and then fell to minimal levels at day 12 (Rosenfeld et al,
1988 & 1990; Sarrieau et al, 1988). Thus the MR is thought to be the
receptor responsible for the physiological effects of corticosterone
during brain development, and GR may become important when
glucocorticoid levels are elevated, e.g. after stress. Consequently, it
remains unclear how the brain is protected from elevated glucocorticoid
secretion following stress during this critical period of development.
Similarly to the adult, lip-OHSD might also regulate glucocorticoid
access to corticosteroid receptors during postnatal development. Indeed,
the importance of llfi-OHSD has been described in placenta and in foetal
lung ( see introduction, section 1.3.6.). The ontogeny of lip-OHSD mRNA
expression has been studied previously using the cloned hepatic llJi-OHSD
cDNA (Agarwal et al, 1989) in 1,2,3,4,8, and 16-week-old rats in kidney,
liver and lung and showed a tissue-specific developmental pattern
(Krozowski et al, 1990). In this study, we have examined llp-OHSD
bioactivity and mRNA expression in the brain, in comparison with kidney,
during the first two weeks of life to determine whether 11J3-OHSD might
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affect cerebral glucocorticoid exposure during this crucial period of
development.
4.2.2. Results: tissue-specific pattern of lip-OHSD activity and mRNA
during development
Tissues were examined for lip-OHSD activity (see section 2.4) at various
times in neonates and compared to adult values (Fig.4.5). lip-OHSD activity
in the kidney was already high at birth (69±3%) and rose significantly to
adult values (80±1%) by postnatal day 5. By contrast, activity in
hippocampus and cortex, though moderately high at birth (46±4% and
48±5% respectively), fell significantly to a nadir at postnatal day 10 and
then rose gradually to adult values. Cerebellar llp-OHSD activity was high
at birth (61±3%), rose significantly to a peak at postnatal day 10 then fell
to adult values by postnatal day 15.
Northern blot analysis (see section 2.3.2.) was used to investigate the
postnatal development of llp-OHSD mRNA expression. Kidney and
hippocampal RNA extracts were run on a single gel and are thus directly
comparable (Fig.4.6). In addition, the blot was reprobed with human
glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA (Edwards et al,
1985) using the same conditions of hybridisation, to control for RNA
loading. We observed very high levels of lip-OHSD mRNA expression in
hippocampus at every age investigated. However only weak lip-OHSD
mRNA expression was detected in neonatal kidney, compared to
contemporaneous hippocampus or adult kidney. Densitometry against
GAPDH cDNA expression revealed lip-OHSD mRNA was 2.5-3 times more
abundantly expressed in neonatal hippocampus than in kidney. In adults,
by contrast, lip-OHSD mRNA expression was 1.5-2 times higher in kidney
than hippocampus. Adult hippocampus showed a 'single llp-OHSD mRNA
species which was of similar size to the single species present in neonatal
hippocampus. Total RNA from adult kidney was deliberately underloaded to
allow differentiation of the multiple lip-OHSD mRNA species (Fig 4.6). We
detected four species confirming previous data (Krozowski et al, 1990) but
found that one species gave a much more intense signal than the others.


























Figure 4.5. : Ontogeny of lip-OHSD activity in rat brain subregions and
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Figure 4,6. : Ontogeny of lip-OHSD mRNA expression in rat kidney and
hippocampus. Autoradiograph of a Northern blot hybridised
with 32P-labelled lip-OHSD cDNA probe. 15 pg of total RNA
were loaded per lane, except adult kidney (5 jig). Ad= adult rat.
Figure 4.7. : Localisation of lip-OHSD mRNA expression in neonatal brain,
(q) Autoradiograph of a sagital section of 10-day-old rat brain
hybridised with ^5S-labelled llp-OHSD cRNA probe. Note the
high expression in dorsal (dh) and ventral hippocampus (vh),
cerebellar cortex (cc) and neocortex (nc).
Figure 4.8 : Localisation of lip-OHSD mRNA expression in neonatal kidney.
Autoradiograph of longitudinal kidney sections hybridised
with 32p_iabeiied lip-OHSD cRNA probe. All sections were
hybridised with the same probe and exposed to Kodak XAR film
simultaneously for 2 days; expression is thus directly
comparable.
In situ hybridisation confirmed high expression of 11J3-OHSD mRNA in
neuronal layers of the hippocampus, cerebellar cortex and neocortex in
the 10-day-old rat (Fig.4.7). In neonatal kidney, only low expression of
lip-OHSD mRNA could be detected, predominantly in the outer cortex.
Renal cortical expression of ll(3-OHSD mRNA increased with age, but was
much less than adult levels (Fig.4.8).
4.2.3. Discussion
The presence of lip-OHSD activity in perinatal brain has been reported
in previous work, using homogenates or subcellular fractions of whole
brain. lip-OHSD activity was detected in cerebellum, cortex, brain stem
and hypothalamus of fetal baboons, and was particularly high in the
cerebellum of the third trimester primate brain, with 50% conversion of
Cortisol to cortisone (Grosser & Axelrod, 1968). lip-OHSD activity was also
detected in fetal mouse brain (Tye and Burton, 1979) and in fetal sheep
tissues 10 days before term where lip-dehydrogenase was only found in
kiney, cerebrum and cerebellum (Smith et al 1981). In this report we
showed a subregionally-specific developmental pattern of lip-OHSD
activity in hippocampus, cortex and cerebellum, associated with high
expression of a single species of lip-OHSD mRNA.
lip-OHSD mRNA expression is high in neonatal hippocampus and
cerebellum, but does not vary in parallel with the changes in activity.
This might reflect developmental differences in mRNA stability,
translation or post-translational modifications; the latter are known to
affect the bioactivity of lip-OHSD (Agarwal et al, 1990). However, the
association of very low lip-OHSD mRNA expression with high bioactivity
in the early postnatal kidney indicates that another protein with identical
activity may exist, as suggested to occur in parotid, mammary gland and
mesenteric arcade (Krozowski et al, 1990).
The biological importance of the various ontogenic patterns of lip-OHSD
activity in the central nervous system remains to be determined. We have
describe in section 4.1 how lip-OHSD activity is affected by glucocorticoid
levels in the adult rat brain but not kidney. Since the developmental
patterns of lip-OHSD activity in the neonatal hippocampus and cortex
parallel changes in circulating corticosterone levels this may merely
reflect glucocorticoid regulation of enzyme activity in the neonatal
period. However, lip-OHSD activity in neonatal cerebellum shows a
distinct pattern, although adult cerebellar ll(3-OHSD activity is also
affected by glucocorticoid levels. Therefore, other tissue-specific
regulatory factors may be of importance.
Corticosteroid receptors display a considerable degree of plasticity
during development. MR and GR show a different ontogeny in the
developing rat brain and changes in receptor number and capacity are
observed as a consequence of neonatal manipulation (De Kloet, 1991). For
example, handling of neonatal rats, e.g. daily placing the neonatal
animals in a new environment for 15 min., is associated with increased
concentrations of GR in the hippocampus and in the amygdala but no
changes elsewhere in the brain. This increased GR concentration led to
greater hippocampal sensitivity to glucocorticoids and enhanced negative
feedback efficacy in the handled rats. This, in turn, retard hippocampal
neuron loss and spatial memory deficits associated with age in non-
handled rats (Meaney et al, 1988).
The subregional differences in lip-OHSD activity during development
may also relate to a local and time-specific requirement for
corticosterone. The enzyme may provide protection of sensitive neurons,
glia and/or dendrites from elevated corticosteroid levels, for example
during stress. By contrast, reduced lip-OHSD activity may allow exposure
of receptors to physiological corticosteroids ensuring inhibition of cell
proliferation at appropriate times. Interestingly, the effects of synthetic
(non-metabolised) glucocorticoids and corticosterone differ in their
actions on cerebral neurogenesis, perhaps reflecting the activity and
importance of the enzyme in vivo. Administration of dexamethasone or
prednisone to pregnant rat, mice or monkeys result in a lowered body
weight of the pups whereas treatment of rat with low dose of
corticosterone cause trophic effects on the cerebellum at least until 12
days of age (Velasquez & Romano, 1987).
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5.1 Introduction
The non-uniform tissue distribution of lip-OHSD as well as its tissue-
specific response to corticosteroid manipulation and during development
suggest a complex regulation of the expression of lip-OHSD gene. To
understand the molecular mechanisms underlying this regulation, we
decided to isolate the gene encoding rat 11J3-OHSD.
Another reason for cloning 11J3-OHSD gene was the growing body of
evidence suggesting the presence of multiple 11J3-OHSD isoforms.
Immunohistochemical studies using the two antisera raised against the
purified lip-OHSD hepatic enzyme (Lakshmi & Monder, 1988) produced
some surprising results. Although MR abound in distal renal tubules,
immunoreactive enzyme was found only in proximal tubules (Edwards et
al, 1988; Rundle et al, 1989). By contrast, enzyme bioactivity has been
demonstrated both proximally and distally (Edwards et al, 1988; Bonvalet et
al, 1990; Naray-Fejes-Toth et al, 1991). Furthermore, Western blots showed
different sizes of immunoreactive proteins in different tissues (Monder &
Lakshmi, 1990). The first antiserum (56-125) identified a 34 kD protein in
liver, an additional species of 40 kD in kidney, 26 kD in brain, and 47 kD in
testis. The second antiserum (56-126) identified a 34 kD protein in all
tissues, additional 68 kD proteins in liver and kidney (possibly a dimer),
and again a 40 kD protein in kidney. Using the purified rat liver lip-OHSD
protein, an lip-OHSD cDNA has been cloned from a liver cDNA library
(Agarwal et al, 1989). This predicts the amino acid sequence of a protein of
only 31 kD. This discrepancy can be accounted for by the glycosylation of
the protein since when the cDNA was expressed in vitro a 34 kD protein
was produced (Agarwal et al, 1990) but it was reduced to 31 kD when
glycosylation was prevented by a tunicamycin homologue added to the
cells.
Rat liver lip-OHSD cDNA hybridises to a single major mRNA species of
1.7 kb in most tissues including liver, whereas three additional mRNA
species are found in kidney (1.5 kb, 1.6 kb, and 1.9 kb) that are not
explained by differences in polyadenylation (Krozowski et al, 1990) and a
3 kb mRNA was found in colon (Whorwood et al, 1991). In situ
hybridisation using the liver cDNA localises lip-OHSD mRNA in kidney to
proximal, distal and cortical collecting duct epithelia (Yau et al, 1991a;
Stewart et al, 1991a) consistent with the bioactivity of the enzyme but in
contrast with the immunohistochemical distribution.
More recently, cDNA clones have been isolated from a rat kidney
library which are not contiguous with the liver cDNA clone in their 5'
extremity (Krozowski et al, 1992). One of these has been sequenced and
shows an identical open reading frame to the liver cDNA downstream from
amino acid Met 27 (Agarwal et al, 1989). This deleted sequence encodes
hydrophobic amino acids which constitutes a putative signal peptide for
membrane insertion, suggesting that the isoforms may differ in their
intra-cellular localisation.
Kinetically, distinct isoforms have also been described, in particular,
the apparent Km of 11JJ-OHSD for corticosterone in intact cortical
collecting duct cells is a 100-fold lower than the Km of liver llfJ-OHSD
(N£ray-Fejes-T6th et al, 1991).
Thus it appears that kidney contains several isoforms of llp-OHSD
which are kinetically and antigenically distinct from the liver form and
may be encoded by alternative transcripts from the same gene as the liver
form or may be products of an alternative gene. One of our aims was to
determine whether the liver and kidney mRNA isoforms could be encoded
by a single gene.
5.2 Results
5.2.1. Isolation of rat genomic clones and restriction endonuclease
mapping
A Sprague-Dawley rat genomic library was screened by hybridisation
to a 32P radiolabeled cDNA probe (see section 2.1.4.). As we were mainly
interested in the 5' flanking region of the gene, we used the most 5' EcoRI-
EcoRV fragment (460 bp) of the rat cDNA (Argawal et al, 1989) as a probe.
The initial screening identified 4 putative positive clones but one of them
was lost during the second round of screening. Three rounds of screening
were necessary to obtain pure clones. DNA from the three clones were
prepared as described in section 2.1.3.3. and were characterised by
restriction endonuclease mapping. Double digestions with SacI and NotI,
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Figure 5.1. : restriction analysis of the three positives X clones
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oligonucleotides or the cDNA, showed that the 3 clones are nearly identical
(Fig. 5.1) and that a 15 kb clone (XA) encompasses the other two. XA was
thus retained for further analysis. Further digestions with enzymes
present in the vector (X DASHII) polylinker or cutting rarely permitted a
detailed restriction map of XA ( Table 5.1. and Fig.5.2.) to be drawn.
5.2.2. Sequence analysis
In order to start the sequence analysis of this clone, various subclones
in pBluescript vector were constructed (Fig. 5.2.) and oligonucleotides
were derived from the cDNA sequence previously published (Argawal et
al, 1989).
Sequence of oligonucleotides used in this study were as follows:-
OL-A=5'AGCTCTGTAGGACACACAAAGAAAACCTGCAGCTCTTTC3' (+ 36_+74)
OL-B= 5'GGAAAGCACAGAAGCAATGAGTGTCCCCAAAGCCTTGTCT3' (+ 831_+870)
OL-C= 5' GATTGGCTTTGGGTGGGATCC3' (-88_ -68)
OL-D= 5' AACTGCCGTCCAACAGGGACCTGGC3' (+81_+105)
OL-E= 5' CAOTTCTTCCCCTGGAGCAT3' (+876_+896)
B739= 5' GGAAGAGAAATGGCATATCAT 3' (+924_ +944)
942= 5' GCCAGGTCCCTGTTGGACGGCAGTT 3" (+81_+105)
M13 universal primer=5' GTAAAACGACGGCCAGT 3'
M13 reverse primer= 5'AACAGCTATGACCATG3'
The sequencing strategy is depicted in Fig. 5.3. Most of the reactions were
performed with the M13 universal or the reverse primer present at the
flanking sites of insertion in the various subclones (Fig.5.2). The other
oligonucleotides used are indicated.
9 1
Single digests:
SacI EcoRI HindHI BamHI Kpnl
5.5 6.5 6.5 3.7 2.9
2.2 3.6 0.4 0.4 1.5
1 .5 2.8 0.35
0.7 1.8 0.3
Double digests:
SacI + EcoRI Sacl + Hindlll SacI + BamHI Sacl + Kpnl
3.6 4.8 5.3 5.5
2.4 1.5 2.2 2.8
2.2 1.2 1.1 2.4
1.8 0.8 0.7 2.1
1.5 0.7 0.4 1.5 (x2)
1.4 0.6 0.3 0.7
0.7 0.35 0.2 (x2) 0.1
0.6 0.3 (x2)
0.4
EeoRI + Hindlll EcoRI + BamHI EcoRI + Kpnl




























N.B. fragments larger than 9 kb are not shown





























































Figure 5.2, : Restriction map of X A genomic clone and description of the
various subclones generated from it.
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EXON1 EXON 2
-900 -500 -100 +100 +500 +900 +1300




Sacl BamHI Sacl BamHI Pstl Pstl
Figure 5.3. : sequencing stratagy; arrows indicate start of sequencing
reaction.
Total identity between the nucleotide sequence of the first and second
exons of our clone and the sequence of the rat liver cDNA showed that this
clone represents the rat llp-OHSD gene. The nucleotide sequence of exons
1 and 2, the first intron and 890 bp of 5' flanking region is shown in Fig.
5.4 - the nucleotide numbering system employed denotes the predominant
transcriptional start site in liver as +1.
There are a number of noteworthy sequence elements within the
sequenced region, including a poly(dT) stretch at -416 to -391 and (dA-dC)
repeats from +1089 to +1131 in intron B. There is no apparent TATA box but
the sequence contains a number of putative transcription factor binding
sites; a CCAAT box at -74 (GCCAAT) which could also be described as a
palindromic CAAT sequence from -72 to -64 (CAATATTG), 6 CACCC-box
elements at -476, -466, -427, -290, -282, and -82, a GC box (SP1 consensus
binding site) at -299, sequences corresponding to the consensus half site
glucocorticoid responsive element (GRE) TGT^/cCT at +61 and +250, and the
pentanucleotide TGACC, in common to estrogen (ERE) and thyroid (TRE)
responsive elements, at positions -839, +635, and +1295.
5.2.3. Identification of lip-OHSD transcription start sites
Primer extension analysis (see section 2.3.4.) was carried out on RNA
isolated from liver and kidney to determine the start point(s) of
transcription. Oligonucleotides first used for analysis were OL-D,
complementary to bases +81 to +105, and OL-A (+36 to +74), both within
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190 CAGCTATCAG AGAOCAGTTG CATAGCCAAA <
790 TaCATTAAOC CaCTTTAACA ACCTOCTACCTnXTTCCTGTnTOOCCGCCCATCATTCCTnrnTATTC OCrGTAGTAATAAGGGCACTTCCATTOCAC
690 TTGOCTCAGA CTCTTGAACT GAGCTTTXJGTTTCCTOOCAT CTGGGTCTGG CTGGT7TOCA ACTTCTCTTT GATGTTGCAA TOCTTTTTCA TTGAACTGGA
<90 ATTGCTTCAG AAT7GQCIUTTOGGGQCXI2CGOGAAGGCTG AGATTTGGCnCACnTOGCTCTATTTTOCTOGL'J 11J 11 J i i 1 1 11 111 7T7TTmTT
390 ooccxxTGOGCooGACOocxiCTTanTxcrcLi iLiLiurrAQXTCcnrcTrmTTorTTOrAnnrTra-iu-i larrcTanTCTATcnjocrrrrc
290 £ACaXTGQLffiCTODCTO:CTCACAACO:ATTCTTOCAAC«XATTCtrrOCTCTCTt)CAAAa^TCnCTaxrrAOCiAGATCCTCACGAAOGCAOOOCrG
I 90 CACAGTCATC AGCCTGCCCA TCTCCAAGTT OOCTCTTACT CAATGAAATC GAGTAAACATTGTCCATTAT GAAATOCATC ACOCAGGCTC CCAOOGACCA
90 ATtX3ATCtCAiXCAAAaXAAn>TTCCTCTGACAGGCAA G7TCCCTACT GCTGOCTGAG ACTACTCCAG CCTCCttXGT CTXTGATGn^CAATTCAGA
♦ II GOCTCCTGCTCOCTOGGAOGTTCTACAAAC AGCTOCAOGTTTTCTTTUTtJTCKAACAC AGCTCOCTGAOCCAGGTTXCTGrTGCACGGCACITATC AA
Mm Lvt
♦ III A AAA TAC CTC CTC CDC GTCCTGGTG CTCTGCCTGGGTTACTACTATTCT ACA AAT GAA GAG TPC AGA CCA GGTGAGTACC ACTGTGTTCCTCACTAGAGG
Lyi Tyi Leu lj* Pro VtJ Lai Vtl 1-ai Cvi [-en Gly Tvt TVi Tvt Sa Tht Am Gl» Gin Phe Afi Pro
♦211 aacacoctta aaacacaagg cjttctaaag atctagctctgi iih ictat occtacacca ctcagaaaga ogaaooccca atcicagictgtaaaccctg
♦ 311 GATOCTCCAG TCCACAGGCT GCAGGCAGGA CGGGACTGCG AGOGGTGAAC CATACAGCCA GGAGOCTATC CTTTCGATGGC CTOCAOCATG GAAAQCAATG
♦ A11 TCAGATCTAC agaactgaag gtagtaccca gacacatcgc tcagtcagat AGCIGTGaTC tatcgagaca CTGATACOCG AGACOCAAAT aaaaacgaog
♦ ill CTATGAAGTT GATGACTAAG TAGAGGCTCT CTGGACACAT TTTTGPGATA CTTTTTAAAA 7TOOCTTTAG TGTTAGCAAA ATTAGTTATG COCAAAGGTG
♦ 611 AACTTCCCTA GTTTCGOCAA AC7CIGACi5T CTtTGGGCTT GTCTCTCTGA TCTCIOCACA TDGAGATGTTTTAGG AATGA AOGCAAAGAA GCCTCGGCTC
♦ 711 TGGACATCCA GGOCAAACCT GTGTTrGAGA C3COGTTTAT GAATAAOCTT AAGICTTGCTTCAGTGTTTT AOCSGCA7GAG OCAAAATGAT CTOGCTC^CA
♦ 111 GCCTTTGaGT ATCGAAAGTG AGACAAGGCTTTGGGGACACTCATTOCTTCTGTOCTnt3CCA GAA ATGCTCCAGOGG AAG AAA GIG ATT GTC ACTGGGGC
Gin Ma La Gin GTy Lyi Ly» YaI Ht Vtl Tfr Gly All
♦911 CAGCAAAGGG ATCGCA ACA GAA ATG GCA TAT CAT CTC TCA AAA ATG OCA GOC CAT GTG GTA TTC ACT GCA AGO TOG GAG GAA OGG CTC CAG AAGGTGAOC
-JocJjJ G2x Ik GN Art Glu Ma All Tvt Hii l.m Sa l.yi Ma Gtv All Hii Vil Yil I^iTIiAU Ari Sg Ghl Gil—Gh Lct Gin Lyi
♦ 101 1 ATTCTOTAOC CACAGATAAG OCTGCCTTCT TCTGTOCAOC TTATAGTCIGACAdTATGT ACAAAOOCTT CCOCCATACA CACACACACA CACACACACA
♦ nil CACACACACA CACACACACA CTCAGTGITG TTAOCCAGAG TTCTTTGATTATGTATGTTC ACAATTGTAC CTCITCATAC ACATTOCCCA TGGACAGATA
♦ 1211 catgtatyxa gaaactcgga ttcctttacc toctcagtcg tttatgttgtttaocogcac agactcacaa atttgagagccctaggtcat aacagcactc
♦ 1311 acaaactcag atotacctgc acagaaacat ocacccacac ccacaatgca citggaaaca tttgttcata aaocctocag
Figure 5.4.:
Nucleotide sequence of the rat llfJ-OHSD 5'-flanking region and the first 2
exons. Vertical arrows represent probable starts of transcription. All
numbers are relative to the major trancription start site in liver (+1).
Putative transcription factor binding sites are underlined. Putative
hormone responsive elements half sites are identified by horizontal
arrows.
A) Primer extension analyses :
(The asteriks indicate extended fragments obtained with RNA from kidney only.)
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) RNAse protection analyses:
"he asteriks indicate protected fragments obtained with RNA from kidney only.)
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exon 1 (Fig. 5.5.). Extension of OL-D and OL-A indicated that major start site
in liver, also used in kidney, is 105 bp 5' of the start of translation in liver,
in agreement with published findings (Argawal et al) (Fig 5.6.A). An
additional larger extension product was seen with kidney RNA. Extension
of OL-C (-88 to -68) was used to confirm and to map more accurately the
start of this mRNA (Fig. 5.6.B). OL-C was extended to a 196 bp fragment,
indicating that this kidney mRNA initiates at -264.
In order to confirm the transcription start points identified by primer
extension, we performed RNase protection assays (see section 2.3.5.). Two
probes were generated for this purpose complementary to bases -521 to
+74 (riboprobe 1 synthesised from subclone pMP5, Fig. 5.5.) and -88 to +310
(riboprobe 2 synthesised from subclone pMP4, Fig. 5.5.). Using riboprobe 1
the predicted 74 bp protected fragment, resulting from hybridisation to
mRNA initiated from the major start site at +1, was observed in liver and
kidney. In addition a 338 bp protected fragment was detected in kidney
confirming that the 5' end of this renal mRNA maps around -264
(Fig.5.7.A). There is no in-phase open reading frame in this sequence
suggesting that this transcribed sequence is not translated. Analysis using
riboprobe 2, entirely covering exon 1 (Fig. 5.5.), resulted in the predicted
180 bp protected fragment corresponding to exon 1, in both liver and
kidney, and an additional 270 bp protected fragment in kidney which
probably corresponds to exon 1 plus the 5' 88 bp of the probe (5.7.B).
The cloning of a variant lip-OHSD cDNA from a rat kidney library was
reported while we were analysing our genomic clone (Mercer et al, 1991).
This cDNA lacks the 5' region encoding the first 26 aminoacids. Because
our sequence analysis revealed that this deleted region was contained in
exon 1 (Fig.5.4.), we tested the possibility that this mRNA might be
initiated in intron A. For this, we performed RNase protection assays using
an antisense probe complementary to bases +758 to +1389 (riboprobe 3
synthesised from subclone pMP7; Fig. 5.5.). We detected the predicted
protected fragment (135 bp) corresponding to exon 2 in liver and kidney.
An additional 196 bp protected fragment was observed in kidney,
suggesting the presence of a transcript containing 64 bp of intron A (Fig.
5.8.A). This additional fragment is clearly detected in kidney but is also
apparent in liver, as a minor product, with longer exposure of
autoradiographs (data not shown).
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Figure 5,6, ;
(A) Primer extension analysis using OL-D (left) and OL-A (right). L= liver
total RNA, K=kidney total RNA, Y=yeast tRNA. 50 tig aliquots were run per
lane in parallel with a sequencing reaction. Autoradiograms were exposed
for a week at -70° C.
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Figure 5.6 :
(B) Primer extension analysis using using OL-C. K=kidney total RNA,
Y=yeast tRNA. 50 |ig aliquots were run per lane in parallel with a
sequencing reaction. Autoradiograms were exposed for a week at -70°C
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Figure 5,7, ;
(A) RNase protection assay using riboprobe 1 generated from pMP5 (-521
to +74). Kt= whole kidney RNA, Km=kidney medulla RNA; 25 pg aliquots
were run per lane and the autoradiogram exposed for 20 h. (B) Similar




(A) RNase protection assay using riboprobe 3 generated from the Aflll-
Pstl fragment of pMP7 (+758 to +1389). L= liver total RNA, K=kidney total
RNA, Y=yeast tRNA; 50 fig per lane run with a sequencing reaction.
Autoradiogram was exposed for 60h.
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Figure 5.8. :
(B) Primer extension analysis using OL-E; L= liver total RNA, K=kidney
total RNA, Y=yeast tRNA; 50 tig/lane. Autoradiogram was exposed for 1
week.
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The existence of this mRNA was confirmed by primer extension
analysis using OL-E, an oligonucleotide complementary to the beginning
of exon 2 (+934 to +954; Fig. 5.5.). OL-E was extended to give 2 major
products in kidney, one of 204 bp corresponding to the major start site
(+1) and a smaller one of 89 bp, corresponding to initiation at +808, giving
rise to an mRNA with a 65 bp 5' extended exon 2 (Fig. 5.8.B).
5.2.4. Northern analysis of llp-OHSD transcripts
Having identified at least 3 transcription start sites we wanted to
determine the corresponding transcripts. To study this we performed
Northern blot analysis with oligonucleotides specific to particular
transcripts (OL-A, OL-B and OL-C; Fig 5.5.). Hybridisation with a full-length
cDNA showed a single major transcript of 1700 nucleotides (nt) in liver
(on shorter exposure) and 3 mRNA species of 1500 nt, 1600 nt and 1900 nt
in kidney (Fig. 5.9.). OL-A, which is complementary to exon 1 (+36 to +74),
hybridised to kidney mRNAs identical in size to the 1900 nt and 1600 nt
species seen with full-length cDNA, and with liver RNA gave a virtually
identical pattern of hybridisation to that obtained with cDNA. OL-B,
corresponding to intron A sequence (+ 831 to +870) hybridised to a single
species in kidney, identical in size to the 1500 nt species seen with cDNA; a
weak band of the same size is apparent in liver. OL-C, complementary to
bases -88 to -68, hybridised to a 1900 nt species in kidney; no signal was
detected in liver. In summary, the 1900 nt species corresponds to mRNA
initiated at -264 and the 1500 nt species to mRNA initiated at + 808. The 1600
nt species in kidney most probably corresponds to mRNA initiated at +1.
Interestingly, the size of the corresponding mRNA in liver is 1700 nt.
Several smaller hybridizing species are seen using OL-A probe, especially
in liver. They may correspond to related transcripts but have not been
further investigated.
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CDNA OL-A OL-B OL~C
Figure 5.9. :
Autoradiograms of Northern blots of liver (L) and kidney (K) RNA. The
probes used in each hybridization are indicated at the top of the panel. 25 p.g
of RNA were loaded per lane. After OL-A hybridisation, RNA was stripped by
boiling and reprobed with the full-length cDNA. Hybridisation with OL-B
and OL-C were performed on RNA run on adjacent lanes of the same gel used
for OL-A/cDNA so that all 4 autoradiograms could be aligned. Autoradiograms
were exposed 20 h for cDNA, 2 days for OL-A, and 4 days for OL-B and OL-C.




We have isolated a rat lip-OHSD genomic clone and determined the
structure of its 5' flanking region.
Using both primer extension and RNase protection analyses we found 3
separate sites of initiation of transcription in kidney, whereas in liver
only one site predominates. The major liver transcript corresponds to the
previously cloned rat liver and human testis lip-OHSD cDNAs (Agarwal et
al, 1989; Tannin et al, 1991). The open reading frame begins with an ATG
codon lying 105 bp downstream of the Cap site. The first 40 amino acid
residues predicted by this open reading frame are identicasl to the actual
N-terminal amino acid sequence of the purified hepatic llp-OHSD
(Agarwal et al, 1989; Lakshmi & Monder, 1988). The same promoter (+1) is
also used in kidney, although our Northern analyses show that the mRNA
species produced is 100 nt shorter (1600 nt instead of 1700 nt) than that
initiating from this start site in liver. Tissue-specific differences in polyA
tail length may explain this since deadenylation of lip-OHSD mRNA from
liver and kidney converts both the 1700 nt and 1600 nt species to a 1500 nt
species (Krozowski et al, 1990). An additional 1700 nt species previously
reported in renal papilla (Krozowski et al, 1990) was not detected in our
Northern blot experiments, either hybridising with full-length cDNA or
oligonucleotides.
The longest renal mRNA species initiates at -264 resulting in a 1900 nt
transcript. This extended mRNA and the 1600 nt kidney mRNA initiating at
+ 1 (corresponding to the 1700 nt species in liver) are likely to encode
identical proteins since the extra 5' sequence has no potential in-frame
ATG initiation codon. This long 5' untranslated sequence may be associated
with differences in mRNA stability and translatability; formation of
secondary structure (eg stem-loop) within palindromic or complementary
stretches of 5' untranslated region RNA prevents the 40S ribosomal
subunit from migrating to the AUG codon, however long leader sequences
may result in loading of extra 40S ribosqmal subunits and thus
6L. CLVN/A \Q
improvement of the translation (Kozack, 1991). A low translatability of
this mRNA is more likely since its 5' untranslated sequence is GC-rich,
which would favour a stable potential hairpin, and it contains 7 ATG
triplets, all before the 5' end of the +1 mRNA, which could inhibit
initiation at the proper downstream starting codon. Only 5-10% of
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eukaryotic mRNAs possess ATG triplets upstream of the true ATG starting
codon (Kozack, 1991). The purpose of this long transcript is therefore
unclear; Northern analysis show that this mRNA is less abundant than the
+ 1 mRNA in kidney, maybe reflecting a shorter mRNA half-life or a weker
promoter; its expression does not show a developmental pattern that could
have explained the presence of this additional promoter (Krozowski et al,
1990, Moisan et al, 1992a). Moreover, a large variety of tissues has been
examined for lip-OHSD mRNA by Northern blot analysis and this 1900 nt
has never been found elsewhere than in kidney. Heterogeneity of 5'
untranslated region mRNA length has been described in other steroid
dehydrogenases, e.g. human estradiol 17p-dehydrogenase but the
corresponding mRNA is expressed abundantly in a number of tissues
(Luu-The et al, 1989 & 1990).
In addition to the two promoters upstream of exon 1, kidney also exploits
a promoter in intron A, with transcription initiating at +808, 65
nucleotides upstream of exon 2. The resulting 1500 nt mRNA transcript is
also detected in liver, albeit as a minor product. Interestingly, rat liver
contains a llp-OHSD isoform, accounting for less than 10% of the total
enzyme activity, that has the same low apparent Km as the lip-OHSD
activity described in renal cortical collecting duct cells (Monder &
<*_
Lakshmi, 1989; NSray-Fejes-T6th, 1991). This shortest mRNA is predicted to
encode a protein lacking the first 26 hydrophobic amino acid residues of
the full-length "liver-type" enzyme. The lack of the putative membrane
signal sequence may, of course, alter the intracellular location of the
enzyme and is likely to result in differential post-translational
modification. Indeed, when the "liver-type" lip-OHSD cDNA was expressed
into human osteosarcoma cells using recombinant vaccinia virus, it was
found that treatment with Al-tunicamycin (an inhibitor of glycosylation)
markedly reduced 1 ip-dehydrogenase activity (by 50%) whereas 11P -
reductase was not affected (Agarwal et al, 1990). Since this mRNA species
has only been detected in kidney, it is tempting to speculate that it
corresponds to the glycosylated form that would mainly function as an
11 p-dehydrogenase. This hypothesis would fit with the fact that lip-OHSD
in renal aldosterone target cells requires a strong llp-dehydrogenase
activity that would completely inactivate the circulating glucocorticoids.
Whether this isoform is specifically located in the aldosterone target cells
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is not yet known, but the tools required to perform the experiment that
would answer this question are now available, i.e. in situ hybridisation
using the isoform-specific oligonucleotides. A cDNA apparently
corresponding to this transcript has been cloned and the 5' sequence of
this variant renal cDNA was recently published (Krozowski et al, 1992).
Comparison of our intron A sequence and the 5' untranslated end of the
cDNA clone (11-HSD1B) revealed differences. It is unclear whether the two
transcripts truly differ or if a rearrangement has occurred in 11-HSD1B,
but riboprobes spanning +758 to +1389 were protected in our RNase
protection assay (Fig. 5.8.A) indicating that the sequence presented here
is likely to be correct. In contrast to the rat, only one human kidney llj3-
OHSD mRNA species has been detected, corresponding to initiation at a
single site identical to the major start site in liver (+1). This discrepancy
may be due to true species differences or might reflect changes in
pathogical human material or the different experimental conditions
employed. The amount of RNA used in primer extension experiment was 5-
fold greater than that used by Tannin et al (1991) and the autoradiograms
shown in this study have been exposed to film for a much longer time (1
or 2 weeks compared to 20 h).
Though the direct relationship between the putative DNA regulatory
elements and the 3 transcripts remains to be defined, some idea of the
possible regulatory and tissue-specific transcriptional mechanisms can be
inferred. Thus, the two first promoters do not contain any TATA-box.
Often, TATA-less promoters have sequences flanking the site of initiation
(called initiator) that are important for basal transcription. A sequence 2
bp downstream of the -264 start site (GCCATTCTTG) closely resembles the
initiator element of the murine terminal deoxynucleotidyl transferase
gene (GCCATTCTGG), which itself is related to the adenovirus major late
promoter and the immunodeficiency virus-1 promoter (Smale et al, 1989).
Recently, a protein (called TFII-I) has been characterised that recognises
this type of initiator and promotes basal transcription of the
corresponding mRNA (Roy et al, 1991). It would be of interest to test if
TFII-I binds to this initiator-like sequence by band-shift assay and
induces transcription from the -264 promoter in an in vitro transcription
system.
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The sequence surrounding the +1 promoter (TGATGTC*ACAATTCAGA) is
identical to that found in the homologous human llfi-OHSD gene (Tannin
et al, 1991) and may also bind a promoter or tissue-specific protein
complex. The palindromic CCAAT element is in a favorable position to
regulate the liver-type promoter (+1), but not the other promoters. The
predominant induction of transcripts arising from the CCAAT-box
associated promoter (+1) in liver may be due to the very high liver
content of CCAAT-binding factors (McKnight et al, 1989), which have been
implicated in the regulation of genes encoding enzymes involved in
energy metabolism (a hepatic function also ascribed to glucocorticoids).
The GC box and the CACCC elements are well located to regulate the longest
transcript, as well as the +1-derived transcript. The CACCC-box elements,
especially those arranged in tandem, are very similar to the ones found in
the P-globin promoter (Dierks et al, 1983). The most upstream CACCC-box
tandem is in an antisense orientation, as found in the trytophan
oxygenase promoter where these sequences bind a transcription factor
involved cooperatively in steroid hormone (glucocorticoid) induction
(Schule et al, 1988). There are 2 putative GREs within the transcribed
region which might regulate any of the 3 transcripts. Although
glucocorticoid regulation of llfl-OHSD in liver and kidney has not been
shown, we have demonstrated glucocorticoid induction of llfl-OHSD
activity and mRNA expression in hippocampus (Chapter 4), confirming
biochemical findings in cultured fibroblasts (Hammami & Siiteri, 1991);
the major lip-OHSD mRNA species in hippocampus is similar in size to the
liver transcript. In between the CACCC boxes lies a run of 25 thymines
followed by 13 guanines; a polydT sequence has the potential to form a
tighter DNA helix (10 bp per turn instead of 10.6 in B DNA) and has been
reported to influence nucleosome positioning (Peck & Wang, 1981;
Prunell, 1982), in a way suggesting that sequences flanking this polydT
stretch are potential binding sites for regulatory proteins. A polydT
sequence of the same length is found in the 5' flanking region of the
angiotensinogen gene (Brasier et al, 1989). Finally, 3 ERE/TRE half-sites
are present, and sex steroids and perhaps thyroid hormones are known to
affect lip-OHSD activity (Koerner & Hellman, 1964; Lax et al, 1978; Zumoff
et al, 1983; Baggia et al, 1990; Pepe et al, 1988; Smith & Funder, 1991)
The +808 promoter has a run of 5 AT bp (TTTTA) 31 nucleotides 5' of the
Cap site, and an AT-rich region (TTTATGAATAA) 62 bp upstream of the Cap
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site; either might function as a TATA sequence. An element resembling a
CCAAT box (GGCCAAA) is present 87 bp upstream of this third start site.
Functional analysis in an in vitro system will clarify the importance of
these elements.
In addition, Krozowski et al (1992) reported that the sequence analysis
of the 3' end of renal lip-OHSD clones showed the presence of three
alternate sites of poly(A) addition. No correlation was apparent between
the site of poly(A) addition and one or the other type of lip-OHSD cDNA.
The insertion of an AU-rich sequence into the 3' non-coding region of
genes has been shown to destabilise transcripts (Shaw & Kamen, 1986).
These observations suggest that lip-OHSD mRNA can be regulated at the
level of mRNA turnover by the selection of different 3' untranslated
sequences.
In summary, 3 promoters permit independent transcriptional
regulation of each lip-OHSD mRNA and 3 alternative polyadenylation sites
can further influence the turn-over of these mRNA, producing greater
flexibility of control. Thus, tissue-specific and ontogenetic regulation of
lip-OHSD expression and activity may reflect the different array of
regulatory factors present. At least two proteins are produced from this
gene, with differences which probably influence their intracellular
location. A cytosolic or membrane-bound location might, in turn, result in
differential post-translational modification, such as glycosylation, that
modulates the function of the enzyme by selectively stabilising the llp-
dehydrogenase activity. The role of the most 5' promoter is unexplained
and might simply represent an ancestral promoter. Whether additional
genes also encode further isoforms of this crucial enzyme remain to be
determined.
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Our perception of the physiological role of lip-OHSD has rapidly
evolved in the last past four years, thanks to studies carried out all around
the world and employing a variety of approaches and techniques
including clinical science, enzymology, protein chemistry, immunology,
physiology in animals or in cell systems and molecular biology.
It is now thought that this versatile enzyme plays a central role in
influencing the expression of corticosteroid-dependent processes in all
tissues in which it is found. lip-OHSD mediates the amount of intracellular
glucocorticoid accessible to the receptor from the variable supply from
the circulation. In aldosterone-selective cells, lip-OHSD is very active and
unidirectional in order to metabolise completely the glucocorticoid that is
in competition with aldosterone. In cells containing only GR or both
corticosteroid receptors, the purpose of lip-OHSD would rather be to adjust
the glucocorticoid concentrations to physiological limits by partially
inactivating or activating circulating glucocorticoids. An example of this
situation is the putative role of lip-OHSD in brain as described in Chapters
3 & 4.
The importance of lip-OHSD in the brain has yet to be determined
but the work presented in this thesis along with studies carried out
elsewhere (Lakshmi et al, 1991; Seckl et al, 1991; Sakai et al, 1992) provide
good evidence for a biological role of lip-OHSD in this tissue. In Chapter 3,
I reported our work showing lip-OHSD in vitro activity and mRNA
expression in the central nervous system, particularly in hippocampus,
cortex, cerebellum, pituitary and in some nuclei of the hypothalamus. This
distribution was subsequently confirmed by an immunocytochemical
study using two different antisera raised against the hepatic lip-OHSD
(Sakai et al, 1992). Thus, the presence of the enzyme in the central
nervous system is now clearly established and preliminary studies like
those described in Chapter 4 aim to define the role(s) of lip-OHSD in the
brain. We have found that lip-OHSD is induced by glucocorticoids in brain,
particularly in hippocampus. Furthermore, lip-OHSD is highly expressed
in hippocampus, cortex and cerebellum at the early stages of development
when maturation of the brain occurs. The differential pattern of
expression during development suggest that the enzyme has locally
defined functions that vary from region to region, but the working
hypothesis is that lip-OHSD provides a tissue-specific mechanism to adjust
the concentrations of glucocorticoids to the level required by a given
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tissue at a given stage of development or in response to changes in the
environment that affect glucocorticoid levels. In addition to this work, a
possible function for lip-OHSD in brain in vivo has also been suggested by
the following studies: i) using [l^C] 2-deoxyglucose uptake it has been
found that inhibition of llp-OHSD in conscious rats leads to increased
metabolic activity in regions of the brain exhibiting high enzyme activity
and mRNA expression (Seckl et al, 1991); ii) using an in vivo
autoradiographic technique we found that inhibition of cerebral llp-OHSD
by intracerebroventricular administration of glycyrrhetinic acid led to
increased corticosterone uptake in the hippocampus, suggesting that 11(3-
OHSD regulates the access of corticosterone to, at least, part of the
hippocampal MR (Seckl et al, unpublished data); iii)
intracerebroventricular infusion of carbonexolone (an lip-OHSD blocker)
increased blood pressure in rat (Gomez-Sdnchez, 1991).
It would be of particular interest to extend these studies in
hippocampus and in the brain areas thought to be involved in salt appetite
and blood pressure. One way to determine the functional importance of
lip-OHSD is to examine the effect(s) of local inhibition of the enzyme on a
well-characterised feature or function of the organ under test. For
example, a study looking at the effects of inhibition of lip-OHSD in
hippocampus on the survival of the hippocampal neurons in chronically
stressed animals would help to determine whether llp-OHSD protects the
hippocampus from the neurotoxic effects of glucocorticoid
hypersecretion. Another example is studying the effect of lip-OHSD
inhibition in hippocampus on learning and spatial memory as can be
assessed using a Morris swim maze or a multiple radial-arm maze. A
correlation between lip-OHSD activity (and mRNA expression) and the
protective effect of postnatal handling on glucocorticoid hypersecretion
would be very informative. Aldosterone specific actions in the brain could
be tested by looking at the binding of glucocorticoid or mineralococrticoid
agonist and antagonist compounds in the presence or absence of lip-OHSD
inhibition in the organs known to be aldosterone-specific.
However much remains to be learnt about the lip-OHSD enzyme
itself. We now know that the various lip-OHSD mRNA species detected in
kidney are generated from a single gene by differential promoter usage
(Chapter 5), but their physiological significance, subregional distribution
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and regulation remain to be determined. For example, since glycosylation
stabilises the 1lp-dehydrogenase but has no effect on the lip-reductase
component of the enzyme, it would be informative to express the truncated
lip-OHSD protein in vitro using the corresponding cDNA and to determine
what activity it produces knowing that in the same conditions the full-
length lip-OHSD cDNA produces both 1 ip-reductase and 1 ^-dehydrogenase
activities. Also, now that we have derived oligonucleotides probes specific
to a given lip-OHSD mRNA species, their respective tissue distribution and
putative co-localisation with MR or GR can be examined. It would be
interesting to know whether a specific isoform locates only in
mineralocorticoid target cells. Transfection into cells is another way to
examine whether lip-OHSD functions in a paracrine or autocrine manner.
Cells would be cotransfected with i) a vector expressing lip-OHSD, ii) a
vector expressing MR, iii) a vector containing a reporter gene sensitive to
ligand-bound MR. Arriza et al (1987) transfected the two latter vectors
into CV1 cells and showed that the reporter gene is equally sensitive to
aldosterone and corticosterone bound to the MR. It would thus be
interesting to see if high levels of lip-OHSD activity confer aldosterone
specificity to MR in these cells in the presence of competitive
concentrations of glucocorticoids.
Determination of the tissue-specific and hormonal regulation of
the cloned lip-OHSD gene would obviously be of great importance. The
techniques that can now be used include i) gel retardation assays using
nuclear extract of various cell types and oligonucleotides derived from the
sequenced promoter region. This would indicate the DNA sequences that
interact with proteins and maybe determine areas interacting with tissue-
specific factors, ii) promoter assays whereby potential regulatory regions
are inserted upstream of a reporter gene, such as luciferase, whose
activity is easily assayable. Then these regulatory regions would be
further analysed by deletion or mutation. Ultimately, the promoter region
could also be studied in transgenic animals where the transfected gene
would have the advantage to be packaged in chromatin therefore
eliminating artefact due to a vector system as well as revealing if tissue-
specific factors are involved.
Given the discrepancies between enzyme activity and mRNA levels
in parotid and mammary gland (Krozowski et al, 1990) and in kidney
during the course of development (Moisan et al, 1992a), it is likely that
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there is another gene for lip-OHSD. This possibility is currently being
investigated in this laboratory and the first step of the study is the
purification of a NAD-dependent human placental lip-OHSD enzyme. It is
hoped that this enzyme will be different from the previously purified rat
hepatic lip-OHSD and that the corresponding cDNA and gene will be
isolated thereafter.
The availability of the lip-OHSD human gene and cDNA sequence
(cloned using the rat hepatic cDNA) will help us to determine the genetic
defect involved in the "apparent mineralocorticoid excess" patients,
whether it relates to this or another gene, and whether it is likely to result
in deficiency of one particular isoform.
REFERENCES
Abramovitz M, Carriero R, Murphy BEP 1984 Investigation of factors
influencing 118-hydroxysteroid dehydrogenase: Activity in midgestional
human fetal lung monolayer and explant cultures. J Steroid Biochem
21(Suppl.6): 677-684
Abramowitz M, Branchaud CL, Murphy BEP 1982 Cortisol-cortisone
interconversion in human fetal lung: contrasting results using explant
and monolayer cultures suggest that 118-hydroxysteroid dehydrogenase
(EC 1.1.1.146) comprises two enzymes. J Clin Endocrinol Metab 54:563-568
Adamson AC, Tillman WG 1955 Hydrocortisone. Brit Med J ii: 1501
Agarwal AK, Monder C, Eckstein B, White PC 1989 Cloning and expression
of rat cDNA encoding corticosteroid 11 b-dehydrogenase. J Biol Chem
264:18939-18943
Agarwal AK, Tusie-Luna M-T, Monder C, White PC 1990 Expression of 118-
hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol.
Endocrinol 4:1827-1832
Amelung D, Hubener HJ, Roka L, Meyerheim G 1953 Letters to the editor J
Clin Endoc Metab 13:1125
Aronsson M, Fuxe K, Dong Y. 1988 Localization of glucocorticoid receptor
mRNA in the male rat brain by in situ hybridization. Proc Natl Acad Sci
USA 85: 9331-9335.
Arriza JL, Simerly RB, Swanson LW, Evans RM. 1988 The neuronal
mineralocorticoid receptor as a mediator of glucocorticoid response.
Neuron 1: 887-900.
Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE,
Evans RM. 1987 Cloning of human mineralocorticoid receptor com¬
plementary DNA: structural and functional kindship with the
glucocorticoid receptor. Science 237: 268-275.
Baggia S, Albrecht ED, Pepe GJ 1990 Regulation of 118-hydroxysteroid
dehydrogenase activity in the baboon placenta by estrogen. Endocrinol
126:2742-2748
Baldwin DM, Sawyer CH 1974 Effects of dexamethasone on LH release and
ovulation in the cyclic rat Endocrinol 94: 1397-1403
Balmain, A., Krumlauf, R., Vass, J.K.and Birnie, G.D 1982 Cloning and
characterisation of the abundant cytoplasmic 7S RNA from mouse cells,
Nucl Acids Res, 10: 4259-4277.
Bambino TH, Hseuh AJW 1981 Direct inhibitory effects of glucocorticoids
upon testicular leutinizing hormone receptor and steroidogenesis in vivo
and vitro. Endocrinol 108: 2142-2148
Barnett CA, Pritchett EL 1988 Detection of corticosteroid type 1 binding
sites in heart. Mol Cell Endocrinol 56:191-198
Beato M 1989 Gene regulation by steroid hormones. Cell 56:335-344.
Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ 1973 The metabolic
clearance rate, blood production, interconversion, and transplacental
passage of Cortisol and cortisone in pregnancy near term. Pediatr Res 7:
509
Benediktsson R, Yau JLW, Low S, Brett LP, Edwards CRW, Seckl JR. 1992 118-
hydroxysteroid dehydrogenase in the ovary : high expression in the
oocyte. J Endocrinol in press.
Berecek KH, Barron KW, Webb RL, Brody MJ 1982 Vasopresin-central
nervous system interactions in the development of DOCA hypertension.
Hypertension Dallas 4, supp 11:131
Berg JM 1989 DNA binding specificity of steroid receptors. Cell 57: 1065-
1068.
Birmingham MK, Sar M, Stumpf WE. 1984 Localization of aldosterone and
corticosterone in the rat central nervous system, assessed by quantitative
autoradiography. Neurochem Res 9:333-350
Bonthron DT, Morton CC, Orkin SH, Collins T 1988 Platelet-derived growth
factor A chain : gene structure, chromosomal location, and basis for
alternative mRNA splicing. Proc. Natl. Acad. Sci. USA 85:1492-1496
Bonvalet J-P, Doignon I, Blot-Chabaud M, Pradelles P, Farman N 1990
Distribution of 1 lfi-hydroxysteroid dehydrogenase along the rabbit
nephron. J. Clin. Invest. 86:832-837
Brasier AR, Tate JE, Ron D, Habener JF 1989 Multiple cis-acting DNA
regulatory elements mediate hepathic angiotensinogen gene expression.
Mol. Endocrinol. 3:1022-1034.
Brem AS, Matheson KL, Conca T, Morris DJ 1989 Effect of carbenoxolone on
glucocorticoid metabolism and Na transport in toad bladder. Am. J. Physiol.
257:F700-F701
Brinton RE, McEwen BS 1987 Regional distinctions in the regulation of
type I and type II adrenal steroid receptors in the central nervous system.
Neurosci Res Comm 2: 37-45
Burnstein S, Savard K, Dorfman R 1953 The in vivo metabolism of cortisone
Endocrinol. 52: 448
Burton AF, Keutman EH, Waterhouse C 1953 Conversion of cortisone acetate
to other alfa-ketolic steroids. J. Clin. Endoc. & Metab. 13: 48
Bush IE, Hunter SA, Meigs R 1968 Metabolism of 11-oxygenated steroids:
Metabolism in vitro by preparations of liver. Biochem. J. 106:239-258
Carlstedt-Duke J, Okret S, Wrange O, Gustafsson J-A 1982 Immunochemical
analysis of the glucocorticoid receptor: identification of a third domain
separate from the steroid-binding and DNA-binding domains. Proc Natl
Acad Sci USA 79: 4260-4264.
Castello R, Schwarting R, Muller C, Hierholzer K 1989
Immunohistochemical localization of 11-hydroxysteroid dehydrogenase in
rat kidney with a monoclonal antibody. Renal Physiol. Biochem. 12:320-327
Chalepakis G, Arnemann J, Slater E, Briiller H-J, Gross B, Beato M. 1988
Differential gene activation by glucocorticoids and progestins through
the hormone regulatory element of mouse mammary tumor virus. Cell 5 3:
371-382.
Chao HM, Choo PH, McEwen BS. 1989 Glucocorticoid and mineralocorticoid
receptor mRNA expression in rat brain. Neuroendocrinol 50: 365-372
Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem.
162:156-159
Cordingley MG, Riegel AT, Hager GL 1987 Steroid-dependent interaction of
transcription factors with the inducible promoter of mouse mammary
tumor virus in vivo. Cell 48: 261-270.
Csonka GW, Murray M 1971 Clinical evaluation of carbenoxolone in
balanitis. Brit. J. Vener. Dis. 47:179-181
Curnow KM, Tusie-Luna M-T, Pascoe L, Natarajan R, Gu J-L, Nadler JL,
White PC 1991 The product of the CYP11B2 gene is required for aldosterone
biosynthesis in the human adrenal cortex. Mol. Endocrinol. 5: 1513-1522
Danielsen M, Hinck L, Ringold GM 1989 Two amino acid whithin the
knuckle of the first zinc finger specificity DNA response element
activation by the glucocorticoid receptor. Cell 57: 1131-1138.
Danielsen M, Northrop JP, Jonklaas J, Ringold GM 1987 Domains of the
glucocorticoid receptor involved in specific and nonspecific
deoxyribonucleic acid binding, hormone activation, and transcriptional
enhancement. Mol Endocrinol 11: 816-822.
De Kloet RE 1991 Brain corticosteroid receptor balance and homeostatic
control. Frontiers in neuroendocrinology, Raven Press Ltd New York. 12:
95-164
De Kloet ER, Rosenfeld P, van Eekelen JAM, Sutanto W, Levine S 1988 Stress,
glucocorticoids and development. Progr.Brain Res. 73: 101-116.
De Kloet ER, Versteeg DHG, Kovacs GL 1983 Aldosterone blocks the response
to corticosterone in the raphe-hippocampal serotonin system, Brain
Research 264:323
De Kloet ER, Wallach G, McEwen BS 1975 Differences in corticosterone and
dexamethasone binding to rat brain and pituitary. Endocrinology 96:598
Dierks P, van Ooyen A, Cochran MD, Dobkin C, Reiser J, Weissmann C. 1983
Three regions upstream from the Cap site are required for efficient and
accurate transcription of the rabbit b-globin gene in mouse 3T6 cells. Cell
32: 695-706
Domalik LJ, Chaplin DD, Kirkman MS, Wu RC, Welwin L, Howard TA, Seldin
MF, Parker KL. 1991 Different isozymes of mouse 118-hydroxylase produce
mineralocorticoids and glucocorticoids. Mol. Endocrinol. 5: 1853-1861
Dui-vrv «>- \ ■. Sc e AAl«VyAc/<vr
Edwards CRW, Burt D, Mclntyre MA, de Kloet ER, Stewart PM, Brett L,
Sutanto WS, Monder C 1988 Localisation of 118-hydroxysteroid
dehydrogenase—tissue-specific protector of the mineralocorticoid
receptor. Lancet 2: 986-989
Edwards CRW, Hayman A 1991 Enzyme protection of the mineralocorticoid
receptor: evidence in favour of the hemi-acetal structure of aldosterone.
In Aldosterone: fundamental aspects Colloque INSERM Vol 215: 67-76
Edwards YH, Lloyd JC, McMillan SL, Benham FJ 1985 Human
glyceraldehyde-3-phosphate dehydrogenase: mRNA levels and enzyme
activity in developing muscle. Mol. Cell. Biol. 5:2147-2149
Eik-Nes KB, Brizee KR 1965 Biochem Biophys Acta 97:320
Evans RM, 1988 The steroid and thyroid hormone receptor superfamily.
Science 240:889-894
Evans RM, Arriza JL 1989 A molecular mechanism for the actions of
glucocorticoid hormones in the nervous system. Neuron 2:1105-1112
Evans RM, Hollenberg SM 1988 Zinc fingers: gilt by association. Cell 52: 1-
3.
Feinberg AP, Vogelstein B 1983 A technique for radiolabelling DNA
restriction endonuclease fragments to high specific activity. Anal.
Biochem. 132: 6
I
Fluart^y SJ, Epstein AN. 1983 Sodium appetite elicited by
intracerebroventricular infusion of angiotensin II in the rat. II:
synergistic interaction with systemic mineralocorticoids. Behav Neurosci
97: 745-758.
Frankel AD, Pabo CO 1988 Fingering too many proteins. Cell 53: 675.
Fuller PJ, Verity K 1990 Colonic sodium-potassium adenosine triphosphate
subunit gene expression: ontogeny and regulation by adrenocortical
steroids Endocrinology 127:32-38
Fuller PJ, Verity K 1991 Regulation of Na, K-ATPase gene expression by
adrenocortical steroid hormones. In Aldosterone: fundamental aspects
Colloque INSERM Vol 215 p323(Abstract)
Funder JW, Duval D, Meyer P 1973 Cardiac glucocorticoid receptors: the
binding of tritiated dexamethasone in rat and dog heart. Endocrinology
93:1300-1308
Funder JW, Pearce PT, Smith R, Campbell J 1989 Vascular type 1 aldosterone
binding sites are physiological mineralocorticoid receptors.
Endocrinology 125:2224-2226
Funder JW, Pearce PT, Smith R, Smith AI. 1988 Mineralocorticoid action:
target tissue specificity is enzyme, not receptor, mediated. Science 242 :
583-585.
Funder JW, Sheppard K 1987 Adrenocortical steroids and the brain. Ann.
Rev. Physiol. 49:397-411
Fuxe K, Wikstrom A-C, Okret S, Agnati LF, Harfstrand A, Yu Z-Y, Granholm
L, Zoli M, Vale W, Gustafsson J-A 1985 Mapping of glucocorticoid receptor
immunoreactive neurons in the rat tel- and diencephalon using a
monoclonal antibody against rat liver glucocorticoid receptor.
Endocrinology 117:1803
Gaeggeler H-P, Edwards CRW, Rossier BC 1989 Steroid metabolism
determines mineralocorticoid specificity in the toad bladder. Am. J.
Physiol. 257:F690-F695
Ganis FM, Axelrod LR, Miller LL 1956 The metabolism of hydrocortisone by
kidney tissue in vitro. J. Biol. Chem. 218:841-852
Giannopoulos G, Jackson K, Tulchinsky D 1982 Glucocorticoid metabolism
in human placenta, decidua, myometrium and fetal membranes J Steroid
Biochem 17: 371-374
Gigu&re V, Labrie F, C6t6 J, Coy DH, Suerias-Diaz J, Schally AV 1982
Stimulation of cyclic AMP accumulation and corticotropin release by
synthetic ovine corticotropin releasing factor in rat : site of
glucocorticoid action. Proc Natl Acad Sci USA 79: 3466-3469.
Glock GE, McLean P 1955 Levels of oxidized and reduced diphosphopyridine
nucleotide and triphosphopyridine nucleotide in animal tissues. Biochem.
J. 61:388-390
G6mez-Sanchez EP 1991 What is the role of the central nervous system in
mineralocorticoid hypertension? Am J Hypertension 4: 374-381
mf
Goodfriend TL, Gibbons GH, Dzau VJ, et al. Interaction of signals
influencing renin release. Annu Rev Physiol 46:291-308
Green S, Chambon P. 1988 Nuclear receptors enhance our understanding
of transcription regulation. Trends in Genetics 4: 309-313.
Grosser BI, Bliss EL 1963 Fed Proc 22: 271
Grosser BI 1966 1 lB-hydroxysteroid metabolism by mouse brain and
glioma 261. J Neurochem 13:475-478
Grosser BI & Axelrod. 1968 Conversion of Cortisol to Cortisol acetate and
cortisone by the developing primate brain. Steroids 11 : 827-836
AroWc 1 • Tee Addend uw\
Hammami MM, Siiteri PK 1991 Regulation of 1 lB-hydroxysteroid
dehydrogenase activity in human skin fibroblasts: enzymatic modulation
of glucocorticoid action. J Clin Endocrinol Metab 73:326-334
Hammond GL 1990 Molecular properties of corticosteroid binding globulin
and sex-steroid binding proteins. Endocrinol Rev 11: 65-79
HSrd T, Kellenbach E, Boelens R, Maler BA, Dahlman K, Freedman LP,
Carlstedt-Duke J, Yamamoto KR, Gustafsson J-A 1990 Solution structure of
the glucocorticoid receptor DNA-binding domain. Science 249: 157-160.
Hardy RN 1981 The adrenal cortex. In: Endocrine physiology,
Physiological Principles in Medicine Series, Arnold ed. Chapter 9 pl08.
Hartman FA, Spoor HJ 1940 Cortin and the sodium factor of the adrenal.
Endocrinol. 26: 871-878
Hellman L, Bradlow L, Adesman J, Fukushima DK, Kulp JL, Gallagher TF
1954 The fate of hydrocortisone-4-^C in man J. Clin. Invest. 33: 1106
Henderson GS, Conary JT, Davidson JM, Stewart SJ, House FS, McCurley TL.
1991 A reliable method for northern blot analysis using synthetic
oligonucleotide probes. Biotechniques 10:190-197
Herman JP, Patel PD, Akil H, Watson SJ. 1989 Localization and regulation of
glucocorticoid and mineralocorticoid receptor mRNAs in the hippocampal
formation of the rat. Mol Endocrinol 3: 1886-1894
a\ IMS '• ^te A «LJ Cv\ 4 O
Hollenberg SM, Evans RM 1988 Multiple and cooperative trans-activation
domains of the human glucocorticoid receptor. Cell 55: 899-906.
Hurlock B, Talalay P 1959 Microsomal 3-alfa and 11-beta hydroxysteroid
dehydrogenase Arch Biochem Biophys 80: 468-470
Inazu N, Iwata N, Satoh T. 1990 Inhibitory effect of glucocorticoid and
stimulatory effect of human chorionic gonadotropin on ovarian carbonyl
reductase Life Sci 46: 841-848
Jahn EA, Moguilewsky M, Houdebine L-M Djiane J 1987 Binding and action
of glucocorticoids and mineralocorticoids in rabbit mammary gland.
Exclusive participation of glucocorticoids type II receptors for stimulation
of casein synthesis. Mol Cell Endocr 52: 205-212
Jones MT, Gillham B. 1988 Factors involved in the regulation of
adreocorticotropic hormone/b-lipotropic hormone. Physiol Rev 68:743-818
Kenouch S, Blot-Chabaud M, Bonvalet J-P, Farman N 1991 118-
hydroxysteroid dehydrogenase activity along the mouse nephron In
Aldosterone: fundamental aspects Colloque INSERM Vol 215 p344 (Abstract)
King RJB 1992 Effects of steroid hormones and related compounds on gene
transcription Clin Endocrinol 36: 1-14
Koerner D 1966 118-hydroxysteroid dehydrogenase of lung and testis
Endocrinol. 79: 935-936
Koerner DR, Hellman L 1964 Effect of thyroxine administration on the 118-
hydroxysteroid dehydrogenases in rat liver and kidney. Endocrinology
75:592-601
Kolanowski J, Corcelle-Cerf F, Lammerant J 1981 Cortisol uptake, release
and conversion into cortisone by the heart muscle in dogs. J. Steroid
Biochem. 14:773-781
Kornel L, Kanamarlapudi N, Travers T, Taff DJ, Patel N, Chen C, Baum RM,
Raynor WJ 1982 Studies on high affinity binding of mineralo- and
glucocorticoids in rabbit aorta cytosol. J. Steroid Biochem. 16:245-264
Kozack, M. 1991 An analysis of vertebrate mRNA sequences: intimations of
translational control. J Cell Biol 115: 887-903
Kozack, M. 1991 Structural features in eukaryotic mRNAs that modulate the
initiation of translation J Biol Chem 266: 19867-19870
Krozowski ZS, Funder JW 1983 Renal mineralocorticoid receptors and
hippocampal corticosterone-binding species have identical intrinsic
steroid specificity. Proc. Natnl. Acad. Sci. USA 80:6056-6060
Krozowski ZS, Stuchberry S, White PC, Monder C, Funder JW 1990
Characterisation of 116-hydroxysteroid dehydrogenase gene expression:
identification of multiple unique forms of messenger ribonucleic acid in
the rat kidney. Endocrinology 127:3009-3013
^ p k.* -eJr ^ ^ ^ A «L «L-e«o A.uiw.
Lakshmi V, Monder C 1988 Purification and characterization of the
corticosteroid 118-dehydrogenase component of the rat liver 118-
hydroxysteroid dehydrogenase complex. Endocrinol. 123:2390-2398
Lakshmi V, Sakai RR, McEwen BS, Monder C 1991 Regional distribution of
118-hydroxysteroid dehydrogenase in rat brain Endocrinology 128:1741-
1748
Latif SA, Conca TJ, Morris DJ 1990 The effects of the liquorice derivative,
glycyrrhetinic acid, on hepatic 3alpha- and 3B-hydroxysteroid
dehydrogenases and 5alpha- and 5S-reductase pathways of metabolism of
aldosterone in male rats. Steroids 55:52-58
Lauber M, Muller J 1989 Purification and characterisation of two distinct
forms of rat adrenal cytochrome P450 11B: functional and structural
aspects. Arch Biochem Biophys 274: 109-119
Lax ER, Ghraf R, Schriefers H 1978 The hormonal regulation of hepatic
microsomal 1 lB-hydroxysteroid dehydrogenase activity in the rat. Acta
Endocrinol. 89:352-358
Lee MS, Gippert GP, Soman KV, Case DA, Wright PE 1989 Three-dimensional
solution structure of a single zinc finger DNA-binding domain. Science
245:635-637.
Levin N, Shinsotto J, Dallman MF 1988 Corticosterone acts on the brain to
inhibit adrenalectomy induced adrenocorticotropin secretion Endocrinol.
122:694-701
L6pez Bernal A, Flint APF, Anderson ABM, Turnbull AC 1980 11 p-
hydroxysteroid dehydrogenase activity (E.C. 1.1.1.146) in human placenta
and decidua. J Steroid Biochem 13: 1081-1087
Lopez Bernal A, Anderson ABM, Turnbull AC 1982 The lack of influence of
labor on human placental 1 lp-hydroxysteroid dehydrogenase activity J
Clin Endocrinol Metab 54: 1251-1254
Lopez Bernal A, Craft IL 1981 Corticosteroid metabolism in vitro by human
placenta, fetal membranes and decidua in early and late gestation.
Placenta 2:279
Lundblad JR, Roberts JL 1988 Regulation of proopiomelanocortin gene
expression in pituitary. Endocrinol Rev 9: 135-157
Luttge WG, Rupp ME, Davda MM. 1989 Aldosterone-stimulated down-
regulation of both type I and type II adrenocorticosteroid receptors in
mouse brain is mediated via type I receptors. Endocrinol. 125: 817-824.
Luu-The VL, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G,
C6t6 J, B6rub6 D, Gagn6 R, Labrie F. 1989 Characterization of cDNAs for
human estradiol 17(i -dehydrogenase and assigment of the gene to
chromosome 17: evidence for two mRNA species with distinct 5'-end
termini in human placenta Mol Endocrinol 3:1301-1309
Luu-The V, Labrie C, Simard J, Lachance Y, Zhao HF, Couet J, Leblanc G,
Labrie F. 1990 Structure of two in tandem human 17(i-hydroxysteroid
dehydrogenase genes Mol Endocrinol 4: 268-275
MacHover Reinisch J, Simon NG 1978 Prenatal exposure to prednisone in
humans and animals retards intrauterine growth. Science 202: 436-438
Mader S, Kumar V, de Verneuil H, Chambon P 1989 Three amino acids of
the oestrogen receptor are essential to its ability to distinguish an
oestrogen from a glucocorticoid-responsive element. Nature 338: 271-274.
Magarinos AM, Coirini H, De Nicola AF, McEwen BS 1986 Mineralocorticoid
regulation of salt intake is preserved in hippocampectomised rats.
Neuroendocrinology 44:494-497
Mahesh VB, Ulrich F. 1960 Metabolism of Cortisol and cortisone by various
tissues and subcellular particles. J. Biol. Chem. 235:356-360.
Marks R, Barlow JW, Funder JW 1982 Steroid-induced vasoconstriction;
glucocorticoid antagonist studies. J. Clin. Endocrinol. Metab. 54:1075-1077
WlexVli f i *• -fee A«LcLe.v>tic>iw
Mason HL, Myers CS, Kendall EC 1936 The chemistry of the crystalline
substances isolated from the adrenal gland. J. Biol. Chem. 114: 613-631
Matsukawa N, Nonaka ZY, Higaki J, Ogihara T, Okamoto M 1990 Molecular
cloning and expression of cDNAs encoding rat aldosterone synthase:
variants of cytochrome P-450np, Biochem Biophys Res Commun 169: 245-
252
McEwen BS, de Kloet ER, Rostene W 1986a Adrenal steroid receptors and
action in the nervous system. Physiol. Rev. 66:1121-1188
McEwen BS, Lambdin LT, Rainbow TC, De Nicola AF 1986b Aldosterone
effects on salt appetite in adrenalectomised rats. Neuroendocrinology 43:
38-43
McKnight SL, Lane MD, Gluecksohn-Waelsch S 1989 Is CCAAT/enhancer-
binding protein a central regulator of energy metabolism? Gene Devel
3:2021-2024.
Meaney MJ, Aitken DH, Van Berkel C, Bhatnagar S, Sapolsky RM. 1988
Effect of neonatal handling on age related impairements associated with
the hippocampus Science 239: 766-769
Mercer WR, Krozowski ZS 1992 Localization of an 1 lB-hydroxysteroid
dehydrogenase activity to the distal nephron. Evidence for the existence
of two species of dehydrogenase in the rat kidney. Endocrinol. 130: 540-543
Mercer WR, Obeyesekere V, Smith R, Stuchbery S, Krozowski Z 1991
Characterization of 1 lB-hydroxysteroid dehydrogenase gene expression,
isolation of variant cDNA clones from a rat kidney library. In Aldosterone:
fundamental aspects Colloque INSERM Vol 215 p343 (Abstract)
Messing J 1983 New M13 vectors for cloning. Methods Enzymol. 101:20
Meyer JS 1985 Biochemical effects of corticosteroid on neural tissues.
Physiol. Dev. 65: 946-1020
Meyer WJ, Nicholls NR 1981 Mineralocorticoid binding on cultured smooth
muscle cells and fibroblasts from rat aorta. J. Steroid Biochem. 14:1157-
1168
Migeon C, Sandberg A, Decker H, Smith D, Paul C, Samuels L 1956
Metabolism of 14C-4-cortisol in man. Body distribution and rates of
conjugation J. Clin. Endoc. & Metab. 16 :1137
Miller J, McLachlan AD, Klug A 1985 Repetitive zinc-binding domains in
the protein transcription factor IIIA from Xenopus oocytes. EMBO J 4:1609-
1614.
Moisan M-P, Seckl JR, Edwards CRW 1990a 116-hydroxysteroid
dehydrogenase bioactivity and messenger RNA expression in rat
forebrain: localization in hypothalamus, hippocampus and cortex.
Endocrinology 127:1450-1455
Moisan M-P, Seckl JR, Edwards CRW 1990b 1 lB-hydroxysteroid
dehydrogenase messenger RNA expression, bioactivity and
immunoreactivity in rat cerebellum. J. Neuroendocrinology 2: 854-858
Moisan M-P, Edwards CRW, Seckl JR 1992a Ontogeny of 118-hydroxysteroid
dehydrogenase in rat brain and kidney. Endocrinol. 130:400-404
Moisan M-P, Edwards CRW, Seckl JR 1992b Differential promoter usage by
the rat 1 lB-hydroxysteroid dehydrogenase gene, (submitted)
Monder C, Lakshmi V 1989a Evidence for kinetically distinct forms of
corticosteroid 1lB-dehydrogenase in rat liver microsomes. J Steroid
Biochem 32: 77- 83
Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CRW 1989b
Licorice inhibits corticosteroid 118-dehydrogenase of rat kidney and
liver: in vivo and in vitro studies. Endocrinol. 125:1046-1053.
Monder C, Lakshmi V 1990 Corticosteroid 11-8 dehydrogenase of rat tissues:
immunological studies Endocrinol. 126:2435-2443
Monder C 1991a Corticosteroids, kidneys, sweet roots and dirty drugs. Mol.
Cell. Endocrinol. 78:C95-C98
Monder C 1991b Corticosteroids, receptors, and the organ-specific
functions of 11-8 hydroxysteroid dehydrogenase FASEB J 5: 3047-3054
Murphy BEP 1977 Conversion of Cortisol to cortisone by the human uterus
and its reversal in pregnancy. J Clin Endoc Metab 44:1214-1217
Murphy BEP 1981 Ontogeny of cortisol-cortisone interconversion in
human tissues; a role for cortisone in human fetal development. J Steroid
Biochem 14:811-817
Ndray-Fejes-Toth A, Watlington CO, Fejes-Toth G 1991 118-hydroxysteroid
dehydrogenase activity in the renal target cells of aldosterone. Endocrinol
129:17-21
Nicholas TE, Lugg MA 1982 The physiological significance of 118-
hydroxysteroid dehydrogenase in the rat lung. J Steroid Biochem 17: 113-
118
O'Malley B 1990 The steroid receptor superfamily: more excitement
predicted for the future. Mol Endocrinol 4: 363-369.
Oberfield SE, Levine LS, Carey RM, Greig F, Ulick S, New MI 1983 Metabolic
and blood pressure responses to hydrocortisone in the syndrome of
apparent mineralocorticoid excess. J Clin Endocrinol Metab 56:332-339
Orchinik M, Murray TF, Moore FL 1991 A corticosteroid receptor in neural
membranes. Science 252:1848-1851
Orth DN, Kovacs WJ, De Bold CR 1991 The adrenal cortex. In Williams text
book of endocrinology, 81th edition. Wilson JD & Foster DW Ed.
Osinsky PA 1960 Steroid 11 beta-ol dehydrogenase in human placenta Nature
187: 111
Patel PD, Sherman TG, Goldman DJ, Watson SJ. 1989 Molecular cloning of a
mineralococrticoid (type I) receptor complementary DNA from rat
hippocampus. Mol Endocrinol 3: 1877-1885
Peck LJ, Wang JC 1981 Sequence dependence of the helical repeat of DNA
in solution. Nature 292:375-378
Pepe GJ, Waddel BJ, Stahl SJ, Albrecht ED. 1988 The regulation of
transplacental cortisol-cortisone metabolism by estrogen in pregnant
baboons. Endocrinol 122: 78-83
Peterson NA, Chaikoff IL Jones C. 1965 The in vitro conversion of Cortisol
to cortisone by subcellular brain fractions of young and adult rats J
Neurochem 12:273-278
Peterson RE, Wyngaarder J, Guerra S, Brodie B, Bunim J 1955 J Clin Inves
34: 1779-1794
Phillips DM, Lakshmi V, Monder C 1989 Corticosteroid 118-dehydrogenase
in rat testis. Endocrinol 125:209-216
Picard D, Yamamoto KR 1987 Two signals mediate hormone-dependent
nuclear localization of the glucocorticoid receptor EMBO J 6: 3333-3340
Prunell A 1982 Nucleosome reconstitution on plasmid inserted poly(dA)-
poly(dT). EMBO J 1:173-179
Quinn SJ, Williams GH. 1988 Regulation of aldosterone secretion Annu Rev
Physiol 50: 409-426
Quirk SJ, Gannell JE, Fullerton MJ, Funder JW 1988 Specificity and
mechanism of biphasic action of glucocorticoids on a-lactalbumin
production by rat mammary gland explants Endocrinol 118: 909-914
Quirk SJ, Slattery JA, Funder JW 1990a 11 beta-hydroxysteroid
dehydrogenase activity in the mammary gland. J Steroid Biochem 35:623-
625
Quirk SJ, Slattery JA, Funder JW 1990b Epithelial and adipose cells isolated
from mammary glands of pregnant and lactating rats differ in 1113 -
hydroxysteroid dehydrogenase activity J Steroid Biochem Molec Biol 37:
529-534
Rasmussen 1986 The calcium messenger system New Engl J Med 314: 1164-
1168
l<?€6
Reul JMHM, De Kloet ER. Anatomical resolution of two types of
corticosteroid receptor sites in rat brain with in vivo autoradiography and
computerized image analysis. J Steroid Biochem 24: 269-72
Reul JMHM, de Kloet ER 1985 Two receptor systems for corticosterone in rat
brain: microdissection and differential occupation. Endocrinol 117: 2505
Richard-Foy, Hager GL 1987 Sequence-specific positioning of nucleosomes
over the steroid-inducible MMTV promoter. EMBO J 6: 2321-2328.
Rosenfeld P, Sutanto W, Levine S, De Kloet ER. 1988 Ontogeny of type 1 and
type 2 corticosteroid receptors in the rat hippocampus. Dev Brain Res 42:
113-118
Rosenfeld P, Sutanto W, Levine S, De Kloet ER. 1990 Ontogeny of
mineralococrticoid (type I) receptors in brain and pituitary: an in vivo
autoradiographical study. Dev Brain Res 52: 57-62
Roy AL, Meisterernst M, Pognonec P, Roeder RG 1991 Cooperative
interaction of an initiator-binding transcription initiation factor and the
helix-loop-helix activator USF Nature 354: 245-248
Rundle SE, Funder JW, Lakshmi V, Monder C 1989 The intrarenal
localization of mineralocorticoid receptors and 118-dehydrogenase:
immunocytochemical studies. Endocrinol 125: 1700-1704.
Sanger F, Coulson AR 1975 A rapid method for determining sequences in
DNA by primed synthesis with DNA polymerase. J Mol Biol 91: 441
Sakai RR, Lakshmi V, Monder C, McEwen BS 1992 Immunocytochemical
localization of 11 beta-hydroxysteroid dehydrogenase in hippocampus and
other brain regions of the rat. J Neuroendocrinol 4: 101-106
Sakai RR, Nicolaidis S, Epstein AN 1986 Salt appettite is suppressed by
interference with angiotensin II and aldosterone. Am J Physiol 251: R762-
R768
Sambrook J, Fritsch EF, Maniatis T 1989 Molecular cloning: a laboratory
manual, 2nd edition Cold Spring Harbor laboratory press, Cold Spring
Harbor, NY.
Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H,
Vennstrom B 1986 The c-erb-A protein is a high-affinity receptor for
thyroid hormone. Nature 324: 635-640.
Sapolsky RM, Krey LC, McEwen BS 1986 The neuroendocrinology of stress
and ageing. The glucocorticoid cascade hypothesis, Endocrine Rev 7 284-
301.
Sarrieau A, Sharma S, Meaney MJ 1988 Postnatal development and
environmental regulation of hippocampal glucocorticoid and
mineralocorticoid receptors Dev Brain Res 43 :158-162
Schackleton CHL, Stewart PM 1990 The hypertension of apparent
mineralocorticoid excess syndrome. In : Endocrine hypertension (eds EG
Biglieri & JC Melby), Raven Press, New York ppl55-173.
Schapiro S 1962 Pituitary ACTH and compensatory adrenal hypertrophy in
stress-non-responsive infant rats. Endocrinology 71:986-989
Schreiber JR, Nakamura K, Erickson GF. 1982 Rat ovary glucocorticoid
receptor: identification and characterisation. Steroids 39: 569-584.
Schule R, Muller M, Otsuka-Murakami H, Renkawitz R 1988 Cooperativity of
the glucocorticoid receptor and the CACCC-box binding factor Nature
332:87-90
Schumacher M, Coirini H, Pfaff DW, McEwen BS 1990 Behavioral effects of
progesterone associated with rapid modulation of oxytocin receptors. Science
250: 691-694
Seckl JR, Kelly PAT, Sharkey J 1991 Glycyrrhetinic acid, an inhibitor of
116-hydroxysteroid dehydrogenase, alters local cerebral glucose
utilization in vivo., J Steroid Biochem Molec Biol, 39: 777-779.
Shaw G, Kamen R 1986 A conserved AU sequence from the 3' untranslated
region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659-
667.
Sheppard K, Funder JW 1987 Mineralocorticoid specificity of renal type 1
receptors; in vivo binding studies. Am J Physiol 252:E224-E229
Simpson SA, Tait JF 1953 Physico-chemical methods of detection of a
previously unidentified adrenal hormone. In Mem. Soc. Endocrinology, p
9-24, Eds Eckstein P & Zuckerman S, Dennis Robsin Ltd, London.
Simpson SA, Tait JF, Wettstein A, Neher R, Euw JV, Schindler O, Reichstein
A 1954 Konstitution des aldosterons, des neven mineralocorticoids.
Experentia 10: 132-133
Sloviter RS, Valiquette G, Abrams GM, Ronk EC, Sollas AL, Paul LA, Neubort
S, 1989 Selective loss of hippocampal granule cells in the mature rat brain
after adrenalectomy Science 243 : 535-538.
Smale, S.T. & Baltimore, D. (1989). The "Initiator" as a transcription control
element. Cell 57:103-113.
Smith BT, Torday JS, Giroud CJP 1973 The growth promoting effect of
Cortisol on human fetal lung cells Steroids 22: 515-524
Smith RE, Funder, JW 1991 Renal 1 lB-hydroxysteroid dehydrogenase
activity: Effects of age, sex and altered hormonal status, J Steroid Biochem
Molec Biol, 38: 265-267.
Souness GW, Morris DJ 1989 The antinatriuretic and kaliuretic effects of
the glucocorticoids corticosterone and Cortisol following pretreatment
with carbenoxolone sodium (a liquorice derivative) in the
adrenalectomized rat. Endocrinol 124:1588-1590
Sousa RJ, Tannery NH, Lafer EM 1989 In situ hybridization mapping of
glucocorticoid receptor messenger ribonucleic acid in rat brain. Mol
Endocrinol 3:481
Southern EM 1975 Detection of specific sequences among DNA fragments
separated by gel electrophoresis J Mol Biol 98: 503
Stephen D, Jones C, Schofield JP 1990 A rapid method for isolating high
quality plasmid DNA suitable for DNA sequencing Nucl Acids Res 18: 7463-
7464.
Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW 1988 Syndrome of
apparent mineralocorticoid excess: a defect in the cortisol-cortisone
shuttle. J Clin Inves 82:340-349
Stewart PM, Edwards CRW 1991b The cortisol-cortisone shuttle and
hypertension. J Steroid Biochem 40:501-509
Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW
1987 Mineralocorticoid activity of liquorice: 1 lbeta-hydroxysteroid
dehydrogenase deficiency comes of age. Lancet ii:821 -824
Stewart PM, Whorwood CB, Barber P, Gregory J, Monder C, Franklyn JA,
Sheppard MC 1991a Localization of renal 1lB-hydroxysteroid
dehydrogenase by in situ hybridization: autocrine not paracrine protector
of the mineralocorticoid receptor. Endocrinol 128: 2129-2135
Swanson LW, Sawchenko PE, Rivier J, Vale WW 1983 Organisation of ovine
corticotropin releasing factor (CRF)-immunoreactive cells and fibers in
the rat brain : an immunohistochemical study. Neuroendocrinol. 36: 165-
186
Swanson LW, Simmonds DM . 1989 Differential steroid hormone and neural
influences on peptide mRNA levels in CRH cells of the paraventricular
nucleus: a hybridization histochemical study in the rat. J Comp Neurol 285:
413-435
Tannin GM, Agarwal AK, Monder C, New MI, White PC 1991 The human
gene for 1 lB-hydroxysteroid dehydrogenase. J Biol Chem 266:16653-16658
Tartof KD, Hobbs CA 1987 Improved media for growing plasmid and cosmid
clones Bethesda Re. Lab Focus 9:12
Teelucksingh S, Mackie A, Burt D, Mclntyre M, Brett L, Edwards CRW 1990
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid.
Lancet 335: 1060-1063.
Tora L, White J, Brou C, Tasset D, Webster N, ScheerE, Chambon P. 1989 The
human estrogen receptor has two independent nonacidic transcriptional
activation functions. Cell 59: 477-487.
Torday JS 1980 Glucocorticoid dependence of fetal lung maturation in vitro
Endocrinol 107: 839-844
Tye LM, Burton AF 1979 Variation in the pattern of metabolism of
corticosteroids in fetal mouse tissues Life Sci 26: 35-39
Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosier A,
Bradlow HL, New Ml 1979 A syndrome of apparent mineralocorticoid excess
associated with defects in the peripheral metabolism of Cortisol. J Clin
Endocrinol Metab. 49:757-764
Umesono K, Evans RM 1989 Determinants of target gene specificity for
steroid/thyroid hormone receptors. Cell 57: 1139-1146.
Van Eekelen JAM, Jiang W, de Kloet ER, Bohn MC 1988 Distribution of the
mineralocorticoid and the glucocorticoid receptor mRNAs in the rat
hippocampus. J Neurosci Res 21:88-94
Van Eekelen JAM, Jiang W, de Kloet ER, Bohn MC 1989 Distribution of the
mineralocorticoid and the glucocorticoid receptor mRNAs in the rat
hippocampus. J Neurosci Res 21 :88
Van Eekelen JAM, Kiss JZ, Westphal HM, de Kloet ER. 1987
Immunocytochemical study on the intracellular localisation of the type 2
glucocorticoid receptor in the rat brain. Brain Res 436: 120-128
Velasquez PN, Romano MC 1987 Corticosterone therapy during gestation:
effects on the development of rat cerebellum Int. J. Neurosci. 5:189-194
Viera J, Messing J 1982 The pUC plasmids, an M13mp7-derived system for
insertion mutagenesis and sequencing with synthetic universal primers
Gene 19: 259
Von der Ahe D, RenoirJ-M, Buchou T, Baulieu EE, Beato M 1986 Receptors
for glucocorticosteroid and progesterone recognize distinct features of a
DNA regulatory element. Proc Natl Acad Sci USA 83: 2817-2821.
Von Zerssen, D., Mood and behavioural changes under corticosteroid
therapy. In T. Util, G. Laudahn and W. Herrman (Eds.), Psychotropic
Actions of Hormones, Spectrum Publications, New York, 1976, pp. 195-222.
Waddell BJ, Albrecht ED, Pepe GJ 1988 Effect of estrogen on the metabolism
of Cortisol and cortisone in the baboon fetus at mid-gestation. Biol Reprod
38:1006
Walker BR, Edwards CRW 1991 1 lB-hydroxysteroid dehydrogenase and
enzyme mediated receptor protection: life after liquorice? Clinical
Endocrinol 35:281-289
Walker BR, Yau JLW, Brett LP, Seckl JR, Monder C, Williams BC, Edwards
CRW. 1 lfl-hydroxysteroid dehydrogenase in vascular smooth muscle and
heart: implications for cardiovascular responses to glucocorticoids
Endocrinol 129: 3305-3312
Walker C-D, Scribner KA, Cascio CS, Dallman MF 1991 The pituitary-
adrenocortical system of neonatal rats is responsive to stress throughout
development in a time-dependent and stressor-specific fashion.
Endocrinol 128:1385-1395
Wehling M, Christ M, Theisen K 1992 High affinity aldosterone binding to
plasma membrane rich fractions from mononuclear leukocytes: is there a
membreane receptor for mineralocorticoids? Biochem Biophys Res Comm
181: 1306-1312
Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM 1986 The
c-erb-A gene encodes a thyroid hormone receptor Nature 324: 641-646.
Welsh JrTH, Bambino TH, Hseuh AJW 1982 Mechanism of glucocorticoid-
induced suppression of testicular androgen biosynthesis in vitro. Biology
of reproduction 27: 1138-1146
Whorwood CB, Franklyn JA, Sheppard MC, Stewart PM 1992 Tissue
localization of 1 lB-hydroxysteroid dehydrogenase and its relationship to the
glucocorticoid receptor. J. Steroid Biochem. 41:21-28
Wintersteiner O, Pfiffner JJ 1936 Chemical studies on the adrenal cortex
III. Isolation of two new physiologically inactive compounds. J Biol Chem
116: 291-305
Yagil Y, Koreen R, Krakoff LR. 1986 Role of mineralocorticoids and
glucocorticoids in blood pressure regulation in normotensive rats. Am J
Physiol 251: H1355-1360
Yagil Y, Krakoff LR. 1988 The differential effect of aldosterone and
dexamethasone on pressor responses in adrenalectomized rats.
Hypertension 11:175-178
Yamamoto KR 1985 Steroid receptor regulated transcription of specific
genes and gene networks. Ann Rev Gen 19: 209-252.
Yang K, Smith CL, Hammond GL, Challis JRG 1991 Charactherisation of an
ovine 118-hydroxysteroid dehydrogenase cDNA and distribution of its
mRNA in fetal and adult sheep tissues J. Endocrinol. 131 (supplement)
abstract # 68
Yau JLW, Low SC, Moisan MP, Edwards CRW and Seckl JR 1991b Localisation
of 118-hydroxysteroid dehydrogenase mRNA expression in rat
hypothalamus. J. Endocrinology 129 (supplement) abstract 234
Yau JLW, van Haarst AD, Moisan M-P, Fleming S, Edwards CRW, Seckl JR
1991a 118-hydroxysteroid dehydrogenase mRNA expression in rat kidney.
Am. J. Physiol. 260:F764-F767
Yehuda R, Fairman KR, Meyer JS 1989 Enhanced brain proliferation
following early adrenalectomy in rats. J.Neurochem. 53:241-248
Zumoff B, Bradlow HL, Levin J. 1983 Influence of thyroid function on the
in vivo Cortisol/ cortisone equilibrium in man. J. Steroid Biochem.
18(Suppl 4): 437-440
ADDENDUM
Dunn JDF, Nisula BC, Rodbard D. 1981 Transport of steroid hormones: binding of 21
endogenous steroids to both testosterone-binding globulin and corticosteroid-binding
globulin in human plasma. J Clin Endocrinol Metab 53: 58-68.
Hager GL, Archer TK. 1991 The interaction of steroid receptors with chromatin. In Nuclear
Hormone Receptors (Ed MG Parker), pp 217-234. Academic Press, London.
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld
MG, Evans RM. 1985 Primary structure and expression of a functional human glucocorticoid
receptor cDNA. Nature 318: 635-641.
Hollenberg SM, Giguere V, Segui P, Evans RM. 1987 Colocalization of DNA-binding and
transcriptional activation functions in the human glucocorticoid receptor. Cell 49: 39-46.
Krozowski Z, Obeyesekere V, Smith R, Mercer W 1992 Tissue specific expression of an
11b-hydroxysteroid dehydrogenase with a truncated N-terminal domain. J Biol Chem 267:
2569-2574.
Martinez E, Wahli W 1991 Characterization of hormone response elements. In Nuclear
Hormone Receptor (Ed MG Parker), pp125-154. Academic Press, London.
Smith BT, Tanswell AK, Worthington D, Piercy WN 1981 Local control of glucocoricoid levels
in individual tissues in the fetus: commonality among foregut derivatives. In Intensive Care In
The Newborn, pp 45-50. (Ed L Stern). Masson.
Abbreviations
ACE: angiotensin-converting enzyme
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AVP : arginine vasopressin
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EDTA: ethylene diamine tetraacetic acid
ER : estrogen receptor
ERE: estrogen receptor element
ERR1 : estrogen related receptor
GAPDH: glyceraldehyde phosphate dehydrogenase
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GR: glucocorticoid receptor
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ll/?-Hydroxysteroid Dehydrogenase Bioactivity and
Messenger RNA Expression in Rat Forebrain:
Localization in Hypothalamus, Hippocampus, and
Cortex*
HARIE-PIERRE MOISAN, JONATHAN R. SECKL, AND CHRISTOPHER R. W.
EDWARDS
Jniversity of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh EH4 2XU, UK
ABSTRACT. In peripheral aldosterone target sites (e.g., kid¬
ney), 11/3-hydroxysteroid dehydrogenase (11/3-OHSD) metabo¬
lizes corticosterone to inactive 11-dehydrocorticosterone and
thus protects mineralocorticoid receptors from exposure to cor¬
ticosterone in vivo. We have investigated whether 11/3-OHSD
could account for the site-specific differences in corticosteroid
receptor sensitivity to corticosterone in rat brain. Enzyme activ¬
ity, estimated as the percentage conversion of [3H]corticosterone
to [3H] 11-dehydrocorticosterone in the presence of NADP+ (200
//M), was: hippocampus, 55.8 ± 2.7%; cortex, 52 ± 3.1%; pituitary;
40 ± 2%, hypothalamus, 26.1 ± 1.2%; brain stem, 21.4 ± 1.7%;
and spinal cord, 12.3 ± 1.8%. Northern blots, using [32P]dCTP-
labeled probes from an 11/3-OHSD cDNA clone derived from rat
liver, showed expression of a single mRNA species in all brain
areas, of identical size to 11/3-OHSD mRNA in liver and kidney.
Highest expression was found in hippocampus and cortex. In
situ hybridization, using [35S]UTP-labeled cRNA probes, local¬
ized high mRNA expression to cerebral cortex (particularly
parietal cortex, layer IV), hippocampus (highest in CA3), hypo¬
thalamic medial preoptic area and arcuate nuclei and anterior
pituitary. In conclusion, there is localized 11/3-OHSD mRNA
expression and enzyme bioactivity in rat brain. The distribution
of 11/3-OHSD corresponds to areas of reduced glucocorticoid or
mineralocorticoid receptor affinity for corticosterone. Therefore,
11/3-OHSD may regulate the access of corticosterone to cerebral
mineralocorticoid and/or glucocorticoid receptors and thus mod¬
ulate corticosteroid effects on brain function. (Endocrinology
127: 1450-1455, 1990)
BRAIN contains two types of corticosteroid receptor,mineralocorticoid (type I) and glucocorticoid (type
I) (1, 2). Glucocorticoid receptors are widely distributed
is judged by the presence of immunoreactivity and
nRNA expression in most neurons and glia (3, 4). Min-
ralocorticoid receptors and their mRNA show a more
elective distribution (5, 6), with high levels of aldoste-
one binding sites in the limbic system and lower levels
n cortex, hypothalamus and brain stem (7, 8). Radioli-
;and binding studies, however, suggest that brain corti-
osteroid receptors are more heterogenous in vivo (9).
nhus, in the hippocampus and septum mineralocorticoid
eceptors preferentially bind corticosterone in vivo, and
heir function may even be antagonized by aldosterone
10). In contrast, mineralocorticoid receptors in circum-
entricular areas selectively bind aldosterone and at
hese sites corticosterone and the synthetic glucocorti-
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coid dexamethasone are ineffective (7-9). Aldosterone
itself has well-described actions within the CNS, affect¬
ing salt appetite, blood pressure regulation and neuroen¬
docrine control (8, 11-14). Despite this functional het¬
erogeneity, mineralocorticoid receptors are structurally
identical in all tissues investigated including the kidney
and brain and are translated from a single mRNA species
(6, 15). In vitro, purified or expressed recombinant min¬
eralocorticoid receptor is nonspecific and binds corticos¬
terone and aldosterone with equal affinity (15-17). Glu¬
cocorticoid receptors may also show regional differences
in sensitivity to corticosteroids. Thus, low doses of cor¬
ticosterone can prevent the postadrenalectomy rise of
glucocorticoid receptor levels in hypothalamus and hip¬
pocampus, but not in cortex and cerebellum (7, 18),
whereas low dose dexamethasone (a synthetic glucocor¬
ticoid) prevents the rise in all brain regions. The mech¬
anism^) responsible for these site-specific differences in
ligand sensitivity of cerebral mineralocorticoid and per¬
haps glucocorticoid receptors in vivo, are unknown.
In peripheral aldosterone-selective target tissues, such
as the kidney and salivary gland, corticosterone does not
show mineralocorticoid activity or receptor binding in
1450
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)ivo. In kidney, 11/3-hydroxysteroid dehydrogenase (11/?-
3HSD), an NADP+-dependent microsomal enzyme, me-
abolizes corticosterone to inactive 11-dehydrocorticos-
erone (which cannot bind to mineralocorticoid recep-
ors) (19) and thus protects the nonselective mineralo-
:orticoid receptor from exposure to corticosterone in vivo
20, 21). In the congenital absence of ll/?-OHSD, Cortisol
the predominant glucocorticoid in man; metabolized by
Ll/?-OHSD to inactive cortisone) has potent renal min-
iralocorticoid effects, leading to hypertension and hy¬
pokalemia (22). Similarly, inhibition of ll/?-OHSD by
icorice (or its active metabolite glycyrrhetinic acid or
he derivative carbonoxolone) allows physiological glu-
locorticoids to exhibit mineralocorticoid activity (23). In
iddition to kidney and salivary gland, high levels of 11/3-
9HSD activity have been found in liver, lung and testis
24, 25), but heart has little or no 11/3-OHSD activity
ind cardiac mineraio^ irticoid receptors bind aldosterone
ind corticosterone with similar affinity (20, 21).
As hippocampal mineralocorticoid receptors bind cor-
icosterone and aldosterone with equal affinity in vivo, it
las been suggested that similar specificity-conferring
nechanisms are absent in brain and ll/?-OHSD bioac-
ivity was not found in whole hippocampal extracts in
htro (20, 21). However, early studies in a variety of
ipecies demonstrated ll/?-OHSD bioactivity in whole
irain extracts and this activity was dependent on addi-
ion of exogenous NADP+ to the reaction (26, 27). The
unctional studies outlined above suggest that localized
nineralocorticoid specificity-conferring mechanisms are
iperative within the CNS.
To examine whether ll/?-OHSD is also associated with
;lucocorticoid receptors we recently investigated rat cer-
ibellum (a tissue with high glucocorticoid receptor levels
ind mRNA expression, but very little aldosterone bind-
ng or mineralocorticoid receptor mRNA expression (4,
15, 18), and found ll/?-OHSD mRNA expression and
TADP+-dependent bioactivity in cerebellar cortex (28)
Moisan, M.-P., J. R. Seckl, L. P. Brett, C. Monder, A.
£. Agarwal, P. C. White, and C. R. W. Edwards, submit-
ed for publication). Clearly ll/?-OHSD might be respon-
ible for the localized differences in corticosterone bind-
ng to mineralocorticoid and/or glucocorticoid receptors
n other regions of the brain. We have now investigated




Rats (Wistar, male, 200-250 g, n = 5) were decapitated and
he brains removed and dissected on ice. Tissues were homog-
nized in Krebs-Ringer bicarbonate buffer (118 mM NaCl, 3.8
nM KC1, 1.19 mM KH2P04, 2.54 mM CaCl2-2H20, 1.19 mM
MgS04-7H20, 25 mM NaHC03 and 0.2% glucose) using a
Dounce tissue grinder. The total protein content was estimated
colorimetrically (Bio-Rad protein assay kit), using an aliquot
of the homogenate. 0.5 mg of total protein was incubated with
NADP+ (200 /xM) and 12 nM (final concentration) 1,2,6,7,3H-
corticosterone (specific activity: 84 Ci/mmol, Amersham Inter¬
national) in Krebs-Ringer buffer (+0.2% BSA) for 1 h at 37 C.
After incubation, steroids were extracted with ethyl acetate and
separated by thin-layer chromatography. The percentage con¬
version of [3H]corticosterone to[3H]ll-dehydrocorticosterone
was calculated from the radioactivity of each fraction (20).
RNA preparation
Male rats were decapitated and the brain was rapidly re¬
moved and dissected on ice. Tissue was immediately frozen in
liquid nitrogen. Control tissues included liver (a rich source of
11/3-OHSD and the tissue of origin of the cDNA clone used),
heart (an organ with negligible 11/3-OHSD activity and non¬
selective mineralocorticoid receptors in vivo), kidney, testis and
lung (the latter tissues are areas where in vitro and in vivo
roles for 11/3-OHSD have been established or proposed). Total
RNA was extracted with guanidinium thiocyanate as described
(29). Briefly, 0.1-0.2 g of tissue was homogenized in 1-2 ml of
4 M guanidinium thiocyanate, 0.025 M sodium citrate, 0.5%
sarcosyl and 0.1 M /3-mercaptoethanol. DNA was precipitated
by addition of sodium acetate (0.2 M; pH 4) and proteins were
removed by phenol/chloroform extraction. The aqueous phase
containing RNA was precipitated twice with isopropanol and
resuspended in diethylpyrocarbonate-treated H20. RNA con¬
centration and purity was assayed spectrophotometrically and
aliquots stored at —70 C prior to use. Equivalence of loading
onto gels was confirmed visually by ethidium bromide staining
under ultraviolet illumination.
Northern blot and cDNA/mRNA hybridization
An aliquot of 20 /u.g of total RNA was fractionated on 2%
agarose-2.2 M formaldehyde gels and blotted onto nitrocellulose
(Hybond C extra, Amersham International, UK) by capillary
transfer at 4 C overnight. The nitrocellulose membrane was
prehybridized in 50% formamide, 5 X SSPE, 5 X Denhardt's
solution, 200 jug/ml denatured herring testis DNA, 0.1% SDS,
and 1 mM EDTA. Hybridization was performed in identical
buffer containing radioactively labeled 11/3-OHSD cDNA
probe. The 1.2-kb 11/3-OHSD probe, subcloned in a pBluescript
KS vector (30) was labeled with [32P]dCTP (3000 Ci/mmol,
Amersham International, UK) by oligonucleotide random
priming (BCL, UK) to a specific activity of 1-2 X 109 cpm//xg
DNA and diluted in hybridization buffer (3-6 X 106 cpm/ml).
Hybridization was performed at 42 C overnight and the mem¬
brane washed to a final stringency of 0.2 X SSC; 0.1% SDS at
60°C and exposed to Kodak XAR film.
In situ hybridization
Adult male Wistar rats (180-220 g) were decapitated and the
brain rapidly removed on ice. The forebrain and hindbrain was
separated by a coronal cut of the brain stem and immediately
frozen on Dry Ice. Tissue was stored at —85 C prior to sectioning
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in a cryostat at —20 to —22 C. Coronal sections (10 yum) were
mounted onto gelatin and poly-l-lysine-coated slides, and
stored at —85 C. Tissue sections were fixed in 4% paraformal¬
dehyde/0.1 m phosphate buffer and washed in 2 x SSC made
up in diethylpyrocarbonate-treated sterile water. Prehybridi-
zation buffer containing 50% formamide, 0.6 m NaCl, 10 mm
Tris-HCl (pH 8.5), 0.02% Ficoll, 0.02% polyvinylpyrrolidone,
0.1% BSA, 1 mm EDTA, 0.5 mg/ml denatured salmon sperm
DNA, 0.5 mg/ml total yeast RNA, and 0.05 mg/ml yeast tRNA
were pipetted onto the sections and the slides were incubated
at 50 C for 2 h in sealed boxes.
T3 polymerase (GIBCO BRL, UK) was used to transcribe
1.2-kb 35S-labeled antisense cRNA probe from Sacl-linearized
pBluscript vectors containing the 11/3-OHSD cDNA insert (30).
The proportions of labeled and cold UTP were adjusted to yield
probes of specific activity 10 x 104 Ci/mmol. The cRNA probe
was denatured and added to hybridization buffer (50% form-
amide, 0.6 m NaCl, 10 mm Tris-HCl (pH 7.5), 0.02% Ficoll,
0.02% polyvinylpyrrolidone, 0.1% BSA, 1 mm EDTA, 0.1
mg/ml denatured salmon sperm DNA, 0.05 mg/ml total yeast
RNA, 0.05 mg/ml yeast tRNA, 0.1 g/ml Dextran sulfate, and
10 mm DTT) to a final concentration of 0.05 pmol/ml and
applied to the slides. The slides were incubated overnight at 50
C in sealed boxes. Following hybridization the slides were rinsed
twice in 2 x SSC for 30 min at room temperature prior to
RNase A digestion (30 /ug/ml for 30 min at 37 C). The slides
were washed in reducing salt concentrations to a maximum
stringency of 0.1 x SSC at 60 C for 60 min. After dehydration
in increasing concentrations of ethanol (maximum 90%) in 0.3
m sodium acetate, sections were air dried and exposed to
autoradiographic film (Hyperfilm /3-max, Amersham Interna¬
tional, UK). Similar sections were dipped in photographic
emulsion (Ilford, UK) and stored at 4 C for 20-30 days before
being developed and counterstained with haematoxylin and
eosin.
Controls, carried out to test the specificity of the hybridiza¬
tion method and the 11/3-OHSD probe included pretreatment
of sections with RNase A (100 ,ug/ml for 1 h at 37 C) prior to
hybridization with antisense probe and hybridization using
labeled-cRNA sense probe (not complementary to 11/3-OHSD
mRNA, transcribed by T7 polymerase (Promega, UK) and
applied at 10 x 106 cpm/ml).
Statistics
Data were assessed by ANOVA followed by Scheffe's test.
Significance was set at P < 0.05. Values are expressed as means
± sem.
Results
In homogenates, 11/3-OHSD bioactivity expressed as
the percentage conversion of [3H]corticosterone to [3H]
11-dehydrocorticosterone over 60 min in the presence of
NADP+ (200 yuM) was: hippocampus, 55.8 ± 2.7%; pari¬
etal cortex, 52 ± 3.1%; hypothalamus, 26.1 ± 1.2%; brain
stem, 21.4 ± 1.7%; spinal cord, 12.3 ± 1.8% and pituitary,
40 ± 1% (variance, P < 0.001; Fig. 1). Hippocampus and
cortex showed significantly more activity than all other
80 -i
Fig. 1. 11/3-OHSD bioactivity in rat brain region homogenates, e>
pressed as the percentage conversion of [3H]corticosterone to [:,H]li
dehydrocorticosterone in the presence of NAPD+ (200 yiM) in 60 min
Ce Hi Co Hy St P Sc
ft* •
$ ■
Fig. 2. Nothern blot (20 ng total RNA per lane), hybridized with 32I
labeled 11/3-OHSD cDNA probe under stringent conditions, showir
11/3-OHSD mRNA expression as a single band in all peripheral tissuf
examined except heart, and in all brain subregions. Li = liver, K
kidney, He = heart, T = testis, Lu = lung, Ce = cerebellum, Hi
hippocampus, Co = parietal cortex, Hy = hypothalamus, St = brai
stem, P = pituitary, Sc = spinal cord.
regions (P < 0.05), but somewhat lower activity tha
that we have previously described in cerebellum (64.3 :
2.4%) (28) Moisan, M.-P., J. R. Seckl, L. P. Brett, C
Monder, A. K. Agarwal, P. C. White, and C. R.
Edwards, submitted for publication). Kidney showed 7
± 3% conversion and heart 17 ± 2% under identic!
assay conditions, peripheral tissues of high and low 11/:
OHSD bioactivity respectively (20, 21, 28).
Northern blots (20 yug total RNA) hybridized with 32F
labeled 11/3-OHSD cDNA probes under stringent cond
tions showed 11/3-OHSD mRNA expression in all region
Li K He T Lu
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of the brain, although at levels lower than liver and
kidney (Fig 2). No expression was found in heart. Testis
and lung showed lower expression than brain, although
the lung RNA sample showed some degradation and thus
the level of 11/3-OHSD mRNA in this tissue may have
been underestimated. Within the brain, cortex and hip¬
pocampus showed high 11/3-OHSD mRNA expression,
at levels similar to cerebellum (a tissue we have previ¬
ously shown to have high 11/3-OHSD mRNA expression)
(28) with lower expression in brain stem, spinal cord,
hypothalamus, and pituitary. In situ hybridization using
!5S-labeled cRNA antisense probes (Table 1) confirmed
localized cerebral 11/3-OHSD mRNA expression, with






























































Distribution of 11/3-OHSD mRNA expression by in situ hybridiza-
;ion histochemistry in selected forebrain regions and pituitary. Key: —,
ibsent; ±, very weak (just above background); +, weak; ++, moderate;
f++, strong. (+) denotes higher expression in some areas of the
structure indicated.






Fig. 3. Autoradiogram of a coronal section of rat brain hybridized with
35S-labeled 11/3-OHSD cRNA. Note the high 11/3-OHSD mRNA expres¬
sion in dorsal and ventral hippocampus (dentate gyrus and pyramidal
layer), parietal and cingulate cortex, choroid plexus (lateral ventricle),
and meninges.
(Fig. 3). Neurons in the other layers of parietal cortex
also expressed 11/3-OHSD mRNA and modest expression
was found in the caudal part of the frontal cortex (layer
IV only) cingulate and piriform cortex. Other cortical
neurons did not express 11/3-OHSD mRNA. Most, if not
all, hippocampal neurons showed high expression of 11/3-
OHSD mRNA (Fig. 3), with the highest levels in CA3
pyramidal cells. Hypothalamus generally showed low
11/3-OHSD mRNA expression but localized expression
was found in the anterior part of the medial preoptic
area (including the organ vasculosum of the lamina ter-
minalis; OVLT) and the posterior part of the arcuate
nucleus around the posterior margin of the third ventri¬
cle. There was high mRNA expression in anterior lobe
of pituitary, but the neurointermediate lobe was negative.
Vasculature in the meninges and choroid plexus had high
11/3-OHSD mRNA expression paralleling recent reports
of high enzyme bioactivity in mesenteric blood vessels
(31).
There was no hybridization of 'sense' cRNA probes
under the stringent conditions (0.0165 M Na+ at 60 C)
employed. RNase A pretreatment markedly attenuated
the hybridization signal (data not shown).
Discussion
We found 11/3-OHSD bioactivity and mRNA expres¬
sion in rat brain. In forebrain, as in cerebellum (28), 11/3-
OHSD activity is NADP+-dependent in vitro. In unsup-
plemented hippocampus or whole forebrain enzyme ac¬
tivity is low (20, 26, 27) but is markedly increased, to
levels similar to those found in kidney, when the cosub-
strate NADP+ is added to the incubation medium. This
suggests that depletion of cosubstrate in vitro might be
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responsible for previous negative findings (20, 21). Al¬
though brain levels of NADP+ and other adenine dinu-
cleotides are very low compared to liver, kidney and
other tissues (32), the brain might be expected to syn¬
thesize these molecules as required. Thus, in vivo, low
cerebral NADP+ concentrations may not limit 11/3-
OHSD activity. The activity detected in vitro appears to
represent authentic 11/3-OHSD as all brain areas inves¬
tigated showed expression of a single mRNA species of
identical size to that found in liver and kidney. Further¬
more, we have previously shown that cerebellar 11/3-
OHSD shows similar inhibition to the purified renal
enzyme when inhibited with glycyrrhetinic acid, in vitro
(28, 33) (Moisan, M.-P., J. R. Seckl, L. P. Brett, C.
Monder, A. K. Agarwal, P. C. White, and C. R. W.
Edwards, submitted for publication).
The highest levels of 11/3-OHSD bioactivity were found
in hippocampus and cortex. There was more than 50%
conversion of corticosterone to 11-dehydrocorticosterone
in these structures, levels of activity similar to those
found in kidney where the biological importance of 11/3-
OHSD has been clearly established (20-23). Recent stud¬
ies of hippocampal 11/3-OHSD showed no enzyme activ¬
ity in whole hippocampal extracts (unsupplemented with
NADP+) leading to suggestions that the preferential
binding of corticosterone by hippocampal mineralocor-
ticoid receptors in vivo related to the absence of 11/3-
OHSD activity at this site (20, 21). Our data are at
variance with these findings. Although these conflicting
in vitro studies cannot provide substantial evidence for
a role for 11/3-OHSD in hippocampus in vivo, the high
bioactivity and the presence of high mRNA expression
suggest that 11/3-OHSD may regulate, at least in part,
corticosteroid-receptor interactions in the limbic system.
Indeed, a subpopulation of hippocampal corticosteroid
receptors have been shown to be selective for aldosterone,
rather than corticosterone, in vivo (9). In situ hybridi¬
zation localized 11/3-OHSD mRNA expression to pyram¬
idal and granule cell neuronal layers of the hippocampus
with highest expression in the CA3 field. CA3 neurons
have plentiful mineralcorticoid receptors, but little glu¬
cocorticoid receptor immunoreactivity or mRNA expres¬
sion (3, 4, 8, 34). Whether 11/3-OHSD functions to reg¬
ulate access of corticosterone to hippocampal glucocor¬
ticoid and/or mineralcorticoid receptors remains to be
determined. However, as both 11/3-OHSD and mineral-
cortocoid receptor (and glucocorticoid receptor) mRNAs
are expressed in the majority of hippocampal neurons
colocalization is very probable. This distribution differs
from that described by immunocytochemistry in the
kidney where 11/3-OHSD immunoreactivity and miner-
alocorticoid binding sites are not colocalized and a par¬
acrine regulatory action of 11/3-OHSD has been proposed
(20).
In neocortex there were also high levels of 11/3-OHSI
bioactivity and mRNA expression, predominantly local
ized to parietal cortex, particularly layer IV. This regioi
processes sensory inputs, and has much glucocorticoii
receptor immunoreactivity and mRNA expression (3, 4)
but little mineralocorticoid receptor binding (7,18). Glu
cocorticoids can modulate sensory processing (35). Ii
addition, the postadrenalectomy rise in cortical glucocor
ticoid receptor levels is not down-regulated by corticos
terone, whereas very low dose dexamethasone treatmen
leads to down-regulation (7). As dexamethasone is not;
substrate for 11/3-OHSD these data may suggest tha
11/3-OHSD could regulate the access of corticosterone to
cortical glucocorticoid receptors in vivo. However, n
cortex and hippocampus binding of ligand to mineralo
corticoid receptors may regulate both mineralocorticoii
receptor and glucocorticoid receptor levels, at least b
mice (18), and clearly the in vivo interactions betweei
ligand and the two receptor types are complex.
Much pharmacological and ligand-binding data sug
gest that periventricular areas of the hypothalamus ar
the location of the central aldosterone-mediated effect
on salt and water homeostasis. Thus, circumventricula
organs and anterior hypothalamus show preferential up
take of aldosterone, rather than corticosterone, in viv>
(7, 9). Lesions of the anteroventral third ventricle, AV31
(which includes the medial preoptic area and OVLT
attenuate salt appetite and affect blood pressure (36)
but in contrast hippocampectomy (which removes limbi
system mineralocorticoid receptors) does not alter th
actions of adrenal steroids on salt appetite (37). We hav>
found only very modest 11/3-OHSD mRNA expressioi
and bioactivity in whole hypothalamic extracts, in vitrc
but in situ hybridization demonstrated localized highe
11/3-OHSD mRNA expression in the most anterior re
gion of the medial preoptic area/OVLT and the periven
tricular posterior part of the arcuate nucleus. Thus, 11/3
OHSD predominates in those hypothalamic areas wher
mineralocorticoid receptors are thought to be aldoste
rone-selective and to mediate the central actions of al
dosterone on salt-water homeostasis and neuroendocrin
and hemodynamic control. Clearly, abnormalities of 11/3
OHSD activity might allow excessive binding of corti
costerone to normally 'aldosterone-selective' hypotha
lamic mineralocorticoid receptors leading to neurogeni
hypertension. Certainly lesions of AV3V attenuate o
prevent the development of blood pressure increases ii
mineralocorticoid-salt excess and other models of hyper
tension in rats (36, 38, 39).
Moderately high 11/3-OHSD mRNA expression (am
bioactivity) was also found in anterior pituitary, suggest
ing that 11/3-OHSD might influence the access of corti
costerone to receptors at this site, and providing a pos
sible explanation for observed preferential binding c
11/3-OHSD IN BRAIN 1455
lexamethasone, compared with corticosterone to pitui-
;ary (40). However, any role of 11/3-OHSD in the regu-
ation of the hypothalamic-pituitary adrenal axis by
physiological corticosteroids remains to be determined.
In summary, we provide evidence for regional 11/3-
3HSD mRNA expression and bioactivity in rat brain, in
ritro. Cerebral 11/3-OHSD activity may explain the site-
ipecific differences in binding and actions of physiolog-
cal corticosteroids at both mineralocorticoid and gluco-
;orticoid receptors, in vivo.
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act
ydroxysteroid dehydrogenase (11/?-OHSD) metabolizes corticosterone to inactive 11-dehydrocorticosterone and thus protects
pecific mineralocorticoid receptors from exposure to corticosterone in the kidney in vivo. Clearly, 11/LOHSD might also
ate corticosterone access to glucocorticoid receptors. We have investigated cerebellum, a tissue with high glucocorticoid
tor, but very low mineralocorticoid receptor levels and have shown marked 11/f-OHSD bioactivity with similar co-substrate
ements and inhibition kinetics to the renal enzyme. 11/J-OHSD messenger ribonucleic acid was expressed in cerebellum
as localized in Purkinje and granule cells. This distribution was confirmed immunohistochemically. Thus, we provide evidence
/3-OHSD in cerebellum and suggest that it may regulate the access of corticosterone to glucocorticoid receptors in addition
leralocorticoid receptors.
types of corticosteroid receptors have been classically
bed. Receptors binding aldosterone with high affinity were
1 type I or mineralocorticoid receptors (MR), those that
i high affinity for dexamethasone but bound aldosterone
luch lower affinity were designated type II or glucocorticoid
ors (GR) (1). GR are widely distributed in all tissues, with
alarly high levels of GR in liver, thymus and leucocytes
i brain, in hippocampus, hypothalamus and cerebellum as
s in glia. MR and its mRNA show a more tissue-specific
ution but are found not only in classical aldosterone target
uch as kidney, parotid and colon but also in heart and
MR mRNA is detectable in several brain regions, with the
t levels of expression in the hippocampus and brainstem
tro, the physiological glucocorticoids Cortisol (man, guinea-
nd corticosterone (rat) bind with the same affinity as
;rone to purified (3, 4) or recombinant expressed MR (5).
/er in vivo, although physiological glucocorticoids circulate
-fold molar excess to aldosterone, they do not bind to MR
>sterone-selective target tissues such as kidney or parotid,
ve little mineralocorticoid activity. In heart and hippocam-
R bind corticosterone with high affinity, in vivo. Indeed,
:rone may even antagonize the actions of corticosterone at
ion-selective sites (6). In addition to corticosterone-prefer-
ring sites in the limbic system, in vivo autoradiographic techniques
have also defined aldosterone-preferring binding sites in periven¬
tricular areas of the brain (7). Despite the different in vivo
specificities of the MR in kidney and hippocampus, the receptors
are structurally identical and are translated from identical mRNA
transcripts (2). Until recently the mechanisms conferring site-
specific selectivity to MR in vivo were unclear.
11/5-Hydroxysteroid dehydrogenase (11/J-OHSD) is an
NADP +-dependent microsomal enzyme which catalyses the meta¬
bolism of Cortisol in man (or corticosterone in the rat) to inactive
cortisone (11-dehydrocorticosterone) (8). Enzyme activity is found
in liver, lung, kidney, testis, colon and salivary gland (9, 10). We
have recently demonstrated the crucial role of 11/f-OHSD in
determining MR specificity in vivo (11). Thus, in aldosterone-
selective tissues (kidney, parotid gland) 11/I-OHSD rapidly meta¬
bolizes Cortisol to cortisone and protects MR from exposure to
glucocorticoid. We have shown that the apparent mineralocort¬
icoid excess in congenital 11/I-OHSD deficiency is due to the
mineralocorticoid activity of circulating glucocorticoids (12). Fur¬
thermore, inhibition of 11/J-OHSD in normal subjects with liquor¬
ice, (or its major active component /1-glycyrrhetinic acid or the
hemi-succinate derivative carbenoxolone) reveals potent renal and
colonic mineralocorticoid actions for Cortisol (13). In the rat
kidney, in vivo autoradiography has demonstrated that 11/1-
ondence to: J. R. Seckl, Department of Medicine, Western General Hospital, Edinburgh EH4 2XU, UK.
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OHSD inhibititsn leads to a pattern of [3H]corticosterone binding
indistinguishable from f'HJaldostcrone binding (II). Thus. Il/f-
OHSD appears to protect the non-specific renal MR from expo¬
sure to glucocorticoids in vivn.
Recent data have shown that 11/(-OHSD bioactivity is absent
in hippocampus, which has high levels of both MR and GR (II.
14). apparently confirming some earlier studies using whole brain
homogenates (15) However, experiments performed more than
20 years ago demonstrated NA DP '-dependent 1 l/f-OHSD bioac-
tivity in rodent brain (16. 17). Subregions of brain, other than
hippocampus, have not been studied. In addition to the role of
I l/f-OHSD in regulating cortisol-MR interactions we have
recently found evidence that this enzyme may act to modulate
the access of Cortisol to GR in human skin (18) and clearly any
I l/f-OHSD activity in the nervous system may relate to either or
both receptors. We have now investigated whether 1 l/f-OHSD
bioactivity and or mRNA expression are found in rat cerebellum,
a region which contains high levels of GR and GR mRNA but
very little MR and its mRNA (2. 19, 20). An abstract of aspects
of this work has been presented to the Physiological Society.
Results
In vitro bioactivitv
Cerebellar homogenates showed modest 1 l/f-OHSD activity in
the absence of NADP + , converting 18.3±1% of [3H]corticos-
terone to [3H] 11-dehydrocorticosterone in 60 min. This was
significantly more than heart (negative control tissue with non¬
selective MR) which showed 0.8±0.5% conversion (indistinguish¬
able from the assay blank values). Kidney showed 63.4 ±3.7%
conversion under these conditions. As brain contains very little
NADP+ (21), the co-substrate for 11/l-OHSD, the incubations
were repeated in the presence of excess (200 /iM) NADP*. This
led to a modest increase in activity in kidney (by 15.6±3%) and
heart (by 14.2 ±3%) but a marked increase in 11/S-OHSD activity
in cerebellum (by 46±2.9%) (all P<0.001; ANOVA followed by
unpaired student's Mest) (Fig. 1). Addition of /?-glycyrrhetinic
acid to the reaction significantly reduced the 1 l/f-OHSD activity
of cerebellar homogenates to 36±2.5% (10*8 M), 10.8±0.6%
(10~6 M) and 2.2 + 0.6% (10~4 M) (Fig. 2). The kinetics of
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Fig. 1. 1 l/f-OHSD in vitro activity in homogenates of rat cerebellum
compared to kidney and heart (n = 5). 0.5 mg of total protein was
incubated with 12 nM [3H]corticosterone for 60 min. The co-substrate











Fig. 2. In vitro effect of /f-glycyrrhetinic acid (GE) on I l/f-OHSD activ
in homogenates of rat cerebellum. 0.5 mg total protein was incubal
with 12 nM [3H]corticosterone. 200 /jM NADP* and 10*4 M. 10*6
or 10"8 M GE for 60 min.
Messenger RNA expression and localisation
The expression of 1 l/f-OHSD mRNA was determined in 20
total RNA extracted from rat liver, testis and cerebellum a:
fractionated on denaturing agarose gels. 1 l/f-OHSD mRN
expression was detected by Northern blot hybridization (Fig.
Liver is the original tissue from which the cDNA has be
isolated and cloned (23) and testis is an area where the importan
of the enzyme has been recently described (24). A single band
hybridization was detected in liver, testis and cerebellum. T
intensity of the signal was stronger in cerebellum than in test
demonstrating a high level of 1 l/f-OHSD mRNA expression
cerebellum, although lower than liver.
In situ hybridization with a 1.2 kb [35S]UTP-labelled cRN
antisense probe transcribed in vitro from the cDNA confirm
the presence of 1 l/f-OHSD mRNA in cerebellum. 11/J-OH5
mRNA was localized to the cerebellar cortex with highest expri
sion in the Purkinje and granule cell layers (Fig. 4). Hybridizatf
was markedly attenuated (> 50 x reduction of signal intensil
with RNase A pretreatment (data not shown). No specific hybri
ization with 'sense' cRNA probe was seen under the stringe
conditions employed (Fig. 4). Microscopy of emulsion-coat
sections, counterstained with haematoxylin and eosin. reveal
moderate silver grain intensity over granule cell bodies, wi
higher expression in Purkinje cells (Fig. 5). Very low (but abo
background) expression was found in most other neurons t
not over white matter. There was no difference in the distributi
or relative regional intensity of hybridization using 1.2 or 0.6
probes (data not shown).
Immunocytochemical studies with two separate 11/f-OHS
antisera (1:2-300 dilution) revealed positive staining of Purkit
and granule cell cytoplasm in the cerebellar cortex (Fig.
Further moderately positive immunostaining was located in lar
neurons in the basal cerebellar nuclei. Other cells, including the
in the molecular layer and the underlying brainstem nuclei, w(
largely negative. Diffuse moderately positive staining was fou
in most axons and dendrites, but myelin was negative. Simf
results were found with both fixatives and with both antise:
Preabsorption of the antiserum with concentrated antig
(sonicated rat liver microsomes) prevented immunostaining
G. 3. 1 l/TOHSD mRNA expression in liver (L), testis (T) and cerebellum (C). Each lane contained 20 #ig total RNA.
3. 4. Distribution of 11/1-OHSD mRNA in rat cerebellum by in situ hybridization, using a [35S]-labelled cRNA antisense probe (a). The most intense
pression is seen in the Purkinje cell layer (P), with moderate expression in the granule cell layer (G), but expression in the molecular layer (M) and
lite matter (W) is low. BS — underlying brainstem. A control section hybridized with sense cRNA probes is shown to demonstrate non-specific
iding (b).
irkinje and granule cells (and renal tubules) but only partially
lenuated staining in molecular layer dendrites (Fig. 6). There-
re, the immunostaining in dendrites and axons was considered
be non-specific, presumably analogous to that previously
scribed in kidney using one of these antisera (25). Furthermore,
/J-OHSD activity in soluble (non-microsomal) fractions has not
en reported; the enzyme would therefore not be expected to be
:ated in neuronal processes. Preimmune rabbit serum showed
staining (Fig. 6). Kidney immunostaining corresponded to our
svious findings (11), with positive staining of tubular cells and
staining of glomeruli.
Discussion
We have demonstrated ll/(-OHSD mRNA expression and in
vitro bioactivity in rat cerebellum. Enzyme mRNA expression
and immunoreactivity are localized in the cerebellar cortex.
In the absence of exogenous NADP* cerebellar homogenates
showed modest enzyme activity (18.3 it 1% conversion) compared
with 63.4 + 3.7% conversion of corticosterone to 11-dehydrocort-
icosterone in kidney, a tissue where the biological -inportance of
ll/l-OHSD in vivo has been established (11). However, addition
of excess NADP*, the enzyme co-substrate, increased cerebellar
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Fig. 5. High power photomicrograph of rat cerebellum following in situ
hybridization using [35S]-labelled cRNA antisense probe to 1I/J-OHSD
raRNA demonstrating high expression in Purkinje cells (P) and the
granule cell layer (G). Low background expression is seen over the
molecular layer (M).
11/TOHSD activity to 64.3 + 2.9%. NADP+ led to only a small
increase in renal enzyme activity and conversion remained low
in the negative control heart tissue. Levels of adenine dinucleotides
are low in brain (21), but neuronal concentrations and any
variations of levels in brain subregions are unknown. It is likely
that brain, a tissue that is largely metabolically-dependent on the
circulation, will resynthesize rather than store energy-pathway-
related molecules such as NADP*. Thus, the large discrepancy
between basal and NADP +-supplemented 1I/1-OHSD activity in
cerebellum in vitro may reflect rapid depletion of endogenous
dinucleotide in the reaction mixture. Whether limitation of
NADP+ concentrations plays any role in vivo in the regulation
of ll/l-OHSD activity remains to be determined. Nevertheless,
the maximum cerebellar 11/1-OHSD activity is similar to that
found in kidney, suggesting that the enzyme may have important
physiological effects in cerebellum.
The biological activity of 11/J-OHSD in cerebellum appears to
be mediated by a similar enzyme to that found in kidney and
liver. Thus, not only do these activities have the same co-substrate
requirement, but also both renal and cerebellar enzymes show
similar inhibition kinetics with /J-glycyrrhetinic acid (22). Further¬
more, mRNA for the enzyme is expressed in cerebellum with a
transcript size identical to that found in liver and kidney. Ho\
ever, enzyme identity between tissues must be confirmed at tl
post-translational level. The level of ll/J-OHSD mRNA expre
sion in cerebellum is at least as high as in testis, a tissue wii
well documented enzyme bioactivily (9, 24). Cerebellar mRN
expression is less than that found in liver, the major site i
corticosteroid degradative metabolism.
Immunohistochemically, 11 /J-OHSD was localized to cerebelli
cortex, with the highest staining found in granule and Purkin
cells. There was also non-specific immunostaining in most, if m
all, axons and dendrites (presumably analogous to the noi
specific binding reported using 11/TOHSD antisera in kidne
25). In situ hybridization showed a distribution of 11/TOHS
mRNA similar to that of enzyme immunoreactivity. This is n<
surprising for a microsomal enzyme, which would not be expects
to be exported from the cell of biosynthesis. The specificity i
hybridization was clearly confirmed by the absence of signal whs
sense control probes were employed.
The cerebellar cortex contains very high levels of GR and i
mRNA. In contrast, MR mRNA expression is very low, whs
compared quantitatively (by RNase protection assay) with kidne
hippocampus, cortex, diencephalon, midbrain and pons (2), coi
firming results from ligand binding studies (19). It is uncle;
whether 11/1-OHSD in cerebellum relates to MR or GR. Cerebs
lum, unlike most brain subregions including hippocampus ar
cerebral cortex, does not show down-regulation of GR v
corticosterone-MR binding, suggesting that in cerebellum M
and GR are not significantly colocalized or co-regulated (7, 15
Taken together with the high levels of in vitro enzyme activi
and the very low concentration of MR these data suggest th
the major importance of cerebellar 11/J-OHSD may be in regula
ing access of glucocorticoids to GR. Further studies to determii
the role of 11/J-OHSD in regulating the actions of corticosteroi
in cerebellum are in progress.
Materials and Methods
11 fi-OHSD enzyme assay
Adult male Wistar rats (180 to 220 g) were decapitated and the brai
rapidly removed and dissected on ice. The cerebellum was separated fro
the brainstem by severing the cerebellar peduncules; kidney and hea
were used as positive and negative controls, respectively (11, 14). Tiss
was homogenized in 5 ml of Krebs-Ringer bicarbonate buffer (118 m
NaCl, 3.8 mM KC1, 1.19 mM KH2P04, 2.54 mM CaCl2.2H20, 1.
mM MgS04.7H20, 25 mM NaHC03 and 0.2% glucose) using a doun
tissue grinder. The total protein content of the homogenate was estimat
colorimetrically (Bio-Rad protein assay kit).
Total protein (0.5 mg) was then incubated with a final concentrate
of 12 nM l,2,6,7,[3H)corticosterone (specific activity 84 Ci/mmol; Ami
sham International, UK) in Krebs-Ringer buffer ( + 0.2% bovine seru
albumin) for 60 min at 37 °C. In some experiments, the enzyme c
substrate NADP'' was added before incubation, at a final concentrate
of 200 pM. After incubation, steroids were extracted with ethyl acets
and then separated by thin-layer chromatography. 11/1-OHSD activi
was determined as the percentage conversion of [3H]corticosterone
[3H]11-dehydrocorticosterone (11).
Enzyme inhibition studies
The lljJ-OHSD inhibitor /?-glycyrrhetinic acid was diluted in ethanol
a concentration of 10"2 M and subsequently diluted in water. (?-G;
cyrrhetinic acid was added to cerebellar homogenates at 10"4 M, 10
M, 10"8 M final concentration and 11/3-OHSD activity assayed as abo'
r
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3. 6. Immunohistochemical localization of 11/i-OHSD; (a) antiserum at working dilution of 1:300, (b) preabsorbed antiserum control (1:300), and
) preimmune serum control (1:300). Specific immunostaining is present in Purkinje (P) and granule cell cytoplasm (G). Diffuse staining of dendrites
d axons (e.g. in the molecular layer, M) could not be attenuated by preabsorption and was therefore considered to be non-specific. No staining is
:n with the preimmune serum.
'■/A preparation from cerebellum
lult male Wistar rats (180 to 220 g) were decapitated, the cerebellae
noved as above and immediately frozen in liquid nitrogen. Total RNA
s extracted with guanidinium thiocyanate, as described (26). Briefly,
g of cerebellum was homogenized in 2 ml of 4 M guanidinium
ocyanate, 0.025 M sodium citrate, 0.5% sarcosyl and 0.1 M /J-
rcaptoethanol. DNA was precipitated by addition of sodium acetate
2 M; pH 4) and proteins were removed by phenol/chloroform extrac-
n. The aqueous phase containing the RNA was precipitated twice with
propanol and resuspended in diethylpyrocarbonate-treated H20.
rthern blot and cDNA/mRNA hybridization
enty pg total RNA was fractionated on a 1% agarose-2.2 M formalde-
le gel and blotted on to nitrocellulose (Hybond C extra; Amersham
ernational) by capillary transfer at 4 °C overnight. The nitrocellulose
mbrane was prehybridized in 50% formamide, 5 x SSPE, 5 x
nhardt's solution, 200 pgjm\ denatured herring testis DNA, 0.1% SDS
1 1 mM EDTA Hybridization was performed in identical buffer
itaining radioactively-labelled Il^-OHSD cDNA probe. The 1,265
11/J-OHSD cDNA, subcloned in a pBluescript KS vector (23) was
elled with [32P]dCTP by oligonucleotide random priming (Boehringer
nnheim, UK) to a specific activity of 1-2x10' cpm/pg DNA and
ited in hybridization buffer (3-6 x 106 cpm/ml). Hybridization was
formed at 42 °C overnight and the membrane washed to a final
ngency of 0.5 x SSC; 0.1% SDS at 60 C and exposed to Kodak XAR
hlu hybridization
alt male Wistar rats (180 to 220 g) were decapitated and the brains
idly removed on ice. The cerebellum was separated from the forebrain
a coronal cut of the brainstem and immediately frozen on dry ice. 10
sections were mounted on to gelatin and poly-L-lysine-coated micro-
pe slides and stored at - 70 °C. Tissue sections were fixed in 4%
aformaldehyde/0.1 M phosphate buffer and washed in 2 x SSC. Prehy-
lization buffer containing 50% formamide, 0.6 M NaCl, 10 mM Tris-
1 pH 7.5, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% bovine
im albumin, 1 mM EDTA, 0.5 mg/ml denatured salmon sperm DNA,
mg/ml total yeast RNA and 0.05 mg/ml yeast tRNA was pipetted on
he sections and the slides were incubated at 50 °C for 2 h in sealed
es.
3 polymerase was used to transcribe a 1,204 bp [35S]UTP-labelled
sense cRNA probe from a Sac I-linearized pBluescript vector con¬
taining the 11 /J-OHSD cDNA insert. The [35S]cRNA probe was denatured
and added at a final concentration of 10 x 106 cpm/ml to hybridization
buffer (50% formamide. 0.6 M NaCl, 10 mM Tris-HCl pH 7.5, 0.02%
Ficoll, 0.02% polyvinylpyrrolidone, 0.1% bovine serum albumin, 1 mM
EDTA, 0.1 mg/ml denatured salmon sperm DNA, 0.05 mg/ml total yeast
RNA, 0.05 mg/ml yeast tRNA, 0.1 g/ml Dextran sulphate and 10 mM
dithiothreitol) and applied to the sections. Slides were incubated overnight
at 50 °C in sealed boxes. Following hybridization, slides were rinsed twice
in 2 x SSC for 30 min at room temperature prior to RNase A digestion
(30 pg/ml for 30 min at 37 °C). Slides were washed in reducing salt
concentrations to a final stringency of 0.1 x SSC at 60 °C for 1 h. After
dehydration in increasing concentrations of ethanol in 0.3 M sodium
acetate, sections were exposed to Hyperfilm /?m„ (Amersham Interna¬
tional) for 1 to 2 weeks and developed. Sections were subsequently dipped
in photographic emulsion (Ilford. UK) and stored in light-tight boxes at
4 °C for 21 days before being developed (D19; Ilford) and counterstained
with haematoxylin and eosin.
Control experiments were carried out to test the specificity of both the
hybridization method and the II/J-OHSD probe. First, cerebellar sections
were treated as before but hybridized with a sense probe (not complement¬
ary to 11/J-OHSD mRNA, 10 x 106 cpm ml) transcribed by T7 polymerase
from the cDNA. Secondly, fixed sections were pretreated with RNase A
(100 ^g, ml for I h at 37 °C) prior to hybridization with antisense probe.
Finally, to ensure there was good tissue penetration of the 1.2 kb cRNA
probe, we performed similar in situ hybridization studies with a 597 bp
[35S]UTP-labelled antisense cRNA, using Sty 1-linearized 11/J-OHSD
plasmid.
Immunohislochemistry
Male rats were deeply anaesthetized with pentobarbitone and perfused
through the ascending aorta with 250 ml ice-cold phosphate-buffered
saline followed by 500 ml ice-cold 4 M paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4) or Bouin's solution (24). Tissue was removed
and postfixed overnight. Sections (4 pm) were cut and immunostained as
previously described (11) using two separate polyclonal rabbit antisera
(both at 1:2-300 dilution) raised against purified rat liver 11/1-OHSD (8).
Detection was by the horseradish peroxidase-labelled streptavidin-biotin
method (reagents from DAKO Ltd, UK). Control sections were immunos¬
tained using preimmune rabbit serum. Kidney sections were also immunos¬
tained to give positive (tubules) and negative (glomeruli) tissue controls.
Specificity of immunostaining was controlled by preabsorption of the
858 I !/(-hydroxy steroid dehydrogenase in rat cerebellum
antiserum (1:300 dilution) with sonicated purified rat liver microsomes
(which contain concentrated ll/t-OHSD bioactivity) for 24 h at 4 C.
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J-Hydroxysteroid dehydrogenase (11/3-OHSD) protects non-
cific renal mineralocorticoid receptors from exposure to
:ulating glucocorticoid in vivo by catalyzing the conversion
corticosterone to inactive 11-dehydrocorticosterone. Al-
>ugh 11/3-OHSD bioactivity and aldosterone binding sites
found in distal tubular cells, mineralocorticoid receptor and
l-OHSD immunoreactivities are not colocalized. However,
re are several kidney isoforms of 11/3-OHSD, not all of
ich may be immunoreactive, whereas only a single mRNA
cies has been described. Using in situ hybridization we found
l-OHSD mRNA is highly expressed in all renal tubular
thelia in the rat. It is therefore likely that 11/S-OHSD is
realized with mineralocorticoid receptors in distal tubular
s.
leralocorticoid receptor; in situ hybridization; biotinylated
jprobes
RIFIED OR RECOMBINANT expressed mineralocorticoid
eptors are nonspecific and bind the physiological glu-
orticoids corticosterone (rat) or Cortisol (humans) and
mineralocorticoid aldosterone with equal affinity in
ro (2, 7). However, although corticosterone circulates
L00-fold molar excess to aldosterone, it does not bind
renal mineralocorticoid receptors in vivo. The expla-
ion of this apparent paradox lies in the activity of
l-hydroxysteroid dehydrogenase (11/3-OHSD) which
alyzes the conversion of corticosterone to 11-dehydro-
ticosterone, or Cortisol to cortisone (the 11-dehydro
ducts do not bind to mineralocorticoid receptors). In
osterone-selective target tissues such as kidney, 11/3-
SD acts to protect nonspecific mineralocorticoid
eptors from exposure to corticosterone (or Cortisol) in
3 (4, 6). Patients with congenital 11/3-OHSD defi-
rcy exhibit a syndrome of apparent mineralocorticoid
ess in which Cortisol acts as a mineralocorticoid caus-
hypertension and hypokalemia (12). Similarly, inhi¬
bition of 11/3-OHSD with licorice lead glucocorticoids to
develop renal mineralocorticoid activity (13). In the rat,
renal binding of [3H]corticosterone in vivo (normally
minimal) becomes indistinguishable from [3H]aldoster-
one binding when 11/3-OHSD is inhibited (4).
Establishing the tissue localization of 11/3-OHSD in
kidney has been problematical. Immunohistochemical
studies using monospecific polyclonal antisera raised
against purified rat liver 11/3-OHSD suggest that the
enzyme and mineralocorticoid receptors are not colocal¬
ized, with mineralocorticoid receptor immunoreactivity
and aldosterone binding sites in distal tubular and cor¬
tical collecting duct cells but 11/3-OHSD immunoreactiv¬
ity in proximal tubular and medullary interstitial cells
(4, 11). Therefore a hypothesis of paracrine protection
of renal mineralocorticoid receptors by 11/3-OHSD was
proposed (4). However, corticosteroids diffuse readily
through tissues, and a paracrine mechanism is unlikely
to completely prevent access of glucocorticoids to distal
tubular receptors (5). In addition, enriched rat distal
tubular cells and microdissected distal rabbit nephron
show higher 11/3-OHSD bioactivity than proximal tubu¬
lar fractions (3, 4), and isolated rabbit cortical collecting
duct cells have very high 11/3-OHSD activity (10). Indeed,
primary monolayer cultures of these cells almost com¬
pletely metabolize unilaterally applied [3H]corticoster-
one so that >99% of radioactivity on the contralateral
surface is [ll-3H]dehydrocorticosterone (10). Clearly
11/3-OHSD activity is present in renal aldosterone target
cells.
After the recent isolation of a cDNA encoding rat liver
11/3-OHSD (1), expression of 11/3-OHSD mRNA was
demonstrated in a variety of rat tissues including the
kidney (1, 8). Interestingly, 11/3-OHSD mRNA and min¬
eralocorticoid receptor mRNA were demonstrated in
most, if not all, pyramidal neurons in the CA3 subregion
of the hippocampus, suggesting probable colocalization,
at least in brain (8). We have now examined the distri¬
bution of 11/3-OHSD mRNA in the kidney using in situ
hybridization histochemistry.
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METHODS
Male rats (250-350 g) were anesthetized with pento¬
barbital sodium and perfused intracardially with 250 ml
sterile ice-cold physiological saline followed by 500 ml
ice-cold 4% paraformaldehyde-0.1 M phosphate buffer
(pH 7.4) containing 0.02% diethylpyrocarbonate. The
kidneys were removed and were postfixed in paraform¬
aldehyde solution for 2-4 h and then in 15% sucrose/0.1
M phosphate-buffered saline at 4°C overnight. Tissue
was frozen, and cryostat sections (10 were cut,
mounted onto gelatin and poly-L-lysine-coated slides,
and stored at —85°C. Slides were washed twice in 2 x
saline sodium citrate (SSC) containing 0.02% diethyl¬
pyrocarbonate, treated with proteinase K (1 Mg/ml) for
30 min at 37°C, and washed in 2 X SSC before hybridi¬
zation. In parallel studies rats were decapitated, and the
kidneys were immediately frozen on dry ice and stored
at -85°C. Fresh frozen sections were postfixed in 4%
paraformaldehyde-0.1 M phosphate buffer containing
0.02% diethylpyrocarbonate and washed twice in 2 X
SSC containing 0.02% diethylpyrocarbonate before hy¬
bridization.
For isotopic probes, T3 polymerase (GIBCO) was used
to transcribe 598 bp 35S-uridine triphosphate (UTP)-
labeled antisense cRNA probes from Sty I-linearized
pBluescript vector containing the 1,265 bp 11/3-OHSD
cDNA (1). RNA probes (sp act 10 x 104 Ci/mmol, final
concentration 0.05 pmol/ml) were denatured, added to
hybridization buffer [50% formamide, 0.6 M NaCl, 10
mM tris(hydroxymethyl)aminomethane (Tris) pH 7.5,
0.02% Ficojl, 0.02% polyvinylpyrrolidone, 0.1% BSA, 1
mM EDTA, 0.1 mg/ml salmon sperm DNA, 0.05 mg/ml
total yeast RNA, 0.05 mg/ml yeast tRNA, 0.1 g/ml
dextran sulfate, and 10 mM dithiothreitol (DTT)] and
applied to the slides as described (8). Slides were incu¬
bated overnight at 50°C, rinsed twice in 2 X SSC, treated
with RNase A (30 Mg/ml, 30 min at 37°C), and washed
to a maximum stringency of 0.1 X SSC at 60°C for 60
min. After dehydration in increasing concentrations of
ethanol, slides were exposed to autoradiographic film
(Hyperfilm Bma„ Amersham International). For micro¬
scopic localization, slides were dipped in photographic
emulsion (Ilford), exposed in a light-tight box for 3 wk
before being developed (D19; Ilford) and counterstained
with hematoxylin and eosin. Controls included pretreat-
ment with RNase A (100 Mg/ml for 1 h at 37°C) and
hybridization with noncomplementary "sense" probes.
To confirm the microscopic distribution of 11/3-OHSD
mRNA expression biotinylated 11/3-OHSD cRNA probes
were used, as these gave better cellular resolution, al¬
though a lower signal, than isotopic probes. Best results
were obtained with transcripts of 118 bp Pst I-linearized
11/3-OHSD cDNA and prefixed material. Biotin-ll-UTP
(1 mM) was added to a standard in vitro transcription
reaction (Promega). Sections were hybridized and
washed as with isotopic probes and were then rinsed in
phosphate-buffered saline (PBS). Biotin was detected by
exposure to avidin-biotin peroxidase complex (ABC, Vec¬
tor Elite kit; Vector Laboratories, Peterborough, UK) for
30 min. Sensitivity was increased by subsequent incu¬
bation with biotinylated antiavidin (1:250; Vector Lab-
FIG. 1. Autoradiogram of rat kidney sections hybridized with MS-
labeled lld-OHSD cRNA antisense probe; note high 11/3-OHSD
mRNA expression at the juxtamedullary cortex/outer medulla.
oratories) for 60 min and then repeat exposure to ABC.
Finally, 3,3'-diaminobenzidine was added as chromogen.
Some sections were lightly counterstained with methyl
green. Controls sections were incubated in buffer without
cRNA probe.
RESULTS
Macroscopically 11/3-OHSD mRNA expression was
highest in the juxtamedullary cortex-outer medulla with
lower expression in the outer cortex and inner medulla
(Fig. 1), closely resembling the pattern of [^aldoster¬
one binding in vivo (4). Similar results were obtained
with prefixed and postfixed fresh-frozen specimens, but
signal intensity was highest with fresh-frozen material,
suggesting probe penetration was best using this method.
Microscopic analysis of prefixed sections hybridized
with biotinylated probes demonstrated 11/3-OHSD
mRNA expression in all tubular regions (Fig. 2A), with
high 11/3-OHSD mRNA expression in proximal and dis¬
tal tubular epithelia, including the connecting tubule and
cortical collecting duct. Glomeruli did not show 11/3-
OHSD mRNA expression (Fig. 2A), other than some
hybridization associated with vascular elements, and
expression in medullary loops of Henle and medullary
collecting ducts was very low. No signal was detected in
medullary interstitial cells or the epithelium overlying
the papilla. Fresh-frozen sections showed a similar dis¬
tribution of 11/3-OHSD mRNA, although with less well
preserved tissue architecture, whether biotinylated or
35S-labeled probes were employed. Isotopic probes gave
the highest signal and 11/3-OHSD mRNA expression in
all tubular epithelia, including distal and proximal tu¬
bules, (Fig. 2B) could be clearly seen.
There was no hybridization of sense probes under the
stringent conditions employed. RNase A pretreatment
markedly attenuated hybridization. No "endogenous"
biotin signal was detected in sections incubated in hy¬
bridization buffer without probe.
DISCUSSION
This study clearly demonstrates high 11/3-OHSD
mRNA expression in mineralocorticoid receptor-con¬
taining distal, as well as proximal, tubular epithelia.
There are several possible explanations for the discrep-
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"•■ 2. A: photomicrograph of rat kidney sections hybridized with
aviated-lld-OHSD antisense cRNA probe, visualized by horse-
h peroxidase, and counterstained with methyl green. Signal is seen
n cytoplasm of renal tubular epithelial cells of proximal (P) and
I (D) convoluted tubules. Interstitial cells and glomerular (G)
elium are negative. Original magnification x 180. B: :1,S-labeled
)HSD antisense cRNA probe, visualized by photographic emulsion
rounterstained with hematoxylin and eosin. lld-OHSD mRNA
•ssion was seen in all renal tubular epithelial cells of cortex and
medulla, including those of proximal (P) and distal (D) convo-
tubules.
' between the immunohistochemical localization of
OHSD and our in situ hybridization findings,
rst, the 11/3-OHSD mRNA expressed in distal tu-
r cells may not be translated. However, major non-
slated splicing variants are unlikely, as only a single
VA band has been found in Northern analysis of
from rat kidney and other tissues (1, 8). Alterna-
y, 11/3-OHSD might be synthesized in distal tubule
but subsequently degraded or rapidly transported
to other sites. However, lld-OHSD activity is concen¬
trated in the microsomal fraction, and the enzyme is
thus unlikely to be exported. Furthermore, high lld-
OHSD bioactivity with similar enzymatic characteristics
to recombinant expressed lld-OHSD has been found in
distal tubular preparations (3, 4, 10).
Second, the existing lld-OHSD antisera may not rec¬
ognize the enzyme form(s) found in distal tubular epi-
thelia. lld-OHSD immunoreactivity is present as 34.000,
40,000, and 68,000 species in kidney (9). Further isoforms
are found in other tissues, including a 26,000 species in
brain and a 47,000 band in testis (9). These data suggest
that the enzyme undergoes tissue-specific posttransla-
tional processing; sequence analysis of cloned rat lld-
OHSD cDNA shows potential N-glycosylation sites (1).
The current antisera do not bind to the active site of
lld-OHSD (9), and other biologically active but nonim-
munoreactive isoforms of the gene product may occur.
Thus the antisera may only recognize lld-OHSD forms
present in proximal, but not distal, tubule cells.
Finally, the lld-OHSD activity in distal tubular cells
may represent a separate gene product (5). Genomic blot
hybridization has suggested the presence of more than
one related gene in both rat and human genomes (1).
However, the presence of a single mRNA band in North¬
ern blots (1, 8) and high levels of lld-OHSD mRNA in
both distal and proximal tubule cells in situ under the
stringent conditions of this study suggest that additional
gene products need not be invoked to explain lld-OHSD
activity in aldosterone-target cells of the tubular epithe¬
lium.
Corticosteroid lld-dehydrogenases may play a variety
of roles in the kidney. It is likely that the enzyme in
distal tubular epithelia protects colocalized mineralocor-
ticoid receptors from exposure to circulating glucocorti¬
coid. In contrast, the proximal tubular form might reg¬
ulate access of corticosterone to glucocorticoid receptors,
analogous perhaps to lld-OHSD activity recently de¬
scribed in human skin (14). Alternatively, one renal lld-
OHSD form might be relatively inactive under basal
conditions but could be potentiated by elevated (stress)
levels of glucocorticoid, as occurs for hippocampal lld-
OHSD activity (unpublished observations).
Thus, we have demonstrated lld-OHSD mRNA
expression in both proximal and distal renal tubular
epithelia. Cellular colocalization of lld-OHSD and min-
eralocorticoid receptors in the kidney is very likely.
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ABSTRACT. Close regulation of circulating corticosteroid
levels during the early postnatal period is crucial for normal
development and maturation of the central nervous system. In
the first weeks of life cerebral glucocorticoid receptor concentra¬
tions are low and the hypothalamic-pituitary-adrenal axis is
relatively unresponsive to stress, which might, in part, protect
the developing brain from elevated corticosteroid levels. How¬
ever, central mineralocorticoid receptors are at near adult levels
and free glucocorticoid concentrations may approximate adult
values as corticosteroid binding globulin is absent. Thus other
mechanisms controlling cerebral exposure to corticosteroids may
be of importance. 11/3-Hydroxysteroid dehydrogenase (11/5-
OHSD) determines the access of corticosterone to peripheral
mineralocorticoid and glucocorticoid receptors in adults in vivo
by metabolizing corticosterone to inactive 11-dehydrocorticos-
terone. The enzyme has recently been demonstrated in brain
subregions and may modulate local corticosteroid-receptor in¬
teractions. We therefore examined 11/3-OHSD bioactivity and
messenger RNA (mRNA) expression in the brain, compared
with kidney, during the neonatal period.
11/3-OHSD bioactivity (expressed as the percentage conver¬
sion of corticosterone to 11-dehydrocorticosterone) was moder¬
ately high in hippocampus and parietal cortex at birth (46 ± 4%
and 48 ± 5%, respectively), fell significantly to a nadir (32 ± 1%
and 30 ± 1%, respectively) at postnatal day 10 and then gradually
rose to adult values (52 ± 3% and 58 ± 3%). By contrast, 11/3-
OHSD activity in cerebellum was high at birth (60 ± 3%), rose
significantly to a peak at postnatal day 10 (74 ± 3%), and then
fell to adult values by postnatal day 15 (64 ± 3%). Renal 11/3-
OHSD activity was moderately high (69 ± 3%) at birth and
reached adult values (80 ± 2%) by postnatal day 5. Northern
blots showed high and similar expression of a single species of
11/3-OHSD mRNA from birth to adulthood in the hippocampus.
Only low expression of 11/3-OHSD (two or three separate spe¬
cies) was found in the kidney during the first 2 weeks of life,
whereas, in adults high expression of 11/3-OHSD mRNA was
detected in kidney (four species). Using in situ hybridization
high 11/3-OHSD mRNA expression was localized to the neuronal
layers of the postnatal hippocampus, neocortex, and cerebellum,
and low but detectable expression was found in the neonatal
renal cortex. Thus, 11/3-OHSD is highly expressed in rat brain
subregions in the early postnatal period with specific develop¬
mental patterns of activity. The discrepancy between 11/3-OHSD
mRNA expression and bioactivity in the developing kidney is
unexplained and may reflect the presence of more than one gene
product with similar bioactivity. The enzyme may play an im¬
portant role in the developing brain by protecting tissues from
(or exposing them to) elevated corticosterone levels. (Endocri¬
nology 130: 400-404, 1992)
GLUCOCORTICOIDS play an important role duringdevelopment, affecting the growth and differentia¬
tion of a number of tissues and organs, including the
central nervous system (for review see 1). High dose
glucocorticoid administration during the early postnatal
period in rodents leads to permanent inhibition of brain
growth, with reduced neurogenesis and glial prolifera¬
tion, attenuated dendrite formation and behavioral and
neuroendocrine impairments (2). Conversely, adrenal¬
ectomy of 11-day-old rats is followed by neuronal and
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glial proliferation (3) which is reversed by corticosteror
replacement. Hence corticosterone is thought to exert a
antiproliferative effect on postnatal neurogenesis an
glial mitosis in the normal intact animal. These effecl
are most marked during the first 2 weeks of life and thi
close control of circulating glucocorticoid levels duriri
this time appears critical for normal brain developmen
Low and constant levels of circulating glucocorticoic
were thought to be ensured by the hyporesponsivenes
of the hypothalamic-pituitary-adrenal (HPA) axis t
stressful stimuli during the first 2 weeks of life and th
absence of circadian fluctuations in plasma glucocort
coid concentrations in neonates (4). However, it has bee
recently found that various stressors trigger an adul'
like pituitary ACTH response in 10-day-old rats, th
magnitude of which is affected by corticosterone (5
Although the corticosterone response is smaller than thi
400
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seen in the adult, CBG levels are very low in the neonate
and free glucocorticoid levels may be similar. Further¬
more. brain mineralocorticoid receptors (MR, type I)
which. at least in part, mediate corticosterone feedback
on the HPA axis (6), are at near adult levels within 3
days of birth, although glucocorticoid receptor (GR, type
II) levels are low (7). Consequently, it remains unclear
how the brain is protected from elevated glucocorticoid
secretion after stress during this critical period of devel¬
opment.
113-Hydroxysteroid dehydrogenase (113-OHSD) is an
NADP^-dependent microsomal enzyme that catalyzes
the conversion of the physiological glucocorticoid corti¬
costerone to inactive 11-dehydrocorticosterone (Cortisol
to cortisone in man). Although purified MR bind both
aldosterone and corticosterone with high affinity in vitro,
selective binding of aldosterone to renal MR in vivo, in
the face of 100-fold excess circulating corticosterone is
ensured by 113-OHSD which rapidly inactivates corti¬
costerone (8, 9). We, and others, have recently shown
that 11/3-OHSD is also present in brain (10, 11). The
distribution of 113-OHSD in the brain corresponds to
areas of aldosterone-selective MR or attenuated binding
of corticosterone to GR in vivo and we postulated that
113-OHSD may regulate access of corticosterone to cer¬
ebral corticosteroid receptors and thus modulate corti¬
costeroid effects on brain function. Clearly, 113-OHSD
might also regulate glucocorticoid access to corticosteroid
receptors during postnatal development. The ontogeny
of 11/3-OHSD messenger RNA (mRNA) expression has
been studied previously in 1, 2, 3, 4, 8, and 16-week-old
rats in kidney, liver, and lung, and shows a tissue-specific
developmental pattern (12). In this study, we have ex¬
amined 113-OHSD bioactivity and mRNA expression in
the brain, in comparison with kidney, during the first 2
weeks of life to determine whether 11/3-OHSD might




Wistar rats of various ages (1, 5, 10, 15-day-old, and adult)
were decapitated, their brains and kidneys removed, and dis¬
sected on ice. Tissues were assayed as described previously (10).
In brief, 0.5 mg/ml total protein from each tissue homogenate
was incubated with 200 fiU NADP* and 12 nM 1,2,6,7,3H-
corticosterone (SA, 84Ci/mmol, Amersham International, Ay¬
lesbury, UK) in Krebs-Ringer buffer (+0.2% BSA) for 1 h at
37 C. After incubation, steroids were extracted with ethyl
acetate and separated by TLC. The percentage conversion of
H-corticosterone to 3H-11-dehydrocorticosterone was calcu¬
lated from the radioactivity of each fraction.
Northern blot analysis
Kidneys and brains from Wistar rats of various ages were
removed, subregior.- dissected, and immediately frozen on dry
ice. Tissues were pooled where necessary to obtain 50-100 mg.
Total RN'A was extracted by the guanidinium thiocyanate
method, as described (13). Approximately 15 /jg total RNA
from each sample (5 /ig adult kidney) were fractionated on 1%
agarose-0.7 M formaldehyde gels and blotted onto nitrocellulose
(Hybond C extra. Amersham International) by capillary trans¬
fer overnight. Hybridization was performed at 42 C overnight
in 50% formamide with a random primed '"P-labeled 113-
OHSD complementary DNA (cDNA) probe consisting of the
excised pllDH insert (14) and the membrane washed to a final
stringency of 0.2 x SSC, 0.1% sodium dodecyl sulfate at 60 C
and exposed to Kodak XAR film for 2 days. Filters were
rehybridized with human GAPDH cDNA under the same con¬
ditions (15). GAPDH mRNA expression represents a sequence
unrelated to 113-OHSD, whose expression is ubiquitous and
which does not vary much during development in brain and
kidney as judged by our data.
In situ hybridization
Kidneys and brains from Wistar rats of various ages were
removed and immediately frozen on dry ice. Sections (10 /im)
of kidney were cut longitudinally and brain sagittally and were
applied to gelatin and poly-L-lysine-coated slides. Sections were
hybridized, as described previously (10), using either 32P or 35S-
labeled antisense cRNA probes synthesized from Styl-linear-
ized pcllDH vector (SA, ~105 Ci/mmol). Slides were washed
to a maximum stringency of 0.1X SSC at 60 C for an h. Control
slides were incubated with radiolabeled sense RNA Drobes
under identical conditions to test the specificity of h,
tion.
Statistics
Data were compared by analysis of variance followed by
Student's unpaired t test. Significance was set at P < 0.05.
Values are expressed as mean ± SEM.
Results
Tissues were examined for 113-OHSD activity at var¬
ious times and compared to adult values (Fig. 1). 113-
OHSD activity in the kidney was already high at birth
(69 ± 3%) and rose significantly to adult values (80 ±
1%) by postnatal day 5. By contrast, activity in hippo¬
campus and cortex, though moderately high at birth (46
± 4% and 48 ± 5%, respectively), fell significantly to a
nadir at postnatal day 10, and then rose gradually to
adult values. Cerebellar 113-OHSD activity was high at
birth (61 ± 3%), rose significantly to a peak at postnatal
day 10 then fell to adult values by postnatal day 15.
Northern blot analysis was used to investigate the
postnatal development of 113-OHSD mRNA expression.
Kidney and hippocampal RNA extracts were run on a
single gel and are thus directly comparable (Fig. 2). We
observed very high levels of 113-OHSD mRNA expres-
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Fig. 1. Ontogeny of 11/3-OHSD activity in rat brain subregions and
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Fig. 2. Ontogeny of 11/3-OHSD mRNA expression in rat kidney and
hippocampus. Autoradiograph of a northern blot hybridized with 32P-
labeled 1 1/3-OHSD cDN A probe. Fifteen micrograms of total RNA were
loaded per lane, except adult kidney (5 ^g). Ad, Adult rat.
sion in hippocampus at every age investigated. However
only weak 11/i-OHSD mRNA expression was detected in
neonatal kidney, compared to contemporaneous hippo¬
campus or adult kidney. Densitometry, using expression
of human GAPDH cDNA as a control for RNA loading,
revealed 11/3-OHSD mRNA was 2.5-3 times more abun¬
dantly expressed in neonatal hippocampus than in kid¬
ney. In adults, by contrast, 11/3-OHSD mRNA expression
was 1.5-2 times higher in kidney than hippocampus.
Adult hippocampus showed a single 11/3-OHSD mRNA
species which was of similar size to the single species
present in neonatal hippocampus. Total RNA from adult
kidney was deliberately underloaded to allow differentia¬
tion of the multiple 11/3-OHSD mRNA species (Fig. 2).
We detected four species confirming previous data (12)
but found that one species gave a much more intense
signal than the others. Only two or three species were
detected in neonatal kidney.
In situ hybridization confirmed high expression of 11/?-
OHSD mRNA in neuronal layers of the hippocampus,
cerebellar cortex and neocortex in the 10-day-old rat
(Fig. 3). In neonatal kidney, only low expression of 11,;/.
OHSD mRNA could be detected, predominantly in the
outer cortex. Renal cortical expression of 11/3-OHSD
mRNA increased with age. but was much less than adult
levels (Fig. 4). There was no hybridization of sense RN"A
probes (data not shown).
Discussion
There is increasing evidence that 11/3-OHSD plays an
important role in the central nervous system. High levels
of enzyme bioactivity, mRNA expression, and immuno-
reactivity have been detected in the central nervous
system, particularly in hippocampus, cortex, and cere¬
bellum (10, 11, 16), and 11/3-OHSD immunoreactivity
colocalizes with MR-like immunoreactivity in hippocam¬
pus, cortex, hypothalamic paraventricular nucleus, and
amygdala (17). A possible function for 11/3-OHSD in
Fig. 3. Localization of 11/3-OHSD mRNA expression in neonatal
brain. Autoradiograph of a sagital section of 10-day-old rat brain
hybridized with 35S-labeled 113-OHSD cRNA probe. Note the high
expression in dorsal (dh) and ventral hippocampus (vh), cerebellar
cortex (cc) and neocortex (nc). The section was exposed to Hyperfilm
/3-max (Amersham International) for 10 days.
l-day-old f
Fig. 4. Localization of 11/3-OHSD mRNA expression in neonatal kid¬
ney. Autoradiograph of longitudinal kidney sections hybridized with
32P-labeled 11/3-OHSD cRNA probe. All sections were hybridized with
the same probe and exposed to Kodak XAR film simultaneously for 2
days; expression is thus directly comparable.
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brain in vivo has also been suggested. Using [,4C]2-
dt'oxygluco— uptake we found that inhibition of 11.3-
<)HSD in conscious rats leads to increased metabolic
activity in regions of the brain exhibiting high enzyme
activity and mRNA expression (18). Similarly, using an
in vivo autoradiographic technique we found that inhi¬
bition of cerebral 11/3-OHSD by intracerebroventricular
administration of glyeyrrhetinic acid led to increased
corticosterone uptake in the hippocampus, suggesting
1 1/3-OHSD regulates the access of corticosterone to some
hippocampal MR (Seckl J. R., J. A. Russell, M-P.
Moisan, D. Burt, and C. R. W. Edwards, submitted for
publication). 11/3-OHSD also regulates access of corti¬
costerone to GR in peripheral tissues (19-21) and prob¬
ably centrally in the cerebellum (16).
The presence of 11/3-OHSD activity in perinatal brain
has been reported in previous work, using homogenates
or subcellular fractions of whole brain (22, 23). We now
show a subregionally specific developmental pattern of
11/3-OHSD activity in hippocampus, cortex, and cerebel¬
lum, associated with high expression of a single species
of 11/3-OHSD mRNA.
11/3-OHSD mRNA expression is high in neonatal hip¬
pocampus and cerebellum, but does not vary in parallel
with the changes in activity. This could simply be due to
differences in sensitivity of the Northern blot and en¬
zyme bioassay techniques. It might also reflect develop¬
mental differences in mRNA stability, translation, or
posttranslational modifications; the latter are known to
affect the bioactivity of 11/3-OHSD (24). However, the
association of very low 11/3-OHSD mRNA expression
with high bioactivity in the early postnatal kidney indi¬
cates that another protein with identical activity may
exist, as suggested to occur in parotid, mammary gland,
and mesenteric arcade (12). The importance of the mul¬
tiple mRNA species in kidney is unknown, but the ap¬
parent relative levels of expression may either parallel
the abundance of transcriptional variations of the iso¬
lated cDNA or may merely reflect the relative similarities
of these sequences to the cDNA encoding rat liver 11/3-
OHSD.
The biological importance of the various ontogenic
patterns of 11/3-OHSD activity in the central nervous
system remains to be determined. We have recently
shown that 11/3-OHSD activity is affected by glucocor¬
ticoid levels in the adult rat brain but not kidney (25).
Thus, adrenalectomy or the GR-specific antagonist
RU38486 attenuate 11/3-OHSD activity, particularly in
cortex and hippocampus, whereas, dexamethasone re¬
placement up-regulates 11/3-OHSD activity in these tis¬
sues. Since the developmental patterns of 11/3-OHSD
activity in the neonatal hippocampus and cortex parallel
changes in circulating corticosterone levels this may
merely reflect glucocorticoid regulation of enzyme activ¬
ity in the neonatal period. However, 11,3-OHSD activity
in neonatal cerebellum shows a distinct pattern, although
adult cerebellar 11,3-OHSD activity is also affected b\
glucocorticoid levels (25). Therefore other tissue-specific
regulatory factors may be of importance. The subregiona
differences in 113-OHSD activity during development
may also relate to a local and time-specific requirement
for corticosterone. The enzyme may provide protectior
of sensitive neurons, glia, and/or dendrites from elevatec
corticosteroid levels, for example during stress. By con¬
trast, reduced 11/3-OHSD activity may allow exposure ol
receptors to physiological corticosteroids ensuring inhi¬
bition of cell proliferation at appropriate times. Interest¬
ingly, the effects of synthetic (nonmetabolized) glucocor¬
ticoids and corticosterone differ in their actions on cer¬
ebral neurogenesis, perhaps reflecting the activity anc
importance of the enzyme in vivo (26).
In summary, we have found subregionally specific pat¬
terns of development of 11/3-OHSD activity in the neo¬
natal brain with high 113-OHSD mRNA expressi dur¬
ing this period. 11/3-OHSD may determine glucocor ■ oid
effects in the maturing postnatal brain. The kidney
showed high enzyme activity around birth but low mRNA
expression, suggesting 11/3-OHSD in neonatal kidney
may be structurally different from brain.
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Commentary
Multiple isoforms of the cortisol-cortisone shuttle
B. R. Walker and M.-P. Moisan
Human plasma contains similar free concentrations of
the active steroid Cortisol and its inactive metabolite
cortisone. Interconversion of Cortisol and cortisone
(or corticosterone and 11-dehydrocorticosterone in
rats) has been recognized since the 1950s. Until
recently it was thought that separate NADP/
NADPH-dependent enzymes were responsible: 110-
dehydrogenase to convert Cortisol to cortisone and
1 ip-reductase for the reverse reaction (Abramowitz,
Branchaud & Murphy, 1982; Lakshmi & Monder,
1985). It is now known that both activities can be
expressed from the same cDNA clone (Agarwal,
Monder, Eckstein & White, 1989; Agarwal, Tusie-
Luna, Monder & White, 1990), suggesting that a
single 11 P-hydroxysteroid dehydrogenase protein
(lip-OHSD) catalyses both reactions. Recently,
interest in the enzyme was stimulated by observations in
patients with congenital 11 P-dehydrogenase deficiency
(the syndrome of apparent mineralocorticoid excess)
(Ulick, Levine, Gunczler et al. 1979; Stewart, Corrie,
Shackleton & Edwards, 1988) and in volunteers given
the 11 P-dehydrogenase inhibitors liquorice (Stewart,
Valentino, Wallace et al. 1987; Monder, Stewart,
Lakshmi et al. 1989) or carbenoxolone (Stewart,
Wallace, Atherden etal. 1990). In these situations Corti¬
sol acted as a mineralocorticoid. It was hypothesized
that 11 P-dehydrogenase in the kidney is necessary to
protect intrinsically non-specific mineralocorticoid
receptors in distal renal tubules from exposure to Corti¬
sol, and thereby allow specific access for aldosterone.
This was confirmed when administration of 11P-
dehydrogenase inhibitors to rats resulted in binding of
[3H]corticosterone by renal mineralocorticoid recep¬
tors (Edwards, Stewart, Burt et al. 1988; Funder,
Pearce, Smith & Smith, 1988).
Having established the physiological role ofCortisol-
cortisone conversion in the kidney, questions were
raised about its importance elsewhere. Tissues with
mineralocorticoid receptors exhibiting aldosterone
specificity (e.g. salivary glands) have high 11 p-
dehydrogenase activity (Edwards et al. 1988). However,
11 P-dehydrogenase is also active in homogenates of a
wide variety of tissues (see Walker & Edwards, 1991)
where mineralocorticoid receptors are not abundant
(e.g. liver), or where mineralocorticoid receptors are
present but do not display specificity for aldosterone
(e.g. hippocampus: Moisan, Seckl & Edwards, 1990;
Lakshmi, Sakai, McEwen & Monder, 1991). In these
sites the enzyme may fulfil a different function, perhaps
regulating access ofCortisol to glucocorticoid receptors.
This hypothesis is supported by the correlation between
enzyme activity and glucocorticoid receptor-mediated
responses in human skin (Teelucksingh, Mackie, Burt
et al. 1990), rat testis (Phillips, Lakshmi & Monder,
1989), colon (Fuller & Verity, 1990) and mammary
gland (Quirk, Slattery & Funder, 1990). Recently evi¬
dence has emerged which suggests that 1 lp-OHSD in
glucocorticoid target tissues may be a different species
from that in classical mineralocorticoid targets.
Carl Monder's group in New York used 11P-OHSD
purified from rat liver microsomes to raise two rabbit
antisera (Monder & Lakshmi, 1990). Subsequent
studies of immunohistochemical distribution of the
enzyme produced some surprising results. Although
mineralocorticoid receptors abound in distal renal
tubules, immunoreactive enzyme was found only in
proximal tubules (Edwards et al. 1988; Rundle, Funder,
Lakshmi & Monder, 1989). By contrast, enzyme bio-
activity has been demonstrated both proximally and
distally (Edwards et al. 1988; Bonvalet, Doignon, Blot-
Chabaud et al. 1990; Naray-Fejes-Toth, Watlington &
Fejes-Toth, 1991). Furthermore, Western blots showed
different sizes of immunoreactive proteins in different
tissues (Monder & Lakshmi, 1990). The first anti¬
serum (56-125) identified a 34kDa protein in liver,
and additional species of 40 kDa in kidney, 26 kDa
in brain and 47 kDa in testis. The second antiserum
(56-126) identified a 34 kDa protein in all tissues,
additional 68 kDa proteins in liver and kidney (possibly
adimer)andagaina40 kDa protein in kidney. Usingthe
purified rat liver lip-OHSD protein, an ll|3-OHSD
cDNA has been cloned from a liver cDNA library
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(Agarwal et al. 1989). This predicts the amino acid
sequence of a protein of only 31 kDa. This discrepancy
can be accounted for by glycosylation of the protein
since when the cDNA was expressed in vitro a 34 kDa
protein was produced (Agarwal et al. 1990) which was
reduced to 31 kDa by deglycosylation with tunicamy-
cin. Interestingly, tunicamycin also altered the relative
activities of 11 P-dehydrogenase and 11 P-reductase
(Agarwal et al. 1990).
Kinetic data also suggest the presence of multiple
isoforms. This is reflected in experiments examining
the cofactor preference of 11 [^-dehydrogenase for
NADP or NAD and by the differences between tissues
in the equilibrium between Cortisol and cortisone. The
reduction of tetrazolium to diformazan blue in tissue
slices depends on NADPH or NADH generated by
11 P-dehydrogenase. Blue staining only occurred in
distal tubules supplied with NAD rather than NADP
(Mercer & Krozowski, 1991). Similarly, we found that
11 P-dehydrogenase in kidney homogenates utilized
NAD and NADP with equal facility, in contrast with
most tissues where NADP is preferred. 11 P-Reductase
activity is relatively labile in vitro (Agarwal et al. 1990).
It is therefore hard to establish whether different kin¬
etics in vitro reflect a different cortisol-cortisone balance
in vivo. However, in-vivo experiments show that human
kidney has predominant 11 P-dehydrogenase activity
(Whitworth, Stewart, Burt et al. 1989) while liver has
predominant 11 p-reductase, since almost all oral
cortisone is converted on first pass to Cortisol (Stewart
et al. 1990) and hepatic vein cortisone concentrations
are much lower than renal vein (authors' unpublished
data). Thus the presence of different isoforms may
result in different local concentrations of active and
inactive steroid.
The liver cDNA clone has been used as a probe to
study 11P-OHSD expression in various rat tissues. On
Northern blots it apparently cross-hybridized to a
single species of mRNA (approx. 1-7 kb) in most sites
except kidney, where at least three other species were
detected (1-5 kb, l-6kb and 1 -9 kb) (Krozowski,
Stuchberry, White et al. 1990), and colon where a
mRNA of 3 kb was found (Whorwood, Stewart,
Franklyn & Sheppard, 1991). More recently cDNA
clones have been isolated from a rat kidney library
which are not contiguous with the liver cDNA clone in
their 5' extremity (Mercer, Obeyesekere, Smith et al.
1991). One of these has been sequenced and shows an
identical open reading frame to the liver cDNA down¬
stream from amino acid Met 27. Our own data derived
from cloning of the 11 P-OHSD rat gene shows that
these two isoforms (with and without amino acids 1-27)
are generated by differential promoter usage. The
amino acid sequence upstream from Met 27 is very
hydrophobic and contains a putative signal peptide for
membrane insertion, suggesting that the isoforms may
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differ in their intracellular localization. In-situ hybrid¬
ization using the liver probe has shown renal 11P-
OHSD mRNA in both proximal and distal tubules
(Yau, Van Haarst, Moisan et al. 1991; Stewart,
Whorwood, Barber et al. 1991), consistent with the
bioactivity ofthe enzyme but in contrast to the immuno-
histochemical distribution. It remains to be seen
whether renal isoforms will show differential distri¬
bution, with a specific isoform located in mineralocorti-
coid target cells of the distal tubule. Recently, a human
cDNA clone derived from a testis library has been iso¬
lated, and the human 11 P-OHSD gene on chromosome
I has been characterized (Tannin, Agarwal, Monder
et al. 1991). Surprisingly, only one mRNA species was
detected in human kidney using this cDNA as a probe.
However, the similar structure of the human and rat
genes suggests that similar isoforms can be transcribed
in both species.
In summary, there is evidence for multiple isoforms of
II p-OHSD with differences in antigenic epitopes, pro¬
tein size, cofactor binding, substrate/product equilib¬
rium and tissue distribution. At least some of these
isoforms are generated from a single gene. We suggest
that this complex group of enzymes might dictate the
concentration of active steroid in each target site and
thereby offer tissue-specific modulation of corticoster¬
oid receptor activation. Furthermore, while llp-
dehydrogenase protects some receptors by inactivation
ofCortisol to cortisone (e.g. mineralocorticoid receptors
in kidney and glucocorticoid receptors in skin), in other
sites 11 [3-reductase may amplify the exposure of rela¬
tively low affinity glucocorticoid receptors by activation
of cortisone to Cortisol. The isoforms responsible may
be subject to differential regulation. Future studies will
be directed at characterizing more isoforms, particu¬
larly those represented by multiple mRNA species in
kidney. Also further studies of the gene with functional
analysis of the promoter regions may reveal an expla¬
nation for tissue-specific changes in enzyme activity
during development (Moisan, Edwards & Seckl, 1992)
and after glucocorticoid exposure (Moisan, Campbell,
Noble et al. 1991).
What implications does the existence of multiple
11 P-OHSD isoforms have for clinical research? The
analogy between 11 P-OHSD dictating tissue sensi¬
tivity to Cortisol and 5a-reductase dictating sensitivity
to testosterone has been drawn before in a Commen¬
tary in this Journal (Fraser, 1990). Recently, a second
gene for 5a-reductase has been cloned (Andersson,
Berman, Jenkind & Russel, 1991). It codes for a second
enzyme which differs from the first in its tissue distri¬
bution, kinetics and sensitivity to finasteride inhibition.
Furthermore, it is a defect in the second gene which
accounts for male pseudohermaphroditism. It seems
likely that there is another gene forllp-OHSD given the
discrepancies between enzyme bioactivity and mRNA
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levels in rat parotid and mammary gland (Krozowski
et al. 1990) and in kidney during the course of develop-
ment(Moisaneta/. 1992). Congenital deficiency of 11|3-
dehydrogenase (Ulick et al. 1979; Stewart et al. 1988)
is independent of 11 (5-reductase deficiency (Taylor,
Bartlett, Dawson & Enoch, 1984; Phillipou & Higgins,
1985) and appears only to affect mineralocorticoid
target sites. The availability of the known human gene
sequence will help us to establish what genetic defect
afflicts these patients, whether it relates to this or
another gene and whether it is likely to result in
deficiency ofonly one isoform. We have recently found
evidence of 11 P-dehydrogenase deficiency in patients
with essential hypertension, but have not shown that
this relates to abnormal renal mineralocorticoid recep¬
tor activation (Walker, Shackleton & Edwards, 1991a).
It is possible that the defect affects an extrarenal isoform
and is linked with hypertension through another mech¬
anism, perhaps involving deficient 11 P-dehydrogenase
in vascular smooth muscle (Walker, Yau, Brett et al.
19916). Finally, there is evidence that the metabolic
effects of liquorice and carbenoxolone are different,
since carbenoxolone apparently inhibits both 11P-
dehydrogenase and 11 P-reductase and does not pro¬
duce a fall in plasma cortisone levels or a kaliuresis
(Stewart et al. 1990). Thus lip-OHSD inhibitors
may display some isoform specificity. Perhaps we
can exploit this specificity to clarify the physiological
roles of multiple tissue-specific shuttle enzymes which
are central to the balance of active and inactive
corticosteroids.
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Abstract
1 lB-hydroxysteroid dehydrogenase (11B-
OHSD) catalyzes the conversion of
physiological glucocorticoids to inactive
products, thus protecting non-selective renal
mineralocorticoid receptors (MR) from
circulating glucocorticoids (ensuring
aldosterone-selectivity in vivo) and
modulating glucocorticoid access to MR and
glucocorticoid receptors (GR) in other tissues.
Detection of multiple mRNA and
immunoreactive 11B-OHSD species in
kidney, but not liver, extracts suggests the
presence of tissue-specific isoforms. To
determine whether differential promoter usage
might explain the mRNA heterogeneity we
cloned and sequenced rat 11B-OHSD genomic
DNA. Total identity was found between the
nucleotide sequence of exons 1 and 2 and the
previously published rat liver cDNA. Using
both primer extension and RNase protection
analyses we found the predominant
transcription start site in liver (+1) is 105 bp
5' of the start of translation. In kidney 2
additional Cap sites were detected:- (i) 264 bp
5' of exon 1; there is no in-phase open
reading frame suggesting the additional 5'
sequence is not translated, (ii) 65 bp upstream
of exon 2, within intron A; the predicted
truncated protein lacks the first 26
hydrophobic residues. Oligonucleotide probes
specific to transcripts arising from each
promoter confirmed all 3 are employed in
kidney, whereas a single predominant species
was found in liver, thus demonstrating tissue-
specific differential promoter usage of the
11B-OHSD gene.
Introduction
11B-OHSD catalyzes the reversible
conversion of physiological glucocorticoids
(corticosterone in rats, Cortisol in humans) to
inactive products (11-dehydrocorticosterone
and cortisone respectively). In the kidney
11B-OHSD confers in vivo aldosterone-
selectivity on MR which, when purified or
expressed in vitro, bind aldosterone, Cortisol
and corticosterone with equal affinity (1, 2).
11B-OHSD activity is also found in a wide
variety of tissues (for review see 3) where
MR are not abundant (eg liver) or where MR
are present but bind glucocorticoids (eg
hippocampus). At these sites the enzyme may
play a different role, modulating
glucocorticoid access to MR and/or GR.
Liver and kidney 11B-OHSD differ as to
number of mRNA and immunoreactive
species and kinetic constants (4-7). It appears
that kidney contains several isoforms of 11B-
OHSD which are distinct from the liver form.
In this study our aim was to determine
whether the liver and kidney mRNA isoforms
could be encoded by a single gene.
Results:
Cloning and sequencing of llfi-OHSD
genomic DNA.
A rat genomic library was screened by
hybridization to an EcoRI-EcoRV fragment of
rat 11B-OHSD cDNA (6).Three positive
clones were identified; a 15 kb clone
encompassing the other 2 was sequenced.
Identity between the nucleotide sequence of
the first and second exons of this clone and rat
liver cDNA showed that our clone represented
the rat 11B-OHSD gene. The nucleotide
sequence of exons 1 and 2, the first intron and
890 bp of 5' flanking region is illustrated in
Fig 1. Noteworthy sequence elements include
a poly(T) stretch at -416 to -391 and (dA-dC)
repeats from +1089 to +1131 in intron B.
There is no apparent TATA box but the
sequence contains a number of putative
transcription factor binding sites; a CCAAT
box at -74, 6 CACCC-box elements at -476, -
466, -427, -290, -282, and -82, a GC box
(SP1 consensus binding site) at -299,
sequences corresponding to the consensus
half site glucocorticoid responsive element
(GRE) TGTt/CCT at +61 and +250, and the
pentanucleotide TGACC, in common to
estrogen (ERE) and thyroid (TRE) responsive
elements, at positions -839, +635, and
+1295.
Identification of llfi-OHSD transcription start
sites.
Primer extension analysis was carried out
on liver and kidney RNA to determine the
start point(s) of transcription.
Oligonucleotides initially used were OL-D
(complementary to bases +81 to +105) and
OL-A (+36 to +74), both within exon 1 (Fig
2). Extension of OL-D and OL-A indicated
that the major start site in liver, also used in
kidney, is 105 bp 5' of the start of translation
in liver, in agreement with previous findings
(6) (Fig 3A). An additional larger extension
product was seen with kidney RNA.
Extension of OL-C (-88 to -68) (Fig 3B)
indicated this kidney mRNA initiates at -264.
RNase protection assays confirmed these start
sites. Using riboprobe 1 (-521 to +74) the
predicted 74 bp protected fragment resulting
from hybridization to mRNA initiating from
the major start site (+1) was observed in liver
and kidney. An additional longer protected
fragment was detected in kidney confirming
the -264 start site (Fig 3C). Analysis with
riboprobe 2 (-88 to +310), entirely covering
exon 1 (Fig 2), confirmed the +1 start site in
both tissues and a 5'-extended mRNA only in
kidney (not shown).
The cloning of a variant 11B-OHSD cDNA
from a rat kidney library was reported while
we were analysing our genomic clone (8).
This cDNA lacks the 5' region encoding the
first 26 amino acids. Since our sequence
analysis revealed this deleted region
represented exon 1 we tested the possibility
that the corresponding mRNA might initiate in
intron A. RNase protection using riboprobe 3
(+758 to +1389; Fig 2) demonstrated a
protected fragment (135 bp) corresponding to
exon 2 in liver and kidney. An additional 196
bp protected fragment was observed in kidney
suggesting a transcript containing 64 bp of
intron A (Fig. 4A). This mRNA was
confirmed by primer extension using OL-E
(+934 to +954) complementary to exon 2 (Fig
2). OL-E extended to give 2 major products in
kidney, (i) 204 bp corresponding to the +1
start site, and (ii) 89 bp corresponding to
initiation at +808, yielding an mRNA with a
65 bp 5' extended exon 2 (Fig. 4B).
Northern analysis of 11fi-OHSD transcripts.
Northern analysis demonstrated the
presence of transcripts corresponding to the 3
transcription start sites. Hybridization with a
full-length cDNA showed a single major 1700
nt transcript in liver and 3 mRNA species of
1500 nt, 1600 nt and 1900 nt in kidney (Fig.
5). OL-A (complementary to exon 1, +36 to
+74; Fig 2) hybridized to kidney mRNAs
identical in size to the 1900 nt and 1600 nt
species seen with full-length cDNA, and with
liver RNA gave an identical pattern of
hybridization to cDNA. OL-B (intron A
sequence,+831 to +870) hybridized to a
single species in kidney identical in size to the
1500 nt species; a weak band of this size is
apparent in liver. OL-C (-88 to -68)
hybridized to a 1900 nt species in kidney; no
signal was detected in liver. In summary, the
1900 nt species corresponds to mRNA
initiated at -264 and the 1500 nt species to
mRNA initiated at + 808. The 1600 nt species
in kidney most probably corresponds to
mRNA initiated at +1; the corresponding liver
species is 1700 nt.
Discussion
We have isolated a rat 11B-OHSD genomic
clone and determined the structure of its 5'
flanking region. This gene generates at least 3
distinct mRNA species by tissue-specific
differential utilization of promoters. One of
these transcripts is predicted to encode a
truncated 11B-OHSD protein. We found 3
separate sites of initiation of transcription in
kidney, whereas in liver only one site
predominates. The major liver transcript
corresponds to the previously cloned rat liver
and human testis 11B-OHSD cDNAs (6, 9).
The Cap site sequence
(TGATGTC*ACAATTCAGA) is identical to
that found in human liver from the
homologous human 11B-OHSD gene (9). The
same promoter (+1) is also used in kidney,
although the mRNA species produced is 100
nt shorter than that from liver. Tissue-specific
differences in polyA tail length may explain
this difference (7). We could not detect the
1700 nt species previously reported in renal
papilla (7).
The renal mRNA species initiating at -264
(1900 nt) and +1 (1600 nt) are likely to
encode identical proteins since the extra 5'
sequence has no in-frame ATG.
Heterogeneity of 5' untranslated region
mRNA length has been described in other
steroid dehydrogenases and may be associated
with differences in mRNA stability and
translatability (10,11). Kidney also exploits a
promoter in intron A, initiating 65 nt upstream
of exon 2, which has two possible TATA
sequences 31 (TTTTA) and 62
(TTTATGAATAA) nt 5' of the Cap site and a
element resembling a CCAAT box
(GCCAAA) 87 bp upstream. This mRNA is
predicted to encode a protein lacking the first
26 hydrophobic amino acids of 'liver-type'
11B-OHSD which may alter the enzyme's
intracellular localization or post-translational
processing, particularly glycosylation, which
potently influences 11B-OHSD kinetics and
reaction direction (12). A cDNA apparently
corresponding to this transcript has been
recently cloned (8) and, after submission of
our manuscript, its 5' sequence was published
(13). Our intron A sequence and the 5'
untranslated end of the cDNA clone 11-
HSD1B (13) differ. Since riboprobes
spanning +758 to +1389 were protected from
RNase (Fig 4A) the sequence presented here
is likely to be correct.
Though the relationship between the
putative DNA regulatory elements and the 3
transcripts remains to be defined, some idea
of possible regulatory and tissue-specific
transcriptional mechanisms can be inferred.
The CCAAT element is favorably positioned
to regulate the +1 promoter, whose
predominant use in liver may reflect the high
hepatic content of CCAAT-binding factors
(14) implicated in the regulation of genes
related to energy metabolism (a function of
glucocorticoids). The GC box and the
CACCC elements are well located to regulate
both 1900 and 1600 nt transcripts. CACCC
sequences apparently bind a transcription
factor involved cooperatively with GR (15);
there are 2 putative GREs within the
transcribed region and glucocorticoids induce
11B-OHSD activity and mRNA expression in
some tissues (16, 17, Moisan et al,
unpublished data). Finally, 3 promoters
permit independent transcriptional regulation
of each, producing greater flexibility of
control. Thus, tissue-specific and ontogenetic
regulation of 11B-OHSD expression and
activity (18) may reflect the different array of
transcription factors present . Whether
additional genes also encode isoforms of this
crucial enzyme remain to be determined.
Materials and methods
Isolation of genomic clones and sequence
analysis
Approximately 106 plaques of a Sprague
Dawley rat genomic library, cloned into X
DASH™II (Stratagene #945501), were
screened by hybridization with a 5' EcoRI-
EcoRV fragment of pcllDH-1 (6) labeled
with 32P-dCTP by random priming according
to the manufacturer's protocol (Boehringer
Mannheim, UK). DNA from positive clones
was analyzed by restriction endonucleases;
suitable fragments were subcloned into
pBluescript SK (Stratagene) and DNA
sequences determined by the dideoxy
nucleotide chain termination method using a
Sequenase (version 1) kit (United States
Biochemical).
Sequences of oligonucleotides used in this
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Primer extension and RNAse protection
analyses
Oligonucleotides were labeled with 32p.y-
[ATP] and T4 polynucleotide kinase to 1-
2x1 cpm/|ig and 10^ cpm hybridized to
RNA samples (50 |ig) at 60°C for 1 h in 100
mM KC1, 10 mM MgCl2, 25 mM Tris-HCl
pH 8.5. Primer extension reactions were
performed in 30 mM KC1, 8 mM MgCl2, 50
mM Tris-HCl, 500 |iM each dNTP, 50 (ig/ml
actinomycin D, 20 units of RNasin (Promega)
and 50 units of AMV reverse transcriptase at
42°C for 30 min. After phenol-chloroform
extraction and ethanol precipitation, the
reaction product was analyzed on 6%
polyacrylamide gels in comparison with a
sequencing reaction.
For RNase protection assays, 32P[UTP]-
labeled antisense RNA probes were
synthesized using T7 or T3 RNA polymerase.
Templates were degraded using DNase I.
5x10^ cpm of RNA probe was hybridized to
RNA samples (25-50 (ig) overnight at 46°C in
80% formamide, 0.4 M NaCl, 40 mM Pipes
pH 6.7 and 1 mM EDTA. Non-hybridized
RNA was degraded with RNases A (40
(Xg/ml) and T1 (2 |ig/ml) for 1 h at 30°C.
Following proteinase K treatment and phenol-
chloroform extraction, the samples were
ethanol precipitated and analyzed by 6%
PAGE, as above.
Northern analysis
Total RNA was fractionated on 1.2%
agarose-formaldehyde gels and transferred to
Hybond N+ (Amersham International).
Oligonucleotides (20 ng) were labeled with
[32P]-y-dCTP and terminal deoxynucleotidyl
transferase to 2-5x10^ cpm/(j.g and added to
hybridization buffer (lxSSPE, 2x Denhardt's,
1% nonfat dry milk, 10% dextran sulfate, 2%
SDS, 200 pg/ml herring testis DNA, 200
j+g/ml polyadenylic acid). Hybridization was
performed at 60°C for oligonucleotides OL-A
and OL-B, 50°C for OL-C, and final washes
in 0.2xSSC, 0.5% SDS at 50°C for 15 min.
Full-length 11B-0HSD cDNA (1265 bp) was
labeled to 1x10^ cpm/fig with [32P]-a-dCTP
and hybridized at 50°C in 50% formamide, 5x
Denhardt's solution, 5xSSC, 0.5% SDS; final
washes were in O.lxSSC, 0.5% SDS at 60°C,
as described (19).
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Nucleotide sequence of the rat 11S-OHSD 5'-
flanking region and the first 2 exons. Vertical
arrows represent starts of transcription. All
numbers relate to the major trancription start
site in liver (+1). Putative transcription factor
binding sites are underlined and putative
hormone responsive elements half sites are
identified by horizontal arrows.
Figure 2:
Schematic representation of sequenced region
and of probes used in the study. Exons are
represented by heavy bars. Vertical arrows
represent restriction sites and horizontal
arrows indicate direction of oligonucleotides
used in primer extension and Northern
analyses. Riboprobes used in RNase
protection assays are shown.
Figure 3:
(A) Primer extension analysis using OL-D
(left) and OL-A (right). L= liver total RNA,
K=kidney total RNA, Y=yeast tRNA. 50 pg
aliquots were run per lane in parallel with a
sequencing reaction. (B) similar experiment
using OL-C. Autoradiograms were exposed
for a week at -70°C. (C) RNase protection
assay using riboprobe 1 generated from the 5'
most SacI fragment (-521 to +74). Kt= whole
kidney RNA, Km=kidney medulla RNA; 25
pg aliquots were run per lane and the
autoradiogram exposed for 20 h.
Figure 4;
(A) RNase protection assay using riboprobe 3
generated from the Aflll-PstI fragment (+758
to +1389). L= liver total RNA, K=kidney
total RNA, Y=yeast tRNA; 50 pg per lane run
with a sequencing reaction. Autoradiogram
was exposed for 60h.(B) Primer extension
analysis using OL-E; 50 pg/lane.
Autoradiogram was exposed for 1 week.
Figure 5:
Autoradiograms of Northern blots of liver (L)
and kidney (K) RNA. The probes used in
each hybridization are indicated at the top of
the panel. 25 pg of RNA were loaded per
lane. After OL-A hybridization, RNA was
stripped by boiling and reprobed with the full-
length cDNA. Hybridization with OL-B and
OL-C were performed on RNA run on
adjacent lanes of the same gel used for OL-
A/cDNA so that all 4 autoradiograms could be
aligned. Autoradiograms were exposed 20 h
for cDNA, 2 days for OL-A, and 4 days for
OL-B and OL-C. The numbers on the right
indicate the approximative sizes (nt) of the
various species.
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